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CHAPTER 1 
 
INTRODUCTION 
 
1.1 General Introduction. 
Proliferating tumor cells have unique metabolic requirements characterized by enhanced 
cell-autonomous nutrient uptake and reorganization of metabolic pathways to support the 
biosynthesis of macromolecules needed for cell growth and division. This includes the folate-
dependent de novo synthesis of purines and thymidylate for the synthesis of DNA and RNA.  
Early observations made by Farber and colleagues established the importance of folate 
metabolism in cancer progression. Specifically, folic acid supplementation was found to 
stimulate leukemic cell growth and enhance disease progression among children with acute 
lymphoblastic leukemia (ALL) (Farber et al., 1947). Therefore, it was hypothesized that folic 
acid antagonists may inhibit or arrest the proliferation of cancer cells (Farber and Diamond, 
1948). In collaboration with SubbaRow and colleagues of Lederle Laboratories, a series of folic 
acid analogs including aminopterin (AMT) and methotrexate (MTX) were synthesized. This 
collaboration signified one of the first examples of rational drug design in cancer drug discovery. 
When administered to children with ALL in 1948, these antifolates became the first drugs to 
induce remission in this malignancy (Farber, 1949; Farber and Diamond, 1948). Remarkably, 
MTX continues to achieve widespread clinical use as an essential component of multidrug 
regimens for treating ALL (Pui and Evans, 2006), lymphomas, and solid tumors worldwide 
(Jolivet et al., 1983; Monahan, 2001). Thus, targeting folate metabolism and nucleic acid 
synthesis has the potential to affect cancers arising from many different tissues. Unfortunately, 
the efficacy of MTX clinically is limited by a lack of tumor selectivity and the presence of de 
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novo and acquired resistance (Matherly et al., 2007). These limitations have led to decades of 
drug discovery efforts aimed at characterizing more effective antifolates.  
The novel antifolate, pemetrexed (PMX) is one of the antimetabolites that were identified 
through these drug discovery efforts (Taylor et al., 1992). The FDA approval of PMX for the 
treatment of malignant pleural mesothelioma in 2004 (Hazarika et al., 2004) and non-small cell 
lung cancer (NSCLC) in 2008 (Cohen et al., 2009) and the concomitant discovery of the proton-
coupled folate transporter (PCFT), the preferred cellular uptake route of PMX, by Goldman and 
colleagues in 2006 (Qiu et al., 2006) has caused a revival of interest in antifolates for cancer 
therapy (Goldman et al., 2010). This success has shaped a new therapeutic approach to rational 
folate analog design based on targeting delivery into the cancer cell by exploiting the tumor-
specific expression and/or function of folate transporters. This strategy is expected to increase 
the tumor selectivity of these antimetabolites and enhance their therapeutic window. 
This chapter will review the basic biology of PCFT as it relates to the therapeutic 
application of PCFT in tumor targeting.  It will provide an overview of PCFT function, 
expression, and transcriptional regulation, as well as discuss structurally and functionally 
important amino acids and domains. The relationship of PCFT to other folate transporters and 
the consequences of PCFT mutations in human disease will be described. Finally, this chapter 
will begin to establish the feasibility of a treatment strategy that targets solid tumors based on 
PCFT-specific uptake of novel folate based analogs.  
1.2 Folate Metabolism. 
Folates designate the family of B9 vitamins that are essential cofactors necessary for 
various one-carbon transfer reactions in intermediary metabolism. Important among these 
reactions are critical steps in the de novo synthesis of thymidylate and purine nucleotide 
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biosynthesis, the regeneration of methionine from homocysteine, the interconversion of serine 
and glycine, and the catabolism of histidine and formic acid (Matherly and Goldman, 2003; 
Sirotnak and Tolner, 1999; Stokstad, 1990). The folate molecule consists of three structural 
components: a pteridine ring system, a p-aminobenzoic acid (PABA) and an L-glutamate moiety 
(Figure 1.1) (Assaraf, 2007; Zhao et al., 2009a). Mammalian cells are devoid of the metabolic 
enzymes necessary for folate biosynthesis. Thus, all folate requirements must be acquired 
through the diet (Matherly and Goldman, 2003; Sirotnak and Tolner, 1999). Within the 
mammalian cell, folates are converted to various one-carbon-substituted tetrahydrofolate (THF) 
cofactors with a one-carbon moiety at the N5 and/or N10 position at the oxidation level of 
methanol (5-methylTHF), formaldehyde (5,10-methyleneTHF) or formate (10-formylTHF or 
5,10-methenylTHF). Additionally, folates undergo polyglutamylation by folylpoly-γ-glutamate 
synthase (FPGS) in which 2 to 8 linked glutamyl residues are added to the γ-carboxyl on PABA 
of the THF cofactor. Polyglutamates of THF cofactors are polyanions which are impermeable to 
the plasma membrane and hence are retained in cells, thus ensuring high levels of intracellular 
reduced folates (Figure 1.1) (Stokstad, 1990).  
Carbon 3 of serine (derived from glycolytic intermediates) is the primary source of one-
carbon units for cytoplasmic one-carbon metabolism (Davis et al., 2004), mainly through its 
conversion to formate in the mitochondria (Anguera et al., 2006; Barlowe and Appling, 1988; 
Barlowe and Appling, 1990; Garcia-Martinez and Appling, 1993; Gregory et al., 2000; Herbig et 
al., 2002; Kastanos et al., 1997; MacFarlane et al., 2008; Pasternack et al., 1994; Pasternack et 
al., 1996; Patel et al., 2003; Quinlivan et al., 2005; Tibbetts and Appling, 2010). The cytoplasmic 
and mitochondrial compartments are metabolically connected by transport of serine, glycine and 
formate across mitochondrial membranes. Once transported into the mitochondria, the one- 
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Figure 1.1 Structure of 5-methyl tetrahydrofolate and classical antifolates. 5-methyl-
tetrahydrofolate (THF) is the major dietary form and the dominant folate found in blood. The 
folate molecule consists of a 6-methylpteridine moiety with A and B rings linked at carbon 6 by 
a methylene bridge to p-aminobenzoylglutamic acid. The N5 and/or N10 position can associate 
with a methyl (Panel A), formyl, methylene or methenyl one carbon moiety, which serve as one-
carbon donors in biosynthetic reactions. THF undergoes polyglutamylation by folylpoly-γ-
glutamate synthase (FPGS) in which 2 to 8 linked glutamyl residues are added to the γ-carboxyl 
on PABA of the THF cofactor. Panel B, Antifolates are structural analogs of natural folates that 
inhibit folate-dependent enzymes. Antifolates inhibiting: dihydrofolate reductase (DHFR) are 
aminopterin (AMT), methotrexate (MTX), and praletrexate (PDX); thymidylate synthase (TS) 
are raltitrexed (RTX) and pemetrexed (PMX); β-glycinamide ribonucleotide formyltransferase 
(GARFTase) is lometrexol (LMX). PMX inhibition of 5-amino-4-imidazolecarboxamide 
ribonucleotide formyltransferase (AICARFTase) and MTX polyglutamate inhibition of TS and 
AICARFTase is not illustrated. 
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carbon unit from serine is transferred to THF in a reaction catalyzed by mitochondrial serine 
hydroxymethyltransferase (mSHMT), which generates 5, 10-methyleneTHF and glycine 
(reaction 1m) in Figure 1.2 (Tibbetts and Appling, 2010). In the mitochondria, 5,10-
methyleneTHF is converted into 10-formylTHF by the bifunctional MTHFD2 in embryonic 
tissue (Mejia and MacKenzie, 1985) or MTHFD2L in adult tissues (Bolusani et al., 2011). 
Bifunctional MTHFD2 has both 5,10-methyleneTHF dehydrogenase (reaction 2m) and 5,10-
methenylTHF cyclohydrolase (reaction 3m) activities. 10-formylTHF can then be converted by 
the monofunctional MTHFD1L 10-formylTHF synthetase into formate and reduced THF 
(reaction 4m) (Prasannan et al., 2003). Once exported into the cytoplasm, formate reacts with 
unsubstituted THF, facilitated by the 10-formylTHF synthetase activity of the cytoplasmic 
trifunctional enzyme C1-tetrahydrofolate synthase (referred to as MTHFD1) to produce 10-
formylTHF (reaction 4) (Hum et al., 1988; Paukert et al., 1977; Schirch, 1978; Smith et al., 
1980; Thigpen et al., 1990).  The formyl group of 10-formylTHF can be used in de novo purine 
nucleotide synthesis where it is donated to β-glycinamide ribonucleotide (GAR) and then 5-
amino-4-imidazolecarboxamide ribonucleotide (AICAR), which is catalyzed by GAR 
formyltransferase (GARFTase; reaction 5) and AICAR formyltransferase (AICARFTase; 
reaction 6), respectively.  This leads to a net two carbon transfer from 10-formylTHF to C-2 and 
C-8 of the purine ring, regenerating unsubstituted THF (Hartman and Buchanan, 1959b; Smith et 
al., 1981; Smith et al., 1980).  The 5,10-methenylTHF cyclohydrolase (reaction 3) and 5,10-
methyleneTHF dehydrogenase (reaction 2) activities of the cytosolic trifunctional MTHFD1 can 
also convert 10-formylTHF to 5,10-methenylTHF and subsequently 5,10-methyleneTHF (Hum 
et al., 1988; Paukert et al., 1977; Schirch, 1978; Smith et al., 1980; Thigpen et al., 1990), which 
can donate the one-carbon unit in the irreversible conversion of deoxyuridine monophosphate 
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(dUMP) to thymidylate (dTMP, a precursor to DNA), catalysed by thymidylate synthase (TS) 
(reaction 7 in the cytoplasm and 7n in the nucleus) (Friedkin and Roberts, 1956; Phear and 
Greenberg, 1957).  The resulting dihydrofolate (DHF) (Humphreys and Greenberg, 1958; 
McDougall and Blakley, 1960) is reduced by cytoplasmic DHFR to unsubstituted THF (reaction 
8).  Alternatively, 5,10-methyleneTHF can be reduced in an irreversible reaction by 5,10-
methyleneTHF reductase (MTHFR) to generate 5-methylTHF for entry into the methyl cycle 
(reaction 9). 5-methylTHF can donate a one carbon unit in the B12-dependent regeneration of 
methionine from homocysteine, regenerating the THF, catalyzed by methionine synthase 
(reaction 10) (Hatch et al., 1961). Methionine is a precursor for the synthesis of S-
adenosylmethionine (AdoMet or SAM), a cofactor and methyl group donor for numerous 
methylation reactions, including the methylation of cytosine bases in DNA, histones, RNA, 
neurotransmitters, and other small molecules, phospholipids, and other proteins (Figure 1.2) (Lu, 
2000).  
1.3 Membrane Transport of Folates.   
Due to the highly hydrophilic nature of folates and antifolates, three genetically distinct 
and functionally diverse transport systems are in place to facilitate their uptake into the cells of 
peripheral tissues.   
1.3.1 Reduced Folate Carrier.  
The reduced folate carrier (RFC; SLC19A1), a member of the Major Facilitator 
Superfamily of solute carriers, is a secondary active anionic exchanger and the major transport 
system for reduced folates (Kt ~ 2-4 µM) in mammalian cells and tissues at physiologic pH 
(Figure 1.2) (Goldman et al., 1968; Sirotnak et al., 1968). RFC has a very low affinity for folic 
acid and as the pH is decreased, the activity for reduced folates is diminished so that there is little 
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Figure 1.2 Folate transporters, folate metabolic pathways and intracellular enzyme targets 
of antifolates. Folate and antifolate transport across biological membranes is mediated by the 
reduced folate carrier (RFC), the proton-coupled folate transporter (PCFT) and the folate 
receptor (FR). Reactions 1-4 are in both the cytoplasmic and mitochondrial (m) compartments. 
Reactions 1 and 9 are also present in the nucleus (n). The numbered reactions are catalyzed by 
the following enzymes: 1, 1n and 1m, serine hydroxymethyltransferase (SHMT). In the 
mitochondria, reactions 2m and 3m are catalyzed by bifunctional MTHFD2 or MTHFD2L and 
4m is catalyzed by monofunctional MTHFD1L. In the cytoplasm, reactions 4, 3 and 2: 10-
formylTHF synthetase, 5,10-methenylTHF cyclohydrolase and 5,10-methyleneTHF 
dehydrogenase, respectively, are catalyzed by trifunctional C1-THF synthase in the cytoplasm 
(MTHFD1); 5, β-glycinamide ribonucleotide formyltransferase (GARFTase); 6, 5-amino-4-
imidazolecarboxamide ribonucleotide formyltransferase (AICARFTase); 7 and 7n, thymidylate 
synthase (TS); 8, dihydrofolate reductase (DHFR); 9, 5,10-methyleneTHF reductase (MTHFR); 
10, methionine synthase. Aminopterin (AMT), methotrexate (MTX), praletrexate (PDX), 
raltitrexed (RTX), lometrexol (LMX), pemetrexed (PMX) (Figure 1.1), ONX-0801 (ONX), 
compound 3, compound 16 and compound 17 (Figure 3.1).   
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activity below pH 6.5. The human RFC gene is located on chromosome 21q22.3, and the gene 
structure appears to be conserved across species, with as many as six non-coding regions and 
alternative promoters (A1, A2, A, B, C, D and E) spanning 35 kb upstream from the major AUG 
translational start in coding exon 1, and five major coding exons with conserved intron-exon 
boundaries. This gives 15 distinct 5’untranslated regions fused to a common splice acceptor at 
position -49 and the same 1,776 bp coding sequence, which encodes a protein consisting of 591 
amino acids (Flatley et al., 2004; Matherly et al., 2007; Payton et al., 2007; Whetstine et al., 
2002a). Promoter activity has been confirmed for the 5’ regions proximal to the A1/A2, A, B, C 
and D non-coding regions. Regulation of RFC gene expression is by both ubiquitous (e.g. Sp, 
USF) and tissue-specific (e.g., Ap2, C/EBp, Ikaros, GATA) transcription factors that, when 
combined, transactivate or repress transcription in response to tissue-specific stimuli.  
Additionally, promoter methylation, general architecture and chromatin structure have all been 
implicated in transcriptional regulation of RFC (Liu et al., 2004; Payton et al., 2005a; Payton et 
al., 2005b; Whetstine et al., 2002b).  
Hydropathy plot analysis of the RFC amino acid sequence predicted a topological model 
of 12 transmembrane domains (TMDs) and both amino- and carboxyl termini oriented to the 
cytosol. This was confirmed by hemagglutin epitope insertion, scanning N-glycosylation 
mutagenesis, and scanning cysteine accessibility methods (Cao and Matherly, 2004; Ferguson 
and Flintoff, 1999; Liu and Matherly, 2002). RFC is N-glycosylated at an N-glycosylation 
consensus site in the first intracellular loop (IL1) between TMD1 and TMD2. A large loop 
domain connecting TMD6 and TMD7 is needed to provide appropriate spacing between TMD1-
TMD6 and TMD7-TMD12 segments for optimal transport. Amino acids localized in TMD4, 
TMD5, TMD7, TMD8, TMD10 and TMD11 were implicated in forming the putative substrate-
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binding pocket (Hou et al., 2005; Hou et al., 2006). This structure is consistent with crystal 
structures for the bacterial Major Facilitator Superfamily proteins, lactose permease (LacY) and 
glycerol-3-phosphate transporter (GlpT) (Abramson et al., 2003; Huang et al., 2003b). Like other 
Major Facilitator Superfamily transporters, RFC exists as a homo-oligomer; however, each 
monomer functions as an independent transport unit and is fully active (Hou and Matherly, 2009; 
Hou et al., 2010). 
Various studies on transcriptional and protein expression levels showed that RFC is 
ubiquitously expressed in tissues where it participates in transporting folate cofactors into cells, 
thus suggesting its integral role in specialized tissues that are important for in vivo folate 
homeostasis. Immunohistochemical analysis demonstrated mouse RFC protein expression on the 
apical brush-border membrane of small intestine and colon, liver hepatocyte membranes, the 
apical surface of the choroid plexus, the basolateral membrane of renal tubular epithelium, and 
the apical membrane of cells lining the spinal canal (Wang et al., 2001b). Measuring 
transcriptional expression of RFC in 76 human tissues and tumor cell lines showed the highest 
levels in placenta and liver, with considerably higher levels in leukocytes, kidney, lung, bone 
marrow and small intestine, and low but detectable levels in heart and skeletal muscle (Whetstine 
et al., 2002a). In at least some tissues (e.g., small intestine), the rodent RFC is responsive to 
dietary folate availability such that under conditions of folate deficiency, increased levels of RFC 
transcripts and proteins are observed (Liu et al., 2005). However, as acidic pH in the gut 
decreases the transport activity of RFC, the significance of this increased expression in the gut is 
unclear. 
1.3.2 Folate Receptor.  
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Folate receptors (FRs),  often referred to as high affinity folate binding proteins, bind and 
transport folic acid, reduced folate, many antifolates and folate conjugates with a high affinity 
(Kd~0.1–1 nM). There are three isoforms of human FR, α, β, and γ, encoded by distinct genes 
(Elwood, 1989; Lacey et al., 1989; Ratnam et al., 1989; Sadasivan and Rothenberg, 1989; Shen 
et al., 1994; Shen et al., 1995), localized on chromosome 11q13.3-q13.5 (Ragoussis et al., 1992). 
The human FR isoforms are homologous, with 68~79% identical amino acid sequences and two 
(β and γ) or three (α) N-glycosylation sites (Roberts et al., 1998; Shen et al., 1997). FRα and β 
are cell surface glycosyl phosphatidylinositol (GPI)-anchored glycopolypeptides, while FRγ 
lacks the signal for GPI-anchor attachment and is therefore a secretory protein with unknown 
function (Shen et al., 1995). Upon binding (anti)folates or folate-conjugates, FR internalizes 
them by a non-classical endocytic mechanism (Figure 1.2) (Rijnboutt et al., 1996; Sabharanjak 
and Mayor, 2004). In this process, folates bind to FRs at the cell membrane, invaginate and bud 
off to form vesicles that are internalized into the intracellular endosomal compartment. Release 
of the ligand from the receptor occurs with a decrease of pH in the endosome and exit from the 
intact vesicle occurs presumably by diffusion or a process that operates optimally at low pH 
(Kamen et al., 1988).  
FR is predominantly expressed on the apical (luminal) surface of polarized epithelial cells 
where it is not in contact with circulating folate (Chancy et al., 2000). In normal tissues, FRα is 
expressed in the brush-border membrane of the choroid plexus, retinal pigment epithelium, 
proximal tubules in kidney, fallopian tubes, uterus and placenta (Elnakat and Ratnam, 2004). 
FRβ expression in normal tissues is only found in placenta and hematopoietic cells (Ratnam et 
al., 1989). In normal bone marrow and peripheral blood cells, expression of FRβ is restricted to 
myelomonocytic lineage such as mature neutrophils, and was reported to have little binding 
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function with folic acid (Pan et al., 2002; Reddy et al., 1999). The polarized expression of FRα 
and β serves to protect normal tissues from FR-targeted cytotoxic agents in the circulation given 
intravenously (Weitman et al., 1992). Overexpression of FRα was reported in several malignant 
tissues including non-mucinous adenocarcinomas of ovary, uterus and cervix and ependymal 
brain tumors (Elnakat and Ratnam, 2004), and was found to positively correlate with tumor 
grade and stage in ovarian tumors (Buist et al., 1995; Garin-Chesa et al., 1993; Veggian et al., 
1989; Wu et al., 1999). The FRα overexpressed in malignant tissues was shown to retain the high 
affinity binding of folate (Ross et al., 1994; Weitman et al., 1992). Malignant expression of FRβ 
is found in all chronic myelogenous leukemia (CML) cells and 70% of acute myelogenous 
leukemia (AML) cells, but not in ALL (Pan et al., 2002; Ross et al., 1999). 
1.3.3 Proton-coupled Folate Transporter.  
In addition to RFC and the FRs, a low-pH folate transport mechanism was observed in 
mammalian cells, but the carrier responsible for this transport activity remained elusive for more 
than three decades.  The transporter that is the basis for this activity and the subject of this 
dissertation has been recently identified and characterized as a proton-coupled folate transporter 
(PCFT; SLC46A1) (Nakai et al., 2007; Qiu et al., 2006; Umapathy et al., 2007; Zhao and 
Goldman, 2007) (Figure 1.2. PCFT is a proton-folate symporter that functions optimally at acidic 
pH by coupling the uptake of folates with the flow of protons down their electrochemical 
concentration gradient. Although human PCFT shares only ~14% amino acid identity with 
human RFC, like RFC, it belongs to the Major Facilitator Superfamily (Zhao and Goldman, 
2007; Zhao et al., 2009a).  Strategies used to clone PCFT included database mining, using the 
conserved amino acid sequence of SLC19 family members, and screening of candidate mRNAs 
in cell lines where the RFC gene was deleted and low pH transport was either retained or 
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markedly decreased (Qiu et al., 2006).  PCFT was initially reported to be a low-affinity heme 
transporter that is pH-independent (Shayeghi et al., 2005).  Although PCFT may be capable of 
heme transport, its primary function appears to be absorption of folates at low pH.   The ability 
of PCFT to transport folate under acidic conditions is important for folate homeostasis, as dietary 
folate absorption in the duodenum and upper jejunum occurs via PCFT (Inoue et al., 2008; Qiu et 
al., 2007). 
1.4 Biology of the Proton-Coupled Folate Transporter.  
1.4.1 PCFT Tissue Expression.  
PCFT is localized to chromosome 17q11.2 in humans and the gene consists of five exons, 
and codes for a 459 amino acid protein with a predicted molecular mass of ~50 kDa. As 
mentioned above, the highest expression levels of PCFT in normal tissues were reported in the 
apical brush-border membrane along the proximal jejunum and duodenum, kidney, liver, 
placenta, spleen, and choroid plexus (Inoue et al., 2008; Qiu et al., 2006; Qiu et al., 2007; 
Urquhart et al., 2010). It has been hypothesized that PCFT may still play a role in folate uptake 
into tissues that do not experience low pH, though whether this is due to localized acidification 
or solely due to the high level of expression, combined with residual transport of 5-methylTHF at 
neutral pH, remains to be determined (Qiu et al., 2006).  Delivery of folates to the central 
nervous system has been proposed to involve PCFT and FRα coupling in the choroid plexus, 
whereby PCFT exports folates from the acidic endocytic compartment created by FRα-mediated 
endocytosis (Zhao et al., 2009b) (Figure 1.2). For the maintenance of cerebrospinal fluid folate, 
the presence of one transporter is inadequate in the absence of the other; therefore, when either 
FR or PCFT is mutated in humans, the syndrome of folate deficiency manifests (Cario et al., 
2009; Steinfeld et al., 2009).    
  
13
A comprehensive examination of PCFT and RFC expression in malignant cell lines and 
tissues has not previously been performed, however, low pH transport of [3H]MTX was detected 
in human solid tumor cell lines from the National Cancer Institute (NCI) 60 tumor panel and 
other sources. In this study MTX influx at pH 5.5 was equal to, or greater than, MTX influx at 
pH 7.4 in 29 of 32 cell lines (Zhao et al., 2004b).  These findings suggest that if the low pH 
transport can be attributed to PCFT-mediated uptake of MTX, designing therapeutics selective 
for PCFT uptake over RFC has the potential of increasing solid tumor selectivity of antifolates.   
1.4.2 Regulation of PCFT Gene Expression.  
Understanding the regulation and silencing of PCFT gene expression is important due to 
the physiologic and pharmacologic importance of PCFT. The PCFT minimal transcriptional 
regulatory region is localized between positions -42 and +96 (the transcriptional start site is +1) 
(Diop-Bove et al., 2009; Stark et al., 2009).  
The promoter of the PCFT gene harbors a 1085-bp CpG island (nucleotides −600 through 
+485) and hence the extent of methylation is a possible mechanism of PCFT transcriptional 
control. Hypermethylation of the PCFT promoter was shown to be associated with low PCFT 
gene and protein expression in CCRF-CEM and Jurkat T-cell leukemia cell lines (Gonen et al., 
2008) and a MTX-resistant HeLa cell line (R1) (Diop-Bove et al., 2009). In both cases, treatment 
with the DNA methyltransferase inhibitor, 5-aza-2’-deoxycytidine, resulted in substantial 
restoration of pH 5.5 transport and PCFT mRNA expression.  Folate status can affect 
methylation of CpG islands of DNA and of histones through their requirement in vitamin-B12-
dependent synthesis of methionine, a precursor of SAM (Stokstad, 1990). To this end, 
hypomethylation can accompany folate deficiency under some conditions (Wasson et al., 2006). 
Hence, control of PCFT expression through methylation provides an elegant method of altering 
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uptake in the face of folate excess or deficiency (Zhao et al., 2011a). Additionally, low dose 5-
aza-2’deoxycytidine treatment may restore PCFT-mediated transport of antifolates in patients 
with acquired resistance due to methylation of the PCFT promoter.  
PCFT mRNA levels are also controlled by 1,25-dihydroxyvitamin D3 (vitamin D3), and 
expression of PCFT is increased in a dose-dependent fashion in Caco-2 cells in vitro and in 
duodenal rat biopsies ex vivo when treated with vitamin D3. Vitamin D receptor (VDR) 
heterodimerizes with retinoid X receptor-α (RXRα) in response to vitamin D3 and binds a VDR 
response element in the PCFT promoter region (-1694/-1680), increasing expression and 
therefore function of PCFT (Eloranta et al., 2009). This finding suggests that vitamin D3 
supplementation could affect the bioavailability or toxicity of PCFT-targeted therapeutics in the 
clinic and may be an important consideration in the design of clinical trials. 
Three adjacent putative binding sites for the nuclear respiratory factor 1 (NRF-1) 
transcription factor were identified in the PCFT minimal promoter. NRF-1 was found to bind and 
transactivate the human PCFT promoter leading to an increase in PCFT mRNA levels (Gonen 
and Assaraf, 2010). NRF-1 is a major regulator of mitochondrial biogenesis (Scarpulla, 2002; 
Scarpulla, 2006; Scarpulla, 2008; Scarpulla, 2011). Folates play an important role in 
mitochondrial integrity, and folate deficiency has been found to cause large mitochondrial 
deletions, cytochrome c dysfunction, membrane depolarization and superoxide overproduction 
(Chang et al., 2007). Interestingly, NRF-1 has been found to up-regulate the bi-directional 
transcription of glutamine phosphoribosylpyrophosphate amidotransferase (GPAT) (reaction 1) 
and phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole 
succinocarboxamide synthetase (PAICS) (reaction 6 and 7) which are both enzymes needed for 
de novo purine biosynthesis (Figure 1.5) (Brayton et al., 1994; Chen et al., 1997). Thus, NRF-1 
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may function to coordinate mitochondrial respiration-biogenesis with folate uptake, folate 
metabolism and de novo purine biosynthesis (Gonen and Assaraf, 2010).  
1.4.3 Hereditary Folate Malabsorption.  
Direct evidence that PCFT is responsible for low-pH transport and intestinal folate 
absorption came from the discovery that homozygous mutations in the coding region of the 
PCFT gene leads to the rare autosomal recessive disorder, hereditary folate malabsorption 
(HFM) (Atabay et al., 2010; Borzutzky et al., 2009; Geller et al., 2002; Lasry et al., 2008; 
Mahadeo et al., 2010; Mahadeo et al., 2011; Meyer et al., 2010; Min et al., 2008; Qiu et al., 
2006; Shin et al., 2011; Shin et al., 2010; Zhao et al., 2007).  HFM is characterized by the onset 
of macrocytic folate-deficiency, anemia, and failure to thrive within the first few months of life. 
This may be accompanied by hypoimmunoglobulinemia associated with infectious 
complications, most frequently Pneumocyctis jiroveci pneumonia. The syndrome is characterized 
by developmental delays, gait disorders, peripheral neuropathies, and, in the absence of adequate 
and timely treatment, seizures (Geller et al., 2002; Mahadeo et al., 2010). Loss of PCFT function 
leads to impaired intestinal folate absorption, resulting in severe folate deficiency and impaired 
transport of folates across the choroid plexus into the central nervous system, reflecting the 
important physiological functions of PCFT folate transport (Zhao et al., 2009a). The fact that 
subjects who are PCFT null develop severe folate deficiency indicates that RFC does not 
contribute significantly to folate absorption under these conditions (pH 5.8-6.0) despite its 
presence in the intestinal epithelium. Many insights into the structure and function of PCFT have 
been gained by mechanistically evaluating the HFM loss-of-function mutations (Figure 1.3; 
Figure 1.4; Table 1.1).  
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Figure 1.4 Amino acid sequence alignment of PCFT homologs from different species. 
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The first exon, particularly nucleotides encoding extracellular loop 1 (EL1) between the first and 
second transmembrane domains, has a high GC content, 65.8% (75% between residues 63 and 
70), and is the most frequent site of PCFT mutations in subjects with HFM (Shin et al., 2011). 
There are five reported mutations. These include four frame-shifts: c.17-18insC, p.E9Gfs (Shin 
et al., 2011); c.194delG, p.G65Afs (Zhao et al., 2007); c.194dupG, p.C66Lfs (Meyer et al., 
2010); and c.204-205delCC, p.N68Kfs (Atabay et al., 2010; Shin et al., 2011) and a stop codon 
(c.GC197AA; p.C66X (Min et al., 2008)) (See Table 1.1 for references describing various HFM 
mutations). These genetic alterations led to truncation of PCFT and loss of PCFT expression and 
function. Additionally, a number of residues identified in patients with HFM, (c.G439C, 
p.G147R in TMD4 (Zhao et al., 2007); c.G466T, p.D156Y in TMD4 (Shin et al., 2010); 
c.C954G, p.S318R in TMD8 (Zhao 2007); c.C1004A, p.A335D in TMD9 (Shin 2011) and 
c.G1012C, p.G338R in TMD9 (Shin 2011)) (Figure 1.3 and Table 1.1) when mutated lead to no 
or very low (13% of wild-type (WT) for G147R) levels of transport of either 5-methylTHF or 
MTX. Point mutations involving either Arg113 to serine (c.C337A, p.R113S (Zhao et al., 2007)) 
or cysteine (c.C337T, p.R113C (Lasry et al., 2008)) and either Arg376 to tryptophan (c.C1126T, 
p.R376W (Mahadeo et al., 2010)) or glutamine (c.G1127A, p.R376Q (Mahadeo et al., 2010)) 
have been found in two unrelated families with HFM.  Characterization of these mutations 
suggested that mutation of Arg113 may affect binding and/or translocation of negatively charged 
folate substrates and mutation of Arg376 may affect proton binding and therefore modulates the 
folate-binding pocket in a substrate-dependent manner. Please see section 1.4.4.3 for a more in 
depth discussion of the importance of these residues for PCFT function. Interestingly, most point 
mutations associated with HFM occur in TMDs or at TMD junctions. TMD4 and 9 contain the 
most mutations (Figure 1.3) (Zhao et al., 2011b). The mutation c.G1082-1A is located in the 
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splice acceptor of intron 2 (intron 2/exon 3 boundary), causing skipping of exon 3 which creates 
a splice variant that results in deletion of 28 amino acids in TMD10 and IL5 (p.Y362_G389del). 
This mutation results in a protein with decreased stability and impaired trafficking to the cell 
membrane and was identified in eight unrelated families of Puerto Rican heritage (Borzutzky et 
al., 2009; Mahadeo et al., 2011; Qiu et al.). Finally, the residue Pro425 in the EL6 was found to 
be mutated (c.C1274G, p.P425R) in a family of Arab descent. This mutation only slightly 
impacted cell surface expression of PCFT, but function was 3.5-5% of WT (Shin et al., 2012; 
Zhao et al., 2007). Interestingly, combined WT and inactive mutant P425R PCFTs were targeted 
to the cell surface by surface biotinylation/Western blotting and confocal microscopy, and 
functionally exhibited a “dominant-positive” phenotype, implying positive cooperativity between 
monomers comprising oligomeric PCFT and functional rescue of mutant by WT PCFT (Hou et 
al., 2011) (see section 1.4.4.4). 
A possible mechanism of resistance to antifolates selective for PCFT-mediated uptake 
may be loss of PCFT function; therefore a better understanding of the impact of mutations on 
PCFT structure and function could provide insight into possibly reversing future cases of 
resistance. 
1.4.4 Structure and Function of PCFT.  
1.4.4.1 Topology.  
Based on hydropathy plot analysis, the membrane topology of PCFT is predicted to 
include twelve TMDs with the N- and C- termini directed into the cytoplasm (Figure 1.3) (Zhao 
and Goldman, 2007; Zhao et al., 2009a).  Orientation of the N- and C- termini was validated by 
immunofluorescence analysis of HA-tagged PCFT.  The loop domain between TMD1 and 
TMD2 was found to be extracellular since the two predicted N-glycosylation sites (Asn58, 
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Asn68) in this region are glycosylated (Figure 1.3).  N-linked glycosylation at the above 
mentioned sites was validated by Peptide: N-Glycosidase (PNGase) F cleavage of the 
oligosaccharide, tunicamycin inhibition of N-linked glycosylation and site-directed mutagenesis 
of Asn58 and Asn68.  Trafficking and function of PCFT was not affected by N-glycosylation 
status (Unal et al., 2008).  In MDCK and Caco-2 cells, C-terminal-tagged yellow fluorescent 
protein (YFP) PCFT was functionally expressed at the apical membrane, which is different from 
the basolateral localization for RFC (Subramanian et al., 2008).  Complete truncation of the 
PCFT C-terminal region had no significant effect on either apical cell surface targeting or 
transport function (Subramanian et al., 2008). A disulfide bond exists that is not important to 
function that links Cys66 in the first extracellular loop to Cys298 in the fourth extracellular loop 
(Zhao et al., 2010).  
1.4.4.2 Transport Characteristics.  
PCFT has similar affinities (Kt ~ 0.5-1.0 µM) for reduced (5-methylTHF, 5-formylTHF) 
and oxidized (folic acid) folates at pH 5.5 and is stereospecific for 5-formylTHF (Zhao and 
Goldman, 2007). Folic acid and MTX uptake in Xenopus laevis oocytes was increased > 200 fold 
at pH 5.5 when injected with PCFT cRNA (Qiu et al., 2006; Qiu et al., 2007).  Increased low-pH 
(pH 5.5) transport was also observed when PCFT cDNA was transiently transfected into HeLa 
cells or stably transfected into HepG2 cells (Zhao et al., 2008).  When PCFT was silenced with 
interfering RNAs, the low-pH transport of Caco-2 was reduced by 80% (Qiu et al., 2006).  PCFT 
transport activity was highest at the lowest pH (pH 5.5) and declined as the pH increased (pH 
7.4).  Uptake by PCFT conformed to Michaelis-Menten kinetics.  The Kt increased and Vmax 
decreased as the pH increased from pH 5.5 to pH 7.4 (Qiu et al., 2006; Zhao and Goldman, 
2007). The activity of PCFT is not affected by removal of extracellular Na+, K+, Ca+2, Mg+2 or 
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Cl- (Qiu et al., 2006).  Dissipation of the transmembrane proton-gradient by carbonylcyanide p-
trifluoromethoxyphenylhydrazone (FCCP) (a proton ionophore) (Qiu et al., 2006) and nigericin 
(a K+/H+-exchanging ionophore) (Inoue et al., 2008) in Xenopus oocytes and HEK293 cells, 
respectively, reduced transport by PCFT.  Studies in Xenopus oocytes have demonstrated that 
folate transport by PCFT is electrogenic, where there is a net translocation of positive charge as 
each negatively charged folate molecule is transported.  Assuming that folates are bivalent 
anions, more than two protons must be co-transported with each folate molecule to account for 
the net transport of positive charge (Qiu et al., 2006; Qiu et al., 2007).  Cellular acidification that 
accompanies folate transport into oocytes was measured, confirming proton coupling (Unal et 
al., 2009a). Conversely, in HEK293 cells, transport by PCFT was insensitive to membrane 
potential, suggesting potential-independent, non-electrogenic transport, although in either case 
there was still a requirement for an inwardly directed proton gradient (Inoue et al., 2008). PCFT 
functions even when there is no transmembrane pH gradient, based partly on the membrane 
potential. At pH 7.4, when the membrane potential is increased, folate-induced currents are 
increased (Qiu et al., 2006; Umapathy et al., 2007). At low pH, PCFT has also been found to 
have channel-like activities, where protons can flow uncoupled from the flow of folates 
(Mahadeo et al., 2010; Unal et al., 2009a). Anionic compounds, sulasalazine and pyrimethamine 
were found to be weak inhibitors of PCFT-mediated uptake with Ki values of 42.3 and 161.1 
µM, respectively. One could envision that the efficiency of intestinal folate absorption or the 
efficacy of orally administered PCFT-selective antifolates for cancer therapy would be affected 
in subjects administered these compounds (Inoue et al., 2008; Nakai et al., 2007; Urquhart et al., 
2010). Hence, it is important to gain a better understanding of PCFT substrate affinity and 
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transport characteristics to create better PCFT substrates and avoid drug interactions during 
clinical administration. 
1.4.4.3 Functionally Important Residues.  
Functional analysis of HFM mutations and mutations generated by site-directed 
mutagenesis have identified residues that are important in PCFT structure and function.  
Arg113 was found to be mutated in two unrelated families of Turkish (c.C337A, 
p.R113S) and Arab (c.C337T, p.R113C) descent by two independent investigators (Lasry et al., 
2008; Zhao et al., 2007). The residue Arg113 is found in the highly conserved (Figure 1.4) IL1 
motif D109XXGRR114 connecting TMD2 and TMD3 in PCFT (Table 1.1; Figure 1.3). When 
expressed in C5 MTXR0.15 CHO cells, R113C PCFT was expressed at the cell surface, but did 
not transport folic acid or MTX (Lasry et al., 2008). Similarly, when R113S PCFT was 
expressed in WT HeLa cells, no protein was found at the cell surface and no transport of 5-
methylTHF was detected (Zhao et al., 2007). Since the recently crystallized E coli GlpT shares 
several structural and functional characteristics with PCFT and is the closest structural homolog 
with 13.8% sequence similarity over 424 aligned amino acid residues (from a total of 459), GlpT 
was used as a template in a homology-based structural model to analyze the structure of the IL1.  
Homology modeling analysis predicted that the DXXGRR motif forms a β-turn whereas the 
cationic R113 residue of PCFT is completely buried in a putative hydrophobic cavity, the walls 
of which are made up of TMD1, TMD3, TMD4, and TMD6.  It was suggested that R113 might 
possibly participate in the binding and/or translocation of negatively charged folate substrates 
(Lasry et al., 2008).  Alanine mutagenesis across this stretch disrupted the β turn and resulted in 
endoplasmic reticulum retention with loss of transport (Subramanian et al., 2008).  
  
24
Arg376 is a highly conserved residue (Figure 1.4) that has been found to be mutated in 
two unrelated families with HFM of Mexican (c.C1126T, p.R376W) (Mahadeo et al., 2010; 
Zhao et al., 2007) and Chinese (c.G1127A, p.R376Q) descent (Table 1.1; Figure 1.3). When 
expressed in R1-11 HeLa cells, R376W was expressed in crude membranes and localized to the 
membrane similar to WT; however, no transport of 5-methylTHF, 5-formylTHF, folic acid, 
MTX and PMX could be detected (Zhao et al., 2007). When explored more rigorously, it was 
found that a positive charge is favored at this residue. Interestingly, when this residue was 
mutated to a polar amino acid, as found in the HFM R376Q mutant, PMX transport activity was 
preserved at saturating concentrations (influx Kt increased and Vmax decreased); however, no or 
very low transport of 5-methylTHF, 5-formylTHF, folic acid and  MTX was detected. This 
mutant was expressed in crude membranes and localized to the membrane at levels 50% of WT. 
The data suggest that mutation of the R376 residue to glutamine impairs proton binding which, 
in turn, modulates the folate-binding pocket and depresses the rate of conformational alteration 
of the carrier, a change that appears to be, in part, substrate dependent (Mahadeo et al., 2010; 
Mahadeo et al., 2011).  
Histidine has been shown to be critical for the function of some of the proton-coupled 
solute carriers (Fei et al., 1997; Lam-Yuk-Tseung et al., 2003; Metzner et al., 2008). There are 
ten His residues in PCFT; of these, His84, 247 and 281 are fully conserved across all species 
(Figure 1.4) and mutation of His281 and His247 to alanines caused loss of MTX transport 
function at pH 5.5 and pH 7.0. H247A (located in IL3) and H281A (located in TMD7) (Figure 
1.3) were expressed to the same extent as WT, except the H247A mutant protein migrated faster 
by SDS PAGE than WT or H281A. This was not due to protein instability. Independent of 
changes in Vmax, H247A had increased affinity for folic acid, 5-formylTHF and 5-methylTHF 
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compared to WT. The affinities for all the different substrates were very similar, which is in 
contrast to results for WT PCFT (Unal et al., 2009a). GlpT was used as a template in a 
homology-based structural model to analyze the role of His247 in PCFT function. The model 
predicted His247 to be localized in a highly electropositive region at the cytoplasmic opening to 
the water-filled translocation pathway. Additionally, the model predicted that His247 interacts 
with Ser172 and limits access of extracellular folate substrates, thus determining the selectivity 
of PCFT for folate. Ser172 mutated to alanine caused a similar change in influx Kt, as caused by 
the His247 mutation. Additionally, the mutant exhibited folate-independent proton transport or 
“slippage”. Mutation of His281 to alanine produced a substantially different phenotype, 
characterized by increased influx Kt and maintenance of a selectivity profile similar to WT 
PCFT. The magnitude of the increase in folic acid transport as a function of pH was far less; 
however there was still folate-induced cellular acidification. Therefore, His281 is not needed in 
proton –coupling but protonation of this residue may result in increased binding of folate 
substrates (Unal et al., 2009a).  
More rigorous evaluation of the HFM mutant, D156Y, revealed that Asp 156 is important 
for protein stability (Table 1.1; Figure 1.3) (Shin et al., 2010). Loss of stability was observed 
with a variety of polar, neutral, or positively charged mutants. However, stability and trafficking 
were preserved with a Gly (relatively polar) or, to a lesser extent, with Ser (polar) substitutions. 
All the residues that are point mutated in HFM are completely conserved across all the species 
analyzed, demonstrating their importance for expression and function of PCFT (Figure 1.4). 
Discovery and characterization of the D156Y mutation in HFM led to rigorous analysis of the 
other 6 conserved Asp residues in PCFT. Only one, Asp109, is shown to be required for 
function. No substitution, irrespective of charge or polarity preserved function, even conservative 
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substitutions. All of the Asp109 mutants were expressed and were detectable at the cell 
membrane at levels similar to WT, but no MTX transport was detected at high MTX 
concentrations and when the extracellular proton concentration was increased. This suggested 
that the loss of activity was not due to an increase in influx Kt, like the R376Q mutation, or that 
there was a decrease in affinity of a proton-binding site that allosterically alters the conformation 
of the folate-binding pocket, like the H281A mutation. Additionally, lack of activity at pH 7.4 
excludes a role of this residue for proton-coupling. The Asp109 is found in IL1 like the R113S 
and R113C HFM mutations. When Asp109 was replaced with other amino acids (even 
glutamate), substrate either does not bind and/or the alternative-access mechanism of transport is 
impaired (Figure 1.3) (Shin et al., 2010).    
Conserved, charged residues located in TMDs are preserved through evolution because 
they usually contribute by intramolecular interactions to the stabilization of transporter tertiary 
structure and are therefore important for function of the carrier (Zvelebil et al., 1987). The 
residue Glu185 when mutated to leucine or alanine resulted in loss of MTX transport at pH 5.5 
due to a decrease in the influx Vmax with no change in influx Kt. The preservation of a negative 
charge at position 185 is essential, since low pH transport was lost for all E185 substitutions 
regardless of charge and polarity except for the similarly charged E185D, which maintained a 
third of WT function. Unexpectedly, transport at pH 7.4 for the E185A mutant was comparable 
to that of WT.  This suggests that Glu185 plays an important role in proton-coupling (Figure 1.3) 
(Unal et al., 2009b). 
1.4.4.4 Oligomerization.  
As mentioned previously, PCFT belongs to the Major Facilitator Superfamily of 
transporters. Since numerous Major Facilitator Superfamily proteins including LacS (Veenhoff 
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et al., 2001), AE1 (Dahl et al., 2003; Taylor et al., 2001), GLUT1 (Zottola et al., 1995), TetA 
(Hickman and Levy, 1988; Yin et al., 2000), and RFC (Hou and Matherly, 2009) have been 
reported to exist as oligomers (e.g., dimers, tetramers, etc.), and given the potential mechanistic 
and regulatory ramifications of such structures for PCFT, the oligomerization status was 
evaluated (Hou et al., 2011). The HFM mutation P425R (described in section 1.4.3 and Zhao et 
al. (2007)) was used in conjunction with an assortment of biochemical and molecular techniques 
to validate the existence of PCFT homo-oligomers. By protein cross-linking, oligomeric PCFT 
appeared to predominate over monomeric PCFT. On a non-denaturing blue-native-PAGE, 
dimeric PCFT was the most predominant species. HA and FLAG/His 10 epitope-tagged PCFT 
protein monomers co-localized to the plasma membrane. PCFT monomers associate when 
analyzed using Ni affinity chromatography. FRET was detected between two YPet and ECFP-
tagged PCFT monomers. Finally, co-expression of WT PCFT with P425R PCFT monomers led 
to a dominant-positive transport phenotype. This appeared to involve co-folding and increased 
surface trafficking of P425R PCFT to the cell surface, as reflected in increased surface levels of 
mutant PCFT protein by surface biotinylation and Western blotting, and by indirect 
immunofluorescence and confocal microscopy. Thus, not only does PCFT exist as a homo-
oligomer but there is functional cooperation between PCFT monomers in facilitating transport of 
folate substrates (Hou et al., 2011). Interestingly, the PCFT primary structure includes GXXXG 
motifs in TMD2 (amino acids 93-97) and TMD4 (amino acids 155-159) (Figure 1.3), analogous 
to “dimerization motifs” implicated in the oligomerization of other amphipathic proteins, 
including, ABCG2 and OAT1 (Duan et al., 2011; Polgar et al., 2010). Additionally, a cluster of 
PCFT nonfunctional mutations have been found in TMD4 (G147R, D156Y and L161R), 
suggesting that this region may be important in oligomerization (Figure 1.3 and Figure 1.4). A 
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better understanding of the structural and regulatory determinants of PCFT oligomerization may 
lead to novel approaches for therapeutically rescuing functionally impaired PCFT mutants in 
HFM or that may arise as a form of resistance to PCFT-selective novel folate analogs, perhaps 
with PCFT peptidomimetics or small molecules.  
1.5 The Role of Antifolates in Cancer Therapy. 
1.5.1 Inhibition of De Novo Thymidylate Biosynthesis Pathway.  
Antifolates that inhibit DHFR, such as the classic antifolates, AMT and MTX, and the 
newer generation antifolates, pralatrexate (PDX) and the non-polyglutamable PT523 (Figure 1.1 
and 1.2), block the regeneration of unsubstituted THF from DHF. This causes a depletion of THF 
cofactors and the accumulation of DHF, resulting in cessation of one-carbon-dependent 
processes (Matherly et al., 1987a; Seither et al., 1989). AMT has a much higher binding affinity 
for RFC and FPGS than MTX and is therefore transported into the cell and metabolized to 
polyglutamates much more rapidly (Smith et al., 1996). This increases the activity of AMT 
clinically, but also increases the toxicity of the compound compared to MTX (Goldin et al., 
1955). PDX was discovered through drug development efforts of F.M. Sirotnak and colleagues at 
Memorial Sloan Kettering Cancer Center and J. DeGraw and coworkers at the Southern 
Research Institute. They found that 10-deaza-AMT was more potent than MTX (Sirotnak et al., 
1984) and that the 10-ethyl derivative of 10-deaza-AMT (edatrexate) had even better efficacy 
both preclinically and clinically (Beinart et al., 2007; Gralla, 1995; Schmid et al., 1985; Shum et 
al., 1988; Sirotnak et al., 1993; Vandenberg et al., 1993). Based on the finding of Jones et al. 
(1981) that the N-10-propargyl analog of 5,8-dideazafolic acid (CB 3717) possessed potent 
inhibitory activity against TS (discussed in more detail below), 10-propargyl-10-deaza-AMT 
(PDX) was synthesized and tested to evaluate the effect of the propargyl group on growth 
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inhibition. It was found that PDX had a 3-fold decreased affinity for DHFR and a 10-fold RFC 
transport advantage compared to MTX, resulting in 5-fold enhanced anti-proliferative activity 
(DeGraw et al., 1993; Sirotnak et al., 1998). In September 2009, the FDA approved the use of 
PDX for the treatment of relapsed, refractory peripheral T-cell lymphoma (Thompson, 2009). 
Since then, PDX has been evaluated clinically either alone or in combination with other agents in 
a wide range of malignancies with promising results (Azzoli et al., 2007; Marchi et al., 2010; 
Toner et al., 2006; Zain and O'Connor, 2010a; Zain and O'Connor, 2010b).  
Raltitrexed (RTX; Tomudex) is a potent TS inhibitor and arose from rational drug design 
efforts of researchers from the Institute for Cancer Research and Astra Zeneca (Figure 1.1 and 
1.2) (Calvert et al., 1980). Previous work demonstrated that 5,8-dideazafolic acid was a weak 
inhibitor of TS; sequential modification of this compound produced N10-propargyl-5,8-
dideazafolic acid or CB3717 (Calvert et al., 1986; Jones et al., 1981). In the initial phase I/II 
clinical trials, this drug had activity against ovarian, liver, and breast cancer but also resulted in 
troublesome hepatic toxicity and dose-limiting nephrotoxicity, which occurred in 70% of patients 
at doses greater than 450 mg/m2 )(Jackman and Calvert, 1995). To try and reduce toxicity, efforts 
were made to make the compound more water soluble at physiological pH; this was achieved by 
removing the 2-amino group and synthesizing a 2-desamino-2-methyl compound (ICI 198583) 
(Jackman et al., 1991b). Finally, replacement of the para-aminobenzoate with a thiophene and 
introduction of a N10-methyl substituent produced ZD1694 or RTX (Jackman et al., 1996; 
Jackman et al., 1991a; Jackman et al., 1991c). RTX had reduced TS inhibition compared to 
CB3717 but showed enhanced cellular uptake by RFC and polyglutamylation, leading to more 
potent tumor growth inhibition both in vitro and in vivo (Gibson et al., 1993; Jackman et al., 
1993; Jackman et al., 1991c). This drug discovery effort exemplifies the power of establishing 
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structure activity relationships (SAR) through careful cellular, biochemical and pharmacological 
evaluation to test each chemical modification. RTX was approved for clinical use outside the US 
for advanced colorectal cancer (Chu et al., 2003).  
Antifolates that target TS (Matsui et al., 1996; Yin et al., 1997), and DHFR (Benigni et 
al., 1983; Lorico et al., 1988) decrease levels of deoxythymidine triphosphate (dTTP), which 
results in a “thymineless” death.  The decreased dTTP levels cause misincorporation of 
deoxyuridine triphosphate (dUTP) in place of dTTP into newly synthesized DNA.  The dUTP is 
recognized as incorrect and cycles of futile excision-repair ensue, ultimately leading to DNA 
strand breaks and cell death (Bronder and Moran, 2003). 
1.5.2 Inhibition of De Novo Purine Biosynthesis Pathway.  
Purines serve as building blocks of RNA and DNA; they regulate enzymatic activity as 
components of vitamins and cofactors, and mediate energy transfer in the cell (King et al., 1983). 
Most differentiated adult cells can satisfy their purine requirements through purine salvage 
mechanisms (Howell et al., 1981; Jackson and Harkrader, 1981; King et al., 1983; LeLeiko et al., 
1983; Mackinnon and Deller, 1973). Conversely, proliferating cells, such as activated T-cells and 
tumor cells, require activation of de novo purine synthesis in order to meet the greater nucleotide 
demands for DNA and RNA synthesis (Denkert et al., 2008; Fairbanks et al., 1995; Howell et al., 
1981; Jackson and Harkrader, 1981; Kondo et al., 2000). Inhibitors of de novo purine 
biosynthesis inhibit lymphocyte and tumor cell growth, which suggests that purine salvage 
pathways are insufficient to support nucleotide synthesis (Christopherson et al., 2002; Hovi et 
al., 1976). Interestingly, even though bone marrow progenitor cells and intestinal crypt cells are 
highly proliferative they rely principally on purine salvage for their purine demands. This is 
reflected in the high levels of purine precursors such as hypoxanthine (~7-11 µM, three to four 
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times higher than plasma levels) in these tissues, which can not only be salvaged but can also 
directly inhibit de novo purine biosynthesis (Howell et al., 1981; King et al., 1983; LeLeiko et 
al., 1983; Mackinnon and Deller, 1973).  
Biosynthetically, adenosine and guanosine nucleotides are derived from inosine 
monophosphate (IMP), which is synthesized from phosphoribosyl pyrophosphate (PRPP) in both 
salvage and de novo synthesis of purines. PRPP is formed by PRPP synthetase which uses ATP 
to activate ribose-5-phosphate (made through the pentose phosphate shunt from glucose). In the 
salvage pathway, PRPP is used by either hypoxanthine phosphoribosyl transferase (HPRT) to 
convert guanine and hypoxanthine back into GMP and IMP, respectively, or by adenine 
phosphoribosyl transferase (APRT) to convert adenine back into AMP (Murray, 1971). While 
the salvage of purines is a one-step conversion, the de novo purine synthesis pathway consists of 
ten reactions catalyzed by 6 enzymes that convert PRPP into IMP, which is subsequently used to 
synthesize AMP and GMP (Figure 1.5). Synthesis of IMP occurs in the cytosol and requires five 
moles of ATP, two moles of glutamine, one mole of glycine, one mole of CO2, one mole of 
aspartate and two moles of formate per mole of IMP. The enzymatic reaction and intermediates 
of the de novo purine biosynthesis pathway were largely characterized in seminal experiments by 
Buchanan and colleagues in avian models in the 1950s and 1960s (Hartman and Buchanan, 
1959a). They have since been found to be conserved in species ranging from bacteria to humans.  
The first reaction is the rate-limiting step and involves the conversion of PRPP into 5-
phosphoribosylamine by glutamine phosphoribosylpyrophosphate amidotransferase (GPAT), 
which entails replacement of the pyrophosphate of PRPP by the amide group of glutamine 
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Figure 1.5 De novo purine nucleotide biosynthesis pathway. The de novo purine nucleotide 
biosynthetic pathway from phosphoribosyl pyrophosphate (PRPP) to IMP is shown. The 
numbered reactions are catalyzed by the following monofunctional enzymes: 1, glutamine 
phosphoribosylpyrophosphate amidotransferase (GPAT); 4, formylglycinamide ribonucleotide 
synthase (FGAM synthetase); 8, adenylosuccinate lyase (ASL). Reactions 2, 3 and 5 are 
catalyzed by the trifunctional glycinamide ribonucleotide (GAR) formyltransferase (GARFTase) 
which contains GAR synthase (GARS; reaction 2), GAR formyltransferase (GARFTase; reaction 
3) and 5-aminoimidazole ribonucleotide synthase (AIRS; reaction 5) activities. Reactions 6 and 7 
are catalyzed by the bifunctional phosphoribosylaminoimidazole carboxylase/ 
phosphoribosylaminoimidazole succinocarboxamide synthetase (PAICS) enzyme, which 
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contains carboxyaminoimidazole ribonucleotide synthase (CAIRS; reaction 6) and 5-
aminoimidazole-4-(N succinylocarboxamide ribonucleotide synthase (SAICARS; reaction 7) 
activities. Reactions 9 and 10 are catalyzed by a bifunctional enzyme, 5-Amino-4-
imidazolecarboxamide ribonucleotide formyltransferase/ IMP cyclohydrolase (ATIC) that 
sequentially catalyzes the last two steps in the pathway for de novo synthesis of IMP. ATIC has 
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) formyltransferase (AICARFTase; 
reaction 9) and inosine monophosphate cyclohydrolase (IMPCH; reaction 10) activities. There 
are two folate-dependent reactions (reaction 3 and 9) in which 10-formyl tetrahydrofolate serves 
as the one-carbon donor catalyzed by GARFTase and AICARFTase. 5-aminoimidazole-4-
carboxamide (AICA) and AICAR can be metabolized to AICAR monophosphate (ZMP) by 
either adenine phosphoribosyl transferase (APRT) or adenosine kinase (AK), thus circumventing 
the reaction catalyzed by GARFTase. For the in situ GARFTase assay, incorporation of 
[14C]glycine into [14C]F-GAR in the presence of azaserine is used as a direct measure of 
GARFTase activity. 
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 (reaction 1). Subsequent steps involve three multifunctional enzymes: a trifunctional protein 
GARFTase, that has GAR synthase (GARS; reaction 2), GAR formyltransferase (GARFTase; 
reaction 3), and 5-aminoimidazole ribonucleotide synthase (AIRS; reaction 5) activities; a 
bifunctional enzyme, phosphoribosylaminoimidazole carboxylase/ 
phosphoribosylaminoimidazole succinocarboxamide synthetase (PAICS), that has 
carboxyaminoimidazole ribonucleotide synthase (CAIRS; reaction 6) and 5-aminoimidazole-4-
(N succinylocarboxamide ribonucleotide synthase (SAICARS; reaction 7) activities; and a 
bifunctional enzyme, 5-Amino-4-imidazolecarboxamide ribonucleotide formyltransferase/ IMP 
cyclohydrolase (ATIC), that has 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase (AICARFTase; reaction 9) and IMP cyclohydrolase (IMPCH; reaction 10) 
activities. The remaining steps are catalyzed by monofunctional enzymes, formylglycinamide 
ribonucleotide synthase (FGAM synthetase; reaction 4) and adenylosuccinate lyase (ASL; 
reaction 8). The formate that is used by GARFTase and AICARFTase to supply the number 2 
and number 8 carbons of the purine ring is carried by THF in the form of 10-formylTHF 
(Hartman and Buchanan, 1959a; Hartman and Buchanan, 1959b). 
In a continued effort to find other inhibitors of folate metabolism at sites other than 
DHFR, a “critical bond blocking” strategy was employed by a joint collaboration between E.C. 
Taylor at Princeton and a team of chemists at Eli Lilly led by Chuan (Joe) Shih. This effort 
resulted in the synthesis of the 6R diastereomer of 5,10-dideazatetrahydrofolate (DDATHF) or 
LMX (Figure 1.1), which is structurally identical to natural THF except the nitrogen atoms at 
positions 5 and 10 that participate in all of the one-carbon transfers are replaced by carbons 
(Moran et al., 1989; Taylor et al., 1985). LMX is transported into the cell by RFC (Westerhof et 
al., 1995), polyglutamylated by FPGS (Baldwin et al., 1991) and inhibits GARFTase leading to 
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ATP and GTP depletion (Figure 1.2) (Beardsley et al., 1989).   Phase I clinical investigation of 
LMX found that without folic acid co-administration, LMX caused severe cumulative toxicity, 
with myelosuppression (anemia, thrombocytopenia and neutropenia) and mucositis being dose 
limiting (Ray et al., 1993). With folic acid co-administration, there was a reduction in the clinical 
toxicity, permitting a dose of greater than 10 times that in the absence of supplementation 
(Roberts et al., 2000a). It was thought that the delayed and cumulative toxicity may result from 
gradual release of LMX metabolites from the liver resulting in an extended γ-phase plasma half 
life (Taber et al., 1991). One hypothesis was that folate depletion increased the expression of FR 
and this was contributing to greater cellular uptake in the liver and hence greater toxicity of 
LMX (Mendelsohn et al., 1996; Pohland et al., 1994). Another hypothesis was that 
thrombocytopenia occurred because platelets have the highest requirement for ATP than any 
other cell of the body. It is delayed because of the long maturation time of megakaryocytes 
(which is probably further extended under conditions of purine shortage), and it may be 
irreversible because the polyglutamate forms of LMX turn over very slowly such that, once 
formed, they are effectively impossible to eliminate (Jackman, 1999). In an effort to reduce 
toxicity, second generation inhibitors were synthesized. LY309887 was designed to have lower 
FRβ affinity (Wang et al., 1992), reduced polyglutamylation (Mendelsohn et al., 1996) and a 9-
fold increased affinity for GARFTase compared to LMX (Budman et al., 2001; Mendelsohn et 
al., 1999). Additionally, structure-based drug-design was used to design AG2034, which was 
based on the X-ray crystal structures of the E. coli GARFTase and of the GARFTase domain of 
the human enzyme. Like LY309887, preclinical enzyme inhibition studies showed that AG2034 
was a potent inhibitor of GARFTase (Almassy et al., 1992; Boritzki et al., 1996). However, 
clinical evaluation of both these compounds demonstrated the same delayed, cumulative toxicity 
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as observed with LMX (Bissett et al., 2001; Boritzki et al., 1996; Budman et al., 2001; Kisliuk, 
2003; Roberts et al., 2000b). Continued toxicity of these compounds, even with altered FR 
affinity, suggests that FR-mediated uptake in the liver is not a major determinant of toxicity and 
implies another transport-mediated process in the liver, most likely RFC (given the neutral pH 
microenvironment), that may be the true source of toxicity. Thus, GARFTase inhibitors with 
PCFT selectivity may have the potential of improving the efficacy and reducing the toxicity of 
antipurine antifolates in the clinic (Goldman et al., 2010).  
GARFTase inhibitors block de novo purine synthesis, leading to a rapid decline in ATP 
and GTP pools (Beardsley et al., 1989; Boritzki et al., 1996; Chen et al., 1998; Pizzorno et al., 
1991).  Unlike TS and DHFR inhibitors, reduction of purine pools does not necessarily induce 
DNA strand breaks.  There are two principle hypotheses as to how GARFTase inhibitors impact 
p53, cell cycle and cell death. The first proposed by Zhang et al. (1998a) states that reduction of 
ribonucleotide pools is sensed by p53, which then stabilizes and accumulates causing arrest at 
the G1 checkpoint and induction of cytostasis (Linke et al., 1996; Zhang et al., 1998a). Tumor 
cells lacking functional p53 or that have other defects in the G1 checkpoint are more sensitive to 
GARFTase inhibitors. Since 50% of human cancers lack a functional G1 checkpoint, GARFTase 
drugs may be selectively active towards these tumors while protecting normal cells with 
functional p53. Moran and colleagues demonstrated that the cytotoxic effects of agents that 
target de novo purine nucleotide biosynthesis are not dependent on p53 status since 
ribonucleotide depletion prevents full activation of p53. Due to low ATP and GTP pools, kinases 
cannot phosphorylate p53 leading to hypophosphorylated and hypoacetylated forms of p53.  In 
these forms, p53 is capable of nuclear retention and binding to the p21 promoter, but remains in 
an inactive pre-initiation complex because of insufficient recruitment of chromatin-remodeling 
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complexes which prevent chromatin accessibility and transcriptional activation of the p21 gene. 
Lack of p21 induction prevents G1 arrest and allows for S-phase entrance of tumor cells; DNA 
replication in the face of low purine levels results in cytotoxicity to the cell regardless of p53 
status (Bronder and Moran, 2002; Bronder and Moran, 2003). If these findings are accurate, 
characteristic growth inhibition by antipurine antifolates is not dependent on p53 status, thus 
increasing the potential of this drug to treat many different malignancies. 
Another consideration involves the purine salvage pathway. In bone marrow 
mononuclear cells, physiologic levels of hypoxanthine inhibited de novo purine biosynthesis and 
the salvage pathway was preferentially used to synthesize purines (King et al., 1983). These 
findings may explain the low rates of de novo purine synthesis in bone marrow tissues and 
suggests that inhibitors of de novo purine synthesis will not be marrow toxic. Additionally, 
methylthioadenosine phosphorylase (MTAP) is an enzyme that releases adenine and methionine 
from methylthioadenosine formed during polyamine biosynthesis (Illei et al., 2003). Whereas 
MTAP has been reported to be abundantly expressed in normal tissues, in many solid tumors the 
MTAP gene is co-deleted with CDKN2A (encodes p16INK4A) (Illei et al., 2003). Thus, many 
solid tumors are deficient in purine salvage and functional purine salvage in normal tissues 
would theoretically protect cells from cell death caused by GARFTase inhibition, increasing 
tumor cell selectivity for GARFTase inhibitors (Bertino et al., 2011; Hori et al., 1996).  
Recently, it was found that upon purine depletion, the human de novo purine biosynthetic 
enzymes colocalize in the cytoplasm to form a multienzyme complex called the “purinosome” 
(An et al., 2008). Purinosome formation is associated with an increased rate of purine 
biosynthesis. The formation of functional multienzyme complexes may produce efficient 
substrate channels that link the 10 catalytic active sites. Purinosomes are dynamically regulated 
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by inhibition of casein kinase 2 (CK2) (An et al., 2010b) and are spatially controlled by the 
matrix of microtubule filaments (An et al., 2010a). It will be important to determine the effect of 
de novo purine synthesis inhibitors on the formation and function of the purinosome. 
Interestingly, the trifunctional MTHFD1 which synthesizes 10-formylTHF through the ATP-
dependent condensation of formate and THF is not associated with the purinosome (An et al., 
2008; An et al., 2010b). Recently, methenylTHF synthase (MTHFS), which catalyzes the 
irreversible and ATP-dependent conversion of 5-formylTHF to 5,10-methenylTHF was found to 
enhance purine biosynthesis by delivering 10-formylTHF to the purinosome in a cell cycle and 
SUMO-dependent fashion (Field et al., 2011). Furthermore, MTHFS expression has been found 
to be elevated in some tumors, which enhances de novo purine biosynthesis and confers partial 
resistance to antifolate purine synthesis inhibitors (Field et al., 2009; Field et al., 2006). Thus, 
MTHFS may be a modifier of GARFTase inhibitor efficacy and determining MTHFS expression 
in malignancies may be an important predictor of antipurine antifolate drug activity. Because of 
its importance of MTHFS in de novo purine biosynthesis, inhibitors have been designed for 
potential use in cancer therapy (Wu et al., 2009). 
1.5.3 Mulitargeted Antifolate.  
In order to meet FDA requirements of purity, efforts were made to eliminate the synthesis 
of both R and S diastereomers of DDATHF by eliminating the chirality at the 6-position of 
LMX. One strategy replaced the 5-deazapteridine ring of LMX with a pyrrolo[2,3-d]pyrimidine 
ring, resulting in LY231514 (PMX; Alimta) (Figure 1.1) (Taylor, 1993; Taylor et al., 1992). This 
structural alteration converted the sp3 center at C6 to sp2 geometry. Cell culture end-product 
reversal and enzymology experiments indicated that this compound potently inhibited TS and 
had weak inhibition of DHFR, GARFTase and AICARFTase (Figure 1.2) (Shih et al., 1997; 
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Taylor et al., 1992). PMX is rapidly transported across the cell membrane by both RFC and 
PCFT (Wang et al., 2004; Westerhof et al., 1995; Zhao et al., 2008), is highly polyglutamylated 
(best known substrate of FPGS) (Shih et al., 1997; Taylor et al., 1992) and is very sensitive to the 
cellular folate status (Taylor et al., 1992; Zhao et al., 2001b). The basis for this latter finding 
involves the inhibitory effects of physiological folates in cells on the polyglutamylation of 
antifolates at the level of FPGS (Andreassi and Moran, 2002) and at the level of drug binding 
their target enzymes. Recently, it was discovered by Moran and colleagues that AICARFTase 
inhibition by PMX causes a marked accumulation of the purine synthesis intermediate 5-amino-
4-imidazolecarboxamide ribotide (ZMP) (Racanelli et al., 2009). ZMP is an AMP mimetic that is 
an activator of AMP-activated protein kinase (AMPK). Activation of AMPK causes 
phosphorylation of AMPK target proteins involved in initiation of cap-dependent translation, 
lipid synthesis and energy metabolism. Two such proteins are the tuberous sclerosis complex 2 
(TSC2) and raptor (component of mTORC1 complex). AMPK phosphorylation in response to 
PMX exposure and ZMP accumulation leads to inhibition of mTOR signaling in colon and lung 
cancer cells (Racanelli et al., 2009; Rothbart et al., 2010). PMX was found to act synergistically 
with sorafenib (a multi-kinase inhibitor) to enhance tumor killing via the promotion of a toxic 
form of autophagy that leads to activation of the intrinsic apoptosis pathway (Bareford et al., 
2011). As mentioned in the introduction, PMX in combination with cisplatin has been approved 
for the treatment of malignant pleural mesothelioma (Hazarika et al., 2004) and NSCLC (Cohen 
et al., 2009). Other phase II clinical trials have been recently completed or are underway to test 
the efficacy of this compound in a wide range of malignancies (Adjei et al., 2010; 
Karapanagiotou et al., 2009; Katirtzoglou et al., 2010; Krug et al., 2009; Martin et al., 2009; 
Matulonis et al., 2008; Patel et al., 2009a; Patel et al., 2009b; Paz-Ares et al., 2010; Pippen et al., 
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2010; Simon et al., 2008). It will be interesting to determine why PMX has significant activity 
against lung carcinomas, which is unusual for an antifolate. 
1.5.4 Polyglutamylation of Antifolates.  
The above-mentioned antifolates with the exception of PT523 are substrates for 
polyglutamylation by FPGS.  Polyglutamation of antifolates leads to augmentation of 
pharmacological activity through their sustained inhibition of THF-dependent enzymes, 
reflecting increased affinities for target enzymes, and abilities to inhibit enzymes that are poorly 
inhibited by monoglutamate antifolate forms (Goldman and Zhao, 2002; Hughes et al., 1999; 
Mendelsohn, 1999).  For example, the crystal structure of GARFTase shows that the surface of 
the protein near the folate binding loop is either neutral or positively charged and, therefore, 
would provide a suitable surface for interaction with a polyglutamate tail. This may explain the 
increased affinity of polyglutamylated drugs such as LMX for GARFTase (Dahms et al., 2005; 
Zhang et al., 2002).  Similar explanations have been provided for other antifolates and 
intracellular targets such as TS (Allegra et al., 1985).  However, inhibition of DHFR by MTX is 
not in itself enhanced by polyglutamylation (Goldman and Matherly, 1985; Matherly et al., 
1987b).  Another important consequence of polyglutamylation involves sustained inhibition of 
intracellular targets since long chain polyglutamates of antifolates are poor substrates for influx 
or efflux transporters.  Therefore, antifolates are retained by cells at high concentrations even 
after extracellular drug levels have been reduced due to clearance (Goldman and Matherly, 1985; 
Matherly et al., 1987b).  It is interesting to note that polyglutamylation is important for 
selectivity of antifolates for tumor cells.  Polyglutamates of MTX have been reported to 
accumulate more in tumor cells than in the bone marrow or intestinal cells, such that the 
metabolic effects of antifolates in normal cells tend to be relatively transient (Fry et al., 1983; 
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Koizumi et al., 1985).  Yet, the effect on normal tissues such as myelosuppression and mucositis 
is still the dose-limiting factor in antifolate treatment. 
1.5.5 Transport as a Determinant of Selectivity and Resistance.  
Transport of antifolates by RFC, PCFT and FR is a very important determinant of drug 
activity and tumor selectivity. Since RFC is ubiquitously expressed and functional at the neutral 
pH surrounding most normal tissues, transport of antifolates by RFC into proliferating normal 
tissues is thought to be the cause of many drug-induced toxicities. The specificities of antifolates 
differ for the various folate uptake mechanisms. RFC can transport all the classic antifolates 
including MTX, AMT, PDX, RTX, LMX, and PMX with high affinities (Figure 1.2) (Matherly 
et al., 2007).  MTX can be transported by PCFT, albeit to a lower extent than RFC (Zhao et al., 
2008).  PMX has a higher affinity for PCFT than RFC at low pH and is the best known substrate 
for PCFT yet described (Zhao and Goldman, 2007). PT523 is not a transport substrate for PCFT 
(Figure 1.2) (Zhao and Goldman, 2007). As mentioned in this section, it has been observed that 
the same or better growth inhibition could be obtained from an analog that had reduced affinity 
for its enzyme target but had greater substrate affinity and therefore uptake by RFC. Examples 
include PDX compared with AMT, and RTX compared with CB3717. This highlights the 
importance of concentrative antifolate uptake to provide sufficient (unbound) intracellular drug 
to sustain maximal inhibition of enzyme targets and for the synthesis of polyglutamates. The 
significance of transport-mediated uptake can also be demonstrated in cases of antifolate 
resistance where loss of RFC expression causes cells to become resistant to antifolates that 
depend on RFC for cellular uptake (Assaraf, 2007; Matherly et al., 2007; Zhao and Goldman, 
2003).  
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Impaired RFC function is an important mechanism of resistance to MTX (Hill et al., 
1979; Niethammer and Jackson, 1975; Sirotnak et al., 1968; Sirotnak et al., 1981) and other 
antifolates in vitro, and it may be associated with clinical resistance to this agent in the treatment 
of ALL (Belkov et al., 1999; Gorlick et al., 1997; Levy et al., 2003; Zhang et al., 1998b), 
osteosarcoma (Guo et al., 1999; Ifergan et al., 2003; Yang et al., 2003) and colorectal cancer 
(Wettergren et al., 2005), as well as primary central nervous system lymphoma (Ferreri et al., 
2004). Impaired transport of antifolates into tumor cells in preclinical and clinical studies has 
been associated with quantitative and/or qualitative alterations in RFC expression and/or 
transport activity (Assaraf, 2007; Matherly et al., 2007; Zhao and Goldman, 2003). RFC function 
can be lost by methylation of a CpG island in the promoter between exons B and A (Worm et al., 
2001), genomic deletion (Chattopadhyay et al., 2006; Ding et al., 2001; Zhao et al., 2004c), 
single point mutations within the open reading frame, mutation of the ATG start codon, 
insertions and frameshifts, truncated proteins, deletions, mutations resulting in RFC instability, 
and loss of RFC alleles due to translocations (Assaraf, 2007; Ding et al., 2001; Matherly et al., 
2007; Rothem et al., 2002; Wong et al., 1999; Zhao and Goldman, 2003; Zhao et al., 1999). 
Treatment of a L1210 murine leukemia cell line with mutagen (ethylmethanesulfonate) followed 
by selection with MTX using 5-CHO-THF in the growth medium produced a spectrum of RFC 
mutations (Assaraf, 2007; Zhao and Goldman, 2003; Zhao et al., 1999). Two RFC point 
mutations (V104M and S46N) that led to MTX resistance but preserved PMX and LMX growth 
inhibition were identified. The first mutation, V104M in the third TMD of RFC had markedly 
impaired transport of MTX and 5-CHO-THF. Despite the fact that the cellular THF-cofactor 
pool was substantially decreased, growth was sustained, consistent with the low levels of folate 
required for normal growth (Zhao et al., 2000b). Cells with this mutation had collateral 
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sensitivity to LMX due to partial maintenance of LMX transport and contraction of the folate 
pools. A second mutation, S46N did not alter the influx Kt for MTX and the natural folates (Zhao 
et al., 1998). Rather, it produced a marked (40-fold) decrease in the Vmax for MTX but a lesser 
(~7–8-fold) decrease in the Vmax for 5-CHO-THF. Sensitivity to PMX was partially preserved 
even though the THF-cofactor pools were similar to cells with wild-type RFC (Zhao et al., 
2000a). The S46N mutation has also been identified in osteosarcoma patient samples from 
patients treated with MTX (Yang et al., 2003) and is therefore a clinically relevant mutation. 
Clinically, complete loss or functional alterations in RFC are rare since tumor cells need RFC-
mediated transport of reduced folates to maintain tumor growth; therefore most clinically 
occurring point mutations are similar to S46NN which have marked loss of carrier affinity and/or 
mobility towards MTX, while preserving THF cofactor transport. Similarly, reductions in RFC 
expression are observed; for example approximately 65% of osteosarcoma samples have 
decreased RFC expression at biopsy and 50% have reduced RFC expression in recurrent or 
metastatic disease (Guo et al., 1999). It has been shown that reduced RFC expression can be 
caused by CpG island promoter hypermethylation and transcriptional silencing due to loss of 
function of transcription factors that regulate the expression of RFC (Worm et al., 2001). 
In addition to impaired transport, antifolate resistance can arise from reduced 
polyglutamylation (Drake et al., 1996; Li et al., 1992; Liani et al., 2003; Mauritz et al., 2002; 
McCloskey et al., 1991; McGuire and Russell, 1998; Pizzorno et al., 1989; Pizzorno et al., 1988; 
Pizzorno et al., 1995; Zhao et al., 2000c), decreased affinity of the drug for its folate dependent 
intracellular target due to mutation (Albrecht et al., 1972; Flintoff and Essani, 1980; Goldie et al., 
1980; Haber et al., 1981; Jackson et al., 1976; McIvor and Simonsen, 1990; Melera et al., 1984; 
Melera et al., 1988; Miyachi et al., 1995; Srimatkandada et al., 1989), increased expression of the 
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enzyme target so that more drug is needed for the same level of inhibition (eg. DHFR (Alt et al., 
1978; Dolnick et al., 1979; Horns et al., 1984; Jackson and Harrap, 1973; Mini et al., 1985; 
Nunberg et al., 1978; Trent et al., 1984; White and Goldman, 1981) and TS (Drake et al., 1996; 
Freemantle et al., 1995; Jackman et al., 1995; Kitchens et al., 1999; O'Connor et al., 1992; 
Sigmond et al., 2003; Tong et al., 1998; Wang et al., 2001a)) and increased expression and 
function of high capacity efflux pumps, such as MRPs that remove the antifolate from cells 
(Assaraf, 2006). Many of the antifolates that came after AMT and MTX were designed in an 
effort to reduce toxicity observed clinically, increase tumor selectivity and to circumvent some of 
the antifolate resistance mechanisms. This dissertation will highlight drug discovery efforts to 
find novel antifolates that are selective for PCFT-mediated uptake and that inhibit GARFTase 
and de novo purine nucleotide synthesis as a way to avoid selectivity and resistance problems. 
These compounds will also be tested in cells that are MTX resistant due to RFC loss to 
determine the impact of RFC function on antifolates that depend on PCFT for uptake. 
1.6 Hijacking the Acidic Tumor Microenvironment for Solid Tumor Targeting. 
To maintain their rapid growth and proliferation, cancer cells have a higher need for 
energy and for biosynthesis of nucleotides than normal differentiated cells. This increased 
biosynthetic demand can be, in part, met by an altered metabolic program known as the Warburg 
effect or aerobic glycolysis in which cancer cells become highly glycolytic even in the presence 
of normal oxygen tension (Lunt and Vander Heiden, 2011). To avoid intracellular acidification, 
glycolytically-produced acid must be extruded from cells. This is achieved by increased 
expression and/or function of plasma membrane ion pumps and transporters such as H+-ATPases 
or vacuolar ATPases (Hinton et al., 2009; Martinez-Zaguilan et al., 1993; Sennoune et al., 2004), 
the Na+/H+ exchanger (NHE1) of the SLA9A family (Chiang et al., 2008; Kumar et al., 2009; 
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McLean et al., 2000; Miraglia et al., 2005), the monocarboxylate-H+ efflux symporter (MCT1 
and MCT4) of the SLC9A family (Chiche et al., 2012; Kennedy and Dewhirst, 2010; Pinheiro et 
al., 2008a; Pinheiro et al., 2008b; Pinheiro et al., 2010), and the carbonic anhydrases CAIX and 
CAXII (Chiche et al., 2009; Ilie et al., 2011; Loncaster et al., 2001; Swietach et al., 2009; 
Wykoff et al., 2000), the Cl-/HCO3- exchanger (CBE) (Alper, 2009) and Na+/HCO3-
cotransporter (NBC) (Boron et al., 2009). The increased activities of these transporters cause 
reversal of the normal intra-extracellular pH gradients, so that cancer cells produce significant 
acidification of the extracellular environment (acidic tumor microenvironment). Extracellular pH 
in tumor cells can be as low as ~6.7-7.1, while they maintain a normal or slightly alkaline 
intracellular pH of ≥7.4. This is in comparison to normal differentiated adult cells which 
maintain an intracellular pH of ~7.2 and an extracellular pH of ~7.4 (Busco et al., 2010; 
Gallagher et al., 2008; Gillies et al., 2002; Stuwe et al., 2007; Webb et al., 2011). Acidification 
of the tumor environment is exacerbated by limited removal of glycolytic waste products due to 
poor perfusion, which is affected by tumor size and abnormal vascularization (Webb et al., 
2011). The resultant H+- electrochemical gradient favors passive weak acid uptake by pH 
partition and, importantly, acts as a driving force for H+-coupled solute transport at the cancer 
cell plasma membrane. Additionally, the decrease in extracellular pH increases the affinity and 
broadens substrate specificity of pH-dependent transporters (Leuthold et al., 2009; Nozawa et al., 
2004; Qiu et al., 2006; Rubio-Aliaga et al., 2003). 
The targeted drug strategy that uses selective uptake of therapeutics into the tumor cell by 
H+-coupled transporters is novel but not unprecedented (Anderson and Thwaites, 2010). 
Aberrant H+-coupled di/tripeptide (PepT1 and PepT2) transport has been characterized in tumor 
cells and overexpression may be useful for targeting a number of experimental and clinical 
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anticancer substrates to tumor cells, including the photodynamic therapy and imaging agent 5-
aminolevulinic acid (Anderson et al., 2010) and the aminopeptidase inhibitor bestatin (Nakanishi 
et al., 2000). Prodrugs of floxuridine and cytarabine may also be transported by PepT1 (Sun et 
al., 2009). Additionally, the H+-coupled amino acid transporter PAT1 and the pH dependent 
OATPs could also be used for mediating uptake of anti-cancer drugs. PAT1 can also transport 5-
aminolevulinic acid (Anderson et al., 2010) and L-cycloserine (Anderson et al., 2004). 
Prominent low-pH transport activities have been observed for several organic anion transporting 
polypeptides (OATPs) (Leuthold et al., 2009); of these, only OATP1A2 is known to have MTX 
transport activity at low pH (Badagnani et al., 2006). Recently, OATP2B1 has been established 
as a low-affinity, but highly selective, low pH antifolate transporter demonstrating the critical 
role that pH, substrate, and substrate concentration can play in identifying the spectrum of 
activities of a transporter (Visentin et al., 2012).  
This dissertation will focus on PCFT-mediated uptake of novel antifolates into the tumor 
cell by harnessing the proton gradient that exists in the tumor microenvironment as a therapeutic 
strategy. 
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CHAPTER 2 
 
THE HUMAN PROTON-COUPLED FOLATE TRANSPORTER IS EXPRESSED AND 
FUNCTIONAL IN HUMAN SOLID TUMORS 
 
2.1 Introduction.  
The anionic nature of folates and antifolates precludes their diffusion across biological 
membranes. Therefore, three genetically distinct and functionally diverse transport systems are 
in place to facilitate uptake of these molecules into the cells of peripheral tissues. Two 
facilitative transporters, RFC and the newly discovered PCFT and two FR isoforms (α and β) 
mediate this uptake.  
RFC is ubiquitously expressed in both normal and tumor tissues, with characteristic patterns 
of localization in intestine, hepatocytes, renal epithelial cells and choroid plexus, which suggest 
specialized roles in these tissues for folate homeostasis (Matherly and Goldman, 2003; Matherly 
et al., 2007; Zhao et al., 2009a). Indeed, given its widespread tissue expression, RFC is 
considered the major transport system for folates in mammalian cells and tissues. 
FRα is predominantly expressed on the apical (luminal) surface of polarized epithelial 
cells where it is not in contact with circulating folate (Chancy et al., 2000). FRα is expressed in 
epithelial cells of the kidney, choroid plexus, retina, uterus, and placenta (Elnakat and Ratnam, 
2004).  Malignant tissue expression includes malignant pleural mesothelioma (Bueno et al., 
2001) and adenocarcinomas of the cervix, uterus, and ovary (Elnakat and Ratnam, 2004). 
Importantly, FRα is overexpressed in up to 90% of ovarian cancers (Toffoli et al., 1997; Wu et 
al., 1999). Close associations were reported between FRα expression levels with grade and 
differentiation status of ovarian tumors (Buist et al., 1995; Garin-Chesa et al., 1993; Veggian et 
al., 1989; Wu et al., 1999). FRβ is expressed in the thymus, spleen, placenta, and CD34+ human 
hematopoietic cells and is needed for normal myelopoiesis (Pan et al., 2002; Reddy et al., 1999). 
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Both acute and chronic myelogenous leukemias express FRβ (Kamen and Smith, 2004; Salazar 
and Ratnam, 2007).  
Human PCFT transcripts were reported to be highly expressed along the proximal 
jejunum, duodenum, kidney, liver, placenta, spleen and choroid plexus and, to a lesser extent, in 
the brain, testis and lung (Inoue et al., 2008; Qiu et al., 2006). Mouse PCFT transcripts were 
highly expressed in the duodenum, proximal jejunum, kidney, liver and to a lesser extent in the 
brain, skin, lung, stomach, and testis. Mouse PCFT protein was found on the apical brush-border 
membrane of the proximal jejunum and duodenum (Qiu et al., 2007). Direct evidence that this 
transporter is responsible for low-pH transport and intestinal folate absorption came from the 
discovery that homozygous mutations in the coding region of the PCFT gene leads to the rare 
autosomal recessive disorder HFM (Atabay et al., 2010; Borzutzky et al., 2009; Geller et al., 
2002; Lasry et al., 2008; Mahadeo et al., 2010; Mahadeo et al., 2011; Meyer et al., 2010; Min et 
al., 2008; Qiu et al., 2006; Shin et al., 2011; Shin et al., 2010; Zhao et al., 2007). Loss of PCFT 
function leads to impaired intestinal folate absorption, resulting in severe folate deficiency, and 
impaired transport of folates across the choroid plexus into the central nervous system. 
Importantly this establishes the critical physiological functions of PCFT folate transport (Zhao et 
al., 2009a).  
The discovery of PCFT may provide a novel transport route for antifolates into tumor 
cells. The ability of PCFT to utilize a proton gradient across the cell membrane to transport 
antifolates intracellularly may provide a new mechanism for tumor targeting, based on the acidic 
tumor microenvironments of solid tumors. To determine whether this approach is plausible, the 
therapeutic potential of PCFT as a means of selectively delivering antifolates into the tumor cell 
must be established. The expression of PCFT and how it compares to RFC and FR expression in 
  
49
human malignancies is largely unestablished. In solid tumor cells, previous results have shown 
that MTX influx at pH 5.5 was equal to, or greater than, influx at pH 7.4 in 29 of 32 cell lines, 
including cell lines from the NCI60 cell line panel (Zhao et al., 2004b). However, it has yet to be 
established what the levels of PCFT are in these and other clinically relevant solid tumor cell 
lines. Further patterns of PCFT expression in tumor specimens have not been previously 
established. This chapter will focus on determining the level of PCFT expression in a wide range 
of solid tumor and leukemia cell lines. The expression of PCFT will be compared in tumor and 
normal tissues at the RNA, protein, and functional levels. Patterns of PCFT expression in both 
normal and tumor tissue will be compared to those for RFC and FR.  
The findings presented in this chapter indeed establish that PCFT is expressed and 
functional in solid tumors and has restricted expression in normal tissues. Thus, PCFT could be 
used in conjunction with the acidic tumor microenvironment to efficiently deliver cytotoxic 
antifolates into the tumor cell. 
2.2 Materials and Methods. 
2.2.1 Chemicals and Reagents.  
  [3’,5’,7-3H]MTX (20 Ci/mmol) was purchased from Moravek Biochemicals (Brea, CA). 
Both labeled and unlabeled MTX were purified by HPLC prior to use (Fry et al., 1982). Other 
chemicals were obtained from commercial sources in the highest available purities. 
2.2.2 Cell Culture. 
The sources and cell culture conditions for the panel of human solid tumor and leukemia 
cell lines used for real-time RT-PCR assays of transcript levels for RFC and PCFT are 
summarized in Table 2.1. HeLa R1-11-RFC6 and R1-11-PCFT4 cells were derived from RFC- 
and PCFT-null R1-11 cells by stable transfection with HA-tagged pZeoSV2(+)-RFC and 
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pZeoSV2(+)-PCFT constructs, respectively (Zhao et al., 2008), and were gifts of Dr. I. David 
Goldman (Albert Einstein School of Medicine, Bronx, NY).  
2.2.3 Real-time RT-PCR Analysis of RFC and PCFT Transcripts. 
2.2.3.1 Origene cDNA Arrays of Tumor and Normal Tissue.   
To expand the transporter expression profiles in normal and malignant human tissues we 
measured the levels of PCFT and RFC transcripts in a wide range of human normal and tumor 
tissues. We used arrays of normalized cDNAs from either 48 pathologist-verified normal tissues 
(e.g., adrenal, small intestine, liver, lung, ovary, etc.; “Human Major Tissue qPCR Array”, 
Origene HMRT102) or 96 normalized cDNAs from pathologist-verified solid tumors and paired 
normal tissues (“TissueScan Oncology qPCR Array”, Origene CSRT101). Real-time RT-PCR 
was performed in a 384 well plate format on a Roche LightCycler 480 using Universal Probes 
(Roche, Indianapolis, IN) and gene-specific primers. Details are included in Table 2.1.  
Transcript levels for PCFT and RFC genes were normalized to those for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and transcripts were quantified using the delta Ct method.  
2.2.3.2 Solid tumor and Leukemia Cell Lines.   
RNAs were isolated from a large variety of human cell lines including solid tumors 
(n=57) and leukemias (n=27) (Table 2.2) using TRIzol reagent (Invitrogen).  cDNAs were 
synthesized using the Superscript reverse transcriptase III kit (Invitrogen)  and purified with the 
QIAquick PCR Purification Kit (Qiagen). PCFT, RFC and FRα transcript levels were measured 
by real-time RT-PCR, which was performed using Universal Probes (Roche, Indianapolis, IN) 
and gene-specific primers. Details are included in Table 2.1. Transcripts were normalized to 
GAPDH and quantified by constructing external standard curves for each gene of interest. 
Standard curves were made by using serial dilutions of linearized templates, prepared by  
  
51
 
  
52
Table 2.2 Leukemia and solid tumor cell lines used for real-time PCR. 
CELL LINE DISEASE ORIGIN SOURCE 
U937 AML Macrophage? ATCC 
CTS AML M1 Peripheral blood Fuse, A. 
Kasumi-1 AML M2 Peripheral blood ATCC 
HL60 AML M2 Peripheral blood ATCC 
MV4-11 AML M5 Peripheral blood ATCC 
THP-1 AML M5 Peripheral blood ATCC 
AML-193 AML M5 Peripheral blood ATCC 
KG-1 AML M6 Bone marrow ATCC 
KG-1a AML M6 Bone marrow ATCC 
K5621 CML Bone marrow ATCC 
CMS AML M7 Peripheral blood Fuse, A. 
MEG-01 CML Bone marrow ATCC 
CMK DS AML M7 Peripheral blood DSMZ 
CMY DS AML M7 Bone marrow Fuse, A. 
697 BP-ALL Bone marrow DSMZ 
Nalm6 BP-ALL Peripheral blood DSMZ 
Uoc B4 BP-ALL CSF Findley, H. 
REH BP-ALL Unknown ATCC 
CCRF-CEM1,2 T-cell ALL Peripheral blood ATCC 
MOLT41 T-cell ALL Peripheral blood DSMZ 
MOLT3 T-cell ALL Peripheral blood DSMZ 
HPB-ALL T-cell ALL Peripheral blood DSMZ 
TALL-1 T-cell ALL Bone marrow DSMZ 
DND 41 T-cell ALL Peripheral blood DSMZ 
ALL-SIL T-cell ALL Peripheral blood DSMZ 
Jurkat T-cell ALL Peripheral blood ATCC 
TE-85 Osteosarcoma Bone Peterson, W.D. 
HTB166 Ewing's sarcoma Bone ATCC 
MCF-71,2 Adenocarcinoma Breast ATCC 
MDA-MB2311,2 Adenocarcinoma Breast ATCC 
MDA-MB4351,2 Adenocarcinoma/Melanoma Breast/Skin? ATCC 
T-47D1 Ductal carcinoma Breast ATCC 
KB Adenocarcinoma Cervix ATCC 
HeLa2 Adenocarcinoma Cervix ATCC 
HCT-1161,2 Colorectal adenocarcinoma Colon ATCC 
SW-6201 Colorectal adenocarcinoma Colon ATCC 
HCT151,2 Colorectal adenocarcinoma Colon ATCC 
Caco-2 Colorectal adenocarcinoma Colon ATCC 
BCPC-3 Adenocarcinoma Pancreas ATCC 
UCVA-1 Adenocarcinoma Pancreas Peterson, W.D. 
786-O1,2 Renal cell adenocarcinoma Kidney ATCC 
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ACHN1,2 Renal cell adenocarcinoma Kidney ATCC 
IGROV-11 Adenocarcinoma Ovary Ratnam, M. 
OVCAR-31,2 Adenocarcinoma Ovary ATCC 
SKOV-31 Adenocarcinoma Ovary ATCC 
HepG22 Hepatocellular carcinoma Liver ATCC 
Hep3B2 Hepatocellular carcinoma Liver ATCC 
Y79 Retinoblastoma Eye, retina ATCC 
SK-MEL51,2 Melanoma Skin ATCC 
SK-MEL-281 Melanoma Skin ATCC 
HTB139 Rabdomyosarcoma Muscle Peterson, W.D. 
SK-N-SH Neuroblastoma Brain ATCC 
SK-N-BE Neuroblastoma Brain ATCC 
SK-N-MC Neuroepithelioma Supraorbital area ATCC 
HT1080 Fibrosarcoma Connective tissue ATCC 
PC-31,2 Adenocarcinoma Prostate ATCC 
DU-1451,2 Carcinoma Prostate ATCC 
H1650 Bronchoalveolar 
adenocarcinoma lung ATCC 
H2122 Adenocarcinoma/NSCLC lung ATCC 
H2030 Adenocarcinoma/NSCLC lung ATCC 
H1573 Adenocarcinoma lung ATCC 
H1781 Bronchoalveolar 
adenocarcinoma lung ATCC 
H3255 Adenocarcinoma/NSCLC lung Gazdar, A.F. 
A5491 Carcinoma lung ATCC 
CRL5807 Bronchioalveolar carcinoma /NSCLC lung 
 
ATCC 
CRL5872 Adenocarcinoma/NSCLC lung ATCC 
CRL58101,2 Adenocarcinoma/NSCLC lung ATCC 
CRL58001,2 Adenocarcinoma/NSCLC lung ATCC 
H596 Adenosquamous carcinoma Lung ATCC 
NCI-H4601,2 Large-cell carcinoma Lung ATCC 
H69 SCLC Lung ATCC 
H446 SCLC Lung ATCC 
H2261 Pleural mesothelioma Pleura ATCC 
H2373 Pleural mesothelioma Pleura Pass, H.I. 
H2452 Pleural mesothelioma Pleura Pass, H.I. 
H2461 Pleural mesothelioma Pleura Pass, H.I. 
H2591 Pleural mesothelioma Pleura Pass, H.I. 
H2595 Pleural mesothelioma Pleura Pass, H.I. 
H2714/HP-1 Pleural mesothelioma Effusion Pass, H.I. 
1 – Cell lines of NCI60 cell line panel 
2 – Cell lines used in the report of (Zhao et al., 2004b)  
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amplification from suitable cDNA templates, subcloned into a TA-cloning vector (PCR-Topo; 
Invitrogen), and restriction digested. 
2.2.4 Determination of PCFT Protein Expression Levels. 
To determine whether transcript levels correlate with increased protein levels, PCFT and 
RFC protein levels in solid tumor cell lines and tissues were measured.  Our laboratory has made 
human PCFT and RFC-specific (Hou et al., 2011; Wong et al., 1998; Wong et al., 1999) 
polyclonal antibodies specific for a carboxyl-termini PCFT peptide (CKADPHLEFQQFPQSP) 
or RFC (PEDSLGAVGPASLEQRQS) peptide.  For PCFT, polyclonal antibody services at 
Invitrogen injected the peptide into rabbits with a hapten-conjugated carrier, after which they 
collected the bleeds and tested antibody specificity by ELISA.  The serum was purified using a 
peptide affinity column synthesized from Affi-Gel 10 (BioRad, Richmond, CA) and the specific 
peptide, using pH 2.5 sodium citrate to elute the antibody.  Specificity was validated by peptide 
competition in both western blot and immunohistochemistry experiments.   
2.2.4.1 Western Blot Analysis of Solid Tumor Cell Lines.   
  For characterizing PCFT protein expression in solid tumor cell lines, sucrose-enriched 
plasma membranes were prepared by differential centrifugation. Briefly, cells were suspended in 
10 mM Tris-HCl, pH 7.0, containing X1 protease inhibitor cocktail tablets (Roche, Indianapolis, 
IN), and disrupted with a Parr nitrogen cavitator (500 psi, 20 min).  The homogenate was spun at 
600 x g to remove cell debris and nuclei; the supernatant was centrifuged at 200,000 x g in a 
Beckman 70Ti rotor for 90 min.  The membrane pellet was suspended in 600 µL of 10 mM Tris-
HCl, pH 7.0, containing the protease inhibitor cocktail, and layered on a discontinuous sucrose 
gradient (2 mL 60% and 2.5 mL 20% sucrose in a SW55Ti rotor).  Centrifugation was for l h at 
58,000 x g.  The 20%-60% interface containing plasma membranes was removed, diluted 
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approximately 10-fold with 10 mM Tris-HCl pH 7.0 (containing proteolytic inhibitors), and 
again centrifuged at 200,000 x g for 60 min to pellet the membranes (Matherly et al., 1991). 
Proteins were quantified with Folin-phenol reagent (Lowry et al., 1951). Membrane proteins 
were electrophoresed on 7.5% polyacrylamide gels in the presence of SDS (Laemmli, 1970) and 
electroblotted onto polyvinylidene difluoride membranes (PVDF) (Pierce, Rockford, IL) 
(Matsudaira, 1987). Immunoreactive PCFT and RFC were detected on membranes with the 
PCFT or RFC-specific polyclonal antibodies described above. An IRDye800CW-conjugated 
goat anti-rabbit IgG (Rockland, Gilbertsville, PA) was used as a secondary antibody, and the 
membranes were scanned with the Odyssey® Imaging System. Densitometry used Odyssey 
software (v 1.2) for quantitating levels of PCFT protein. PCFT levels were normalized to Na+/K+ 
ATPase protein levels (mouse antibody from Novus Biologicals, Littleton, CO) on Westerns.  
2.2.4.2 Immunohistochemistry of Tumor and Normal Tissue Panels.   
  PCFT and RFC-specific peptide antibodies were used with immunohistochemistry to 
profile tissue/cellular distributions and transporter levels in commercially available paraffin 
tissue panels (US Biomax) of normal (FDA995) and malignant tissues (BCN961) from ovary, 
breast, prostate, liver, etc. Specificity was established with normal IgG and (as warranted) the 
addition of blocking peptide to the antibody mix. Panels included malignant tissues from a wide 
range of tumor types and normal tissue types including some samples with established 
expression of PCFT such as the duodenum, kidney, and liver.  Immunohistochemistry was 
performed in collaboration with Mr. Larry Tait from the Karmanos Cancer Institute Imaging 
Core Facility.  
2.2.5 Transport of [3H]MTX in Solid Tumor Cell Lines.   
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  To determine the function of PCFT and RFC in the solid tumor cell lines, transport of 0.5 
µM [3H]MTX was assayed in cell monolayers over 5 min at 37°C in 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES)-buffered saline (20 mM HEPES, 140 mM NaCl, 5 mM 
KCl, 2 mM MgCl2, and 5 mM glucose) at pH 7.2 to determine RFC-mediated transport, or in 4-
morphilinopropane sulfonic (MES)-buffered saline  (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 
mM MgCl2, and 5 mM glucose) at pH 5.5 for determining transport by PCFT (Zhao et al., 
2004b).  Some transport experiments were performed in the presence of 20 nM folic acid to rule 
out uptake by the folate receptor. At the end of the incubations, transport was quenched with ice-
cold Dulbecco’s phosphate-buffered saline (DPBS), cells were washed 3 times with ice-cold 
DPBS, and cellular proteins were solubilized with 0.5 N NaOH. Levels of drug uptake were 
expressed as pmol/mg protein, calculated from direct measurements of radioactivity and protein 
contents of cell homogenates. Radioactivity was measured with a scintillation counter (Model 
LS6500; Beckman-Coulter, Fullerton, CA) and proteins were quantified using Folin-phenol 
reagent (Lowry et al., 1951). MTX was frequently used to characterize RFC and PCFT-mediated 
transport because it is commercially available, it is not metabolized over short intervals, and 
because of the ease and accuracy of influx determinations and distinguishing between free and 
tightly bound drugs within cells. 
2.3 Results 
2.3.1 Expression of RFC and PCFT in Human Normal and Tumor Tissue.  
In order to determine the potential of targeting PCFT for drug uptake it was important to 
establish the expression of PCFT at both the transcript and protein levels in human normal and 
tumor tissues. For normal tissues, transcript levels for RFC and PCFT were measured by  real-
time RT-PCR of normalized Origene cDNA arrays from 48 pathologist-verified normal human 
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tissues. PCFT is expressed in most normal tissues, albeit at low levels. We measured high levels 
of PCFT mRNA in highly metabolic tissues such as the duodenum, kidney, liver, and the adrenal 
and pituitary glands (Figure 2.1, Panel A). This corroborated expression patterns observed in 
mouse tissues (Qiu et al., 2006). For RFC, expression was ubiquitous with the highest levels in 
tissues of the liver, lung, placenta, ovary and retina, and low in the heart and muscle. These 
findings were similar to mRNA expression patterns described by Whetstine et al. (2002a) in 
human tissues measured by northern blotting. The levels of PCFT at the transcript level were 
validated by immunohistochemical detection of PCFT protein using US Biomax tissue arrays of 
FDA approved human normal tissue and a polyclonal PCFT antibody. As demonstrated by real-
time RT-PCR, the levels of PCFT protein were high in the duodenum (Figure 2.1, Panel B) and 
kidney (Figure 2.1, Panel C). Staining was specific since the signal could be competed out with a 
PCFT-specific peptide (data not shown) or when the secondary antibody was not included (data 
not shown). Overall, PCFT transcript and protein expression is more limited than RFC 
expression in normal tissues. For tumor tissues, RFC and PCFT transcripts were measured by 
real-time RT-PCR of normalized Origene cDNA arrays from multiple human primary tumors. 
Significant, albeit variable levels of PCFT transcripts were detected in all tumors tested. The 
expression pattern of PCFT in tumor tissue was similar to levels found in normal tissue, with 
liver tumors showing the highest levels (Figure 2.2, Panel A).  Expression of RFC was high in 
the liver and lung, similar to the normal tissue expression pattern. Interestingly, the level of RFC 
was higher in both breast and colon tumors compared to normal tissue (Figure 2.2, Panel B). The 
continued clinical use of classical antifolates, which are substrates for RFC-mediated uptake, 
including MTX in breast cancer and RTX in colon cancer, may reflect the tumor-specific 
expression of RFC in these tissues. Patterns of transporter expression in primary tumors were 
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Figure 2.1 PCFT and RFC expression in human normal tissues. PCFT (Panel A) and RFC 
(Panel D) transcripts were measured using an Origene cDNA array of 48 pathologist-verified 
human normal tissue by real-time RT-PCR from total RNAs using a Roche480 Light-cycler and 
gene specific Universal probes and primers (Table 2.1). Transcript levels were normalized to 
GAPDH transcripts. Immunohistochemistry of US Biomax tissue arrays of human small intestine 
(Panel B) and kidney (Panel C) normal tissues stained with a polyclonal PCFT antibody. 
Experimental details are provided in the Materials and Methods. 
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Figure 2.2 PCFT and RFC expression in human normal and tumor tissues. PCFT (Panel A) 
and RFC (Panel B) transcripts were measured in an Origene cDNA array of pathologist-verified, 
breast, colon, kidney, liver, lung, ovary, prostate and thyroid human tumor tissue (n=6) cDNAs 
compared to paired normal tissues from the same patient (n=3) by real-time RT-PCR from total 
RNAs using a Roche480 Light-cycler and gene specific Universal probes and primers (Table 
2.1). Transcript levels were normalized to β-actin transcripts. Immunohistochemistry of US 
Biomax tissue arrays of human ovarian (Panel C) and liver (Panel D) tumors stained with a 
polyclonal PCFT antibody. Panel E, the ratio of PCFT to RFC transcript levels. Experimental 
details are provided in the Materials and Methods. 
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confirmed by immunohistochemistry of tissue arrays probed with transporter-specific antibodies. 
Tissue arrays contained multiple cancer and adjacent tissues, single core per case, 16 types of 
common organs and were pathologically confirmed (bladder, brain, breast, colon, esophagus, 
kidney, liver, lung, lymph node, ovary, pancreas, prostate, rectum, skin, stomach and uterine 
cervix). Similar to real-time RT-PCR, the levels of PCFT protein were high in the ovarian and 
liver tumors (Figure 2.2, Panel C and D; respectively) compared to IgG control (data not shown), 
again reflecting PCFT transcript levels obtained from real-time RT-PCR. For the most part, 
PCFT levels are similar in both normal and tumor tissues at both the transcript and protein level.  
The ratios of PCFT to RFC transcript expression in human normal and tumor tissues were 
determined. Thyroid, ovarian and liver tumors had higher tumor PCFT/RFC ratios compared to 
normal tissues (Figure 2.2, Panel E). The ratio of PCFT to RFC expression and function may 
represent a more important indicator of which tumor types will benefit from PCFT-selective 
antifolates. Functional RFC could transport reduced folates into the cell which would compete 
with the antifolate for binding to folate-dependent enzymes, thereby reducing the cytotoxicity of 
antifolates that depend on PCFT for cellular uptake (see Chapter 5).   
2.3.2 Expression and Function of RFC and PCFT in Human Solid Tumor and Leukemia 
Cell Lines.  
Following reports of a low pH transport activity in solid tumor cells lines and to find a 
solid tumor cell line model for our PCFT-targeted therapeutics, we turned our attention to 
establishing an expression profile for PCFT compared to RFC and FRs in a number of cell lines 
derived from human solid tumors and leukemias (Table 2.2). Transcript levels for PCFT along 
with RFC and FRs α and β were measured by real-time RT-PCR and normalized to levels of 
GAPDH. Our results demonstrated significant levels of PCFT transcripts in the majority of 
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human solid tumor cell lines of different origins (e.g., breast, prostate, ovarian, etc.) (Figure 2.3, 
Panel A), and uniformly low PCFT transcript levels in human leukemias, including both ALL 
and AML (Figure 2.3, Panel C). PCFT levels were highest in Caco-2 (colorectal) SKOV3 
(ovarian), HepG2 (hepatoma), HeLa (cervical), and T47D (breast) cancer cells. RFC transcripts 
were detected in all leukemia and solid tumor cell lines with the exception of MDA-MB-231 
breast cancer cells (reported to express very low RFC (Worm et al., 2001)) (Figure 2.3, Panel B 
and D). High levels of FRα were detected in a small subset of ovarian, cervical, and breast 
cancer cell lines and modest FRα levels were measured in ALL (mostly T-cell) sublines (data not 
shown). FRβ transcripts were consistently low-to-undetectable in both solid tumors and 
leukemias, with the highest levels restricted to a small number of AML and T-cell ALLs (data 
not shown). The levels of human PCFT, RFC and FR transcripts in solid tumor and leukemia cell 
lines were published (Kugel Desmoulin et al., 2011).  Real-time RT-PCR was repeated with 
SYBR green and gene-specific primers (Table 2.1), (experimental details are the same as in 
section 5.2.6) and identical results were obtained. 
The level of PCFT and RFC protein expression was validated for ten solid tumor cell 
lines (HepG2, Hep3B, H596, CRL5810, H2595, HCT15, Caco-2, DU145, MDA-MB 321, SK-
MEL5) and four control HeLa cell lines (R1-11-mock (no functional PCFT or RFC), R1-11-
PCFT4 (R1-11-mock stably transfected with PCFT), HeLa (functional PCFT and RFC), R5 
(HeLa cells that express PCFT but not RFC)) by isolating membrane fractions through 
differential centrifugation and sucrose gradients, followed by immunoblotting with PCFT and 
RFC-specific polyclonal antibodies. Relative PCFT and RFC protein levels paralleled levels of 
PCFT (Figure 2.4, Panel A) and RFC (Figure 2.4, Panel B) transcripts, as detected by real-time 
RT-PCR. There were some differences in protein sizes, which likely reflect post-translational  
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Figure 2.3 PCFT and RFC transcript expression in human solid tumor and leukemia cell 
lines. PCFT (Panel A and C) and RFC (Panel B and D) transcripts were measured in 53 human 
solid tumor (Panels A and B) and 27 leukemia (Panels C and D) cell lines by real-time RT-PCR 
from total RNAs using a Roche480 Light-cycler and gene specific Universal probes and primers 
(Table 2.1). Transcript levels were normalized to GAPDH transcripts. Experimental details are 
provided in the Materials and Methods. A table summarizing the characteristics of the 53 tumor 
and 27 leukemia cell lines is also included in Table 2.2. 
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Figure 2.4 PCFT and RFC protein expression in human solid tumor cell lines. PCFT (Panel 
A) and RFC (Panel B). Pure membrane fractions were isolated using a Parr nitrogen cavitator at 
500 psi for 20 min, differential centrifugation and sucrose gradients. Membrane proteins (25 µg) 
were electrophoresed on 7.5% denaturing polyacrylamide gels and immunoblotted with 
polyclonal PCFT and RFC antibodies. Na+/K+ ATPase protein levels were used as loading 
controls. The characteristics of the 14 tumor cell lines are included in Table 2.2. Non-specific 
(NS) band. 
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modifications (e.g., glycosylation (Unal et al., 2008; Wong et al., 1998)). Finally, functional 
validation of transporter expression in solid tumor cell lines was determined by transport of 
[3H]MTX (Figure 2.5) at pH 5.5 for PCFT (Panel A), and at pH 7.2 for RFC ( Panel B). Relative 
uptake of [3H]MTX somewhat paralleled transcript and protein levels for PCFT. More modest 
levels of transport were detected at pH 7.2, although the correlation with RFC protein was 
inexact. The reason for this is unclear. pH 5.5 (PCFT) to pH 7.2 (RFC) transport ratios ranged 
from ~2- to ~9-fold (Figure 2.5, Panel C), demonstrating broad spectrum and high-level PCFT to 
RFC membrane transport in clinically relevant human tumor cell lines, as previously reported 
(Zhao et al., 2004b). 
2.4 Discussion 
Our findings have established the expression patterns and pH-specific transport for PCFT 
in human solid tumor cell lines, primary tumors and normal tissues. We found that expression of 
PCFT transcripts and protein in normal tissues is more limited than for the ubiquitously 
expressed RFC, with high levels in the liver, kidney, and small intestine. In addition, a wide 
range of human solid tumor tissues and cell lines expressed PCFT transcripts and protein, and 
PCFT expression generally correlated with pH-dependent transport function. Goldman and 
colleagues measured low pH transport of MTX into human tumor cell lines (Zhao et al., 2004b). 
Our comprehensive analysis of PCFT expression and function identified PCFT as the low pH 
folate transporter responsible of MTX uptake at acid pH in solid tumor cell lines. While RFC 
protein was likewise detected in most of the tumor cell lines, transport was only modestly 
reflected in levels of RFC protein, suggesting the existence of previously unrecognized 
posttranslational regulatory mechanisms for RFC and/or an unknown non-RFC transport process 
at neutral pH. Finally, we have found the expression of PCFT to be very low in the bone marrow,  
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Figure 2.5 PCFT and RFC function in human solid tumor cell lines. Uptake of 0.5 µM 
[3H]MTX was measured at 37˚C for 5 min in cell monolayers at pH 5.5 (MES-buffered saline) 
(Panel A) or pH 7.2 (HEPES-buffered saline) (Panel B), and internalized [3H]drug was 
normalized to total protein. Panel C, the ratio of [3H]MTX uptake at pH 5.5 / pH 7.2 in WT and 
R5 HeLa cells. A table summarizing the characteristics of the 14 tumor cell lines is included in 
Table 2.2. 
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which would suggest that PCFT-targeted therapeutics may be less marrow toxic compared to 
antifolates presently in clinical use that rely on RFC-mediated uptake at neutral pH. It will be 
important to test normal hematopoietic stem cells to assess the impact of PCFT-selective analogs 
on this cell fraction. 
The importance of PCFT expression in normal tissues to the development of drug 
toxicities will depend on transport function of PCFT in these tissues. Even though PCFT-
mediated transport is maximal at low pH, transport is also detected at pH 7.4 in human cells and 
Xenopus oocytes that express PCFT. This residual PCFT function at pH 7.4 is thought to be 
driven by increases in membrane potential. Whether the level of PCFT-mediated transport at pH 
7.4 in normal tissues is sufficient to cause dose-limiting toxicity of antifolates selective for PCFT 
mediated uptake remains to be determined. Additionally, there are instances of a localized acidic 
environment created by Na+/H+ exchangers at the basolateral membranes of the choroid plexus 
(Segal, 2000) and hepatocyte (Horne, 1993) which may contribute to uptake and toxicity in 
normal tissues generally thought to be at neutral extracellular pH.  
PCFT expression is not static, as it has been found to be modulated by promoter 
methylation, vitamin D3 and the NRF-1 transcription factor. Hypermethylation of the PCFT 
promoter was shown to be associated with low PCFT protein expression in CCRF-CEM and 
Jurkat T-cell leukemia cell lines (Gonen et al., 2008) and a MTX-resistant HeLa cell line (R1) 
(Diop-Bove et al., 2009) and could represent a mechanism of resistance against drugs that use 
PCFT as their primary means of cellular entry. Nutritional status could also affect PCFT 
expression, as VDR heterodimerizes with RXRα in response to vitamin D3 and binds a VDR 
response element in the PCFT promoter region (-1694/-1680), increasing expression of PCFT 
(Eloranta et al., 2009).  Interestingly, mouse PCFT transcript levels increased ~13-fold in the 
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proximal small intestine in mice fed folate-deficient versus folate-replete diets, consistent with 
the critical role that PCFT plays in intestinal folate absorption (Qiu et al., 2007). Interestingly, 
PCFT mRNA expression directly correlated with NRF-1 transcript levels in these tissues and 
was dependent on folate status (C. Cherian, unpublished observation), reaffirming the likely 
importance of NRF-1 in PCFT transcriptional control (Gonen and Assaraf, 2010). Thus, dietary 
increases or decreases in folate and vitamin D3 levels could affect expression of PCFT in normal 
tissues and could impact antifolate toxicity. The extracellular pH surrounding a cell may also 
have an effect on PCFT expression. For instance, treatment of patients with proton pump 
inhibitors, which increase extracellular pH, leads to decreased PCFT expression and folate 
deficiency due to reduced folate uptake from the gut (Urquhart et al., 2010). Of course, 
transcriptional control is most likely not the only mechanism of PCFT regulation. PCFT protein 
expression may also be stimulus controlled, such that decreased extracellular folate or decreased 
extracellular pH may induce cycling of PCFT from intracellular compartments to the cell surface 
in order to facilitate folate uptake. Indeed, PCFT protein has not only been found on the cell 
surface but also in intracellular compartments (Kugel Desmoulin et al., 2010b; Qiu et al., 2006), 
and PCFT has been proposed to aid in the exit of (anti)folate from acidic endosomes (Zhao et al., 
2009b). It may be possible that the presence of intracellular PCFT may have particular regulatory 
significance.     
This chapter has established PCFT expression in many solid tumor cell lines, but whether 
the level of expression and function is enough to transport a cytotoxic dose of antifolates that use 
this mechanism is still unknown. There is some indication that PCFT may facilitate PMX uptake 
and cytotoxicity toward solid tumor cell lines that express moderate levels of PCFT. PMX is a 
transport substrate for both RFC and PCFT-mediated uptake and is the best known substrate for 
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PCFT (Zhao and Goldman, 2007). Upon loss of RFC expression, when PCFT was the sole 
mechanism of PMX transport, uptake by PCFT was sufficient to maintain PMX cytotoxicity 
(Chattopadhyay et al., 2006; Zhao et al., 2004c) (See Chapter 5). Uptake of cytotoxic antifolates 
by RFC not only precludes selectivity, since RFC, as shown in this chapter as well as by 
Whetstine et al. (2002a) is expressed and functional in human normal tissues. However, its 
ability to transport antifolates into tumor cells may be compromised due to reduced transport 
activity at acidic pHs characterizing the tumor microenvironment. This suggests that designing 
drugs with greater affinity for PCFT and not the RFC has the potential to increase tumor 
selectivity without loss of drug activity (Kugel Desmoulin et al., 2011; Kugel Desmoulin et al., 
2010b; Wang et al., 2010; Wang et al., 2011) (see Chapters 3 and 4). Due to the low activity of 
RFC at acidic pHs, tumor cells may favor overexpression of H+-coupled transporters, such as 
PCFT, in order to transport folates to meet their nutritional and metabolic requirements and to 
gain a competitive advantage in the acidic tumor microenvironment (Anderson and Thwaites, 
2010). Hence, PCFT expression and function may increase in more advanced aggressive tumors, 
suggesting that antifolates selectively transported into tumor cells by PCFT would make better, 
more selective drugs that have the potential to improve therapy.  Future studies should look at 
expression of PCFT with increasing tumor stage or grade.  
To determine whether the therapeutic targeting of agents selective for PCFT uptake by 
utilizing tumor acidity to drive drug uptake will be successful, investigators will not only need to 
establish PCFT expression in tumors but also PCFT function. Further, the ability to measure 
tumor pH with accuracy, precision and high spatiotemporal resolution in experimental preclinical 
systems and in human beings will be very important for this therapeutic strategy (Zhang et al., 
2010). Recent advances in optical imaging, PET radiotracers, and magnetic resonance 
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spectroscopy (MRS) and magnetic resonance imaging (MRI) have improved the ability to 
measure tumor pH. Optical techniques such as fluorescence ratio imaging spectroscopy and 
fluorescent lifetime imaging can be used to measure tumor pH. These methods use fluorescent 
probes that have varied fluorescent properties depending on local pH, which can be measured 
optically and converted to a pH distribution map. Positron emission tomography (PET)-based 
approaches use pH-sensitive PET radiotracers including the pH (low) insertion peptide (pHLIP) 
conjugated to 64Cu (Vavere et al., 2009). pHLIP is a peptide that predominantly inserts across a 
lipid bilayer as a monomeric α-helix at an acidic extracellular environment but not at a normal 
physiological pH (Andreev et al., 2007; Fendos and Engelman, 2012). MRS methods are 
generally based on a difference in chemical shifts between pH-dependent and independent 
resonances; several isotopes have been evaluated for determination of tumor pH, such as 31P-
MRS and 1H-MRS with some success. There are still some limitations in spatial and temporal 
resolution (Gillies and Morse, 2005). Hyperpolarized 13C bicarbonate is a technique that uses 13C 
MRI and is based on transferring the polarization of unpaired electrons to neighboring nuclei by 
microwave irradiation of the sample (Hu et al., 2008). Finally, an alternative approach uses MRI 
and relies on agitating the relaxivity of water with pH-dependent relaxation agents (Aime et al., 
1999; Garcia-Martin et al., 2006; Zhang et al., 1999). With the improvement of in vivo pH 
measurements, it may be possible to target treatment to those tumors that are more acidic, thus 
focusing therapy on the population of patients that will most benefit from PCFT-selective agents.  
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CHAPTER 3 
 
THE IDENTIFICATION OF NOVEL ANTIFOLATES WITH PCFT-SELECTIVE 
UPTAKE 
 
3.1 Introduction. 
The activities of RFC, PCFT and FR folate transport systems toward antifolate substrates 
in tissues and tumors reflect their relative expression levels, along with their specificities for 
different antifolates and transport kinetics. With this said, antifolates selective for RFC, which 
include all classical antifolates presently approved by the FDA, can be envisaged to possess 
limited selectivity toward tumors over normal proliferative tissues such as bone marrow since 
these tissues all express RFC (Chapter 2 and Whetstine et al. (2002a)). The therapeutic approach 
of rational folate analog design that is based on targeting delivery into cancer cells by exploiting 
the tumor-specific patterns of expression and/or function of PCFT and FR may lead to more 
tumor-selective therapeutics. This approach is not entirely unprecedented, as recent efforts have 
focused on targeting FR as a means of delivering cytotoxic antifolates into the tumor cell. For 
instance, ONX0801 (previously BGC945) which is selectively transported by FRs and inhibits 
TS as its primary target (Gibbs et al., 2005; Theti et al., 2003) has recently been licensed by 
Onyx Pharmaceuticals and is currently in Phase I in the United Kingdom. Another approach 
links a variety of lipid soluble drugs, structurally unrelated to folates, to folic acid via a covalent 
bond. The complex binds FR on the cell surface, is endocytosed, the bond is broken in the 
reducing environment of the endosome, and the drug diffuses out of the endosome to inactivate 
its intracellular target. Several such agents have been designed. BMS-753493 is a molecule born 
from collaboration between scientists at Endocyte Inc. and Bristol Myers Squibb. It represents a 
folic acid conjugate that was constructed with a semi-synthetic analog of Epothilone A (a 
microtubule inhibitor). BMS-753493 is currently being evaluated for safety and efficacy in Phase 
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II clinical trials sponsored by Bristol Myers Squibb. EC-145 (Endocyte) is a desacetylvinblastine 
monohydrazide – folic acid complex (Reddy et al., 2007). A randomized Phase II trial is near 
completion in which EC-145 with Doxil was compared to Doxil alone for the treatment of 
platinum-resistant ovarian cancers (Dosio et al., 2010). Farletuzumab is a humanized MoAb with 
high affinity for FRα. Preclinical studies have demonstrated that farletuzumab mediates robust 
antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro, 
inhibits tumor growth in ovarian tumor xenografts, and displays a safe toxicology profile in non 
human-primates (Kalli, 2007; Smith-Jones et al., 2008). Farletuzumab has shown clinical 
efficacy in early phase trials as single agent and combination therapy with minimal drug-specific 
toxicity (Spannuth et al., 2010). The Phase III development plan in ovarian cancer patients 
includes combination chemotherapy studies in both platinum-sensitive (recently launched) and 
platinum-resistant (planned) recurrent disease (Bellati et al., 2011). 
Based on the clinical successes of PMX, and in an effort to design novel antifolates with 
specificities other than RFC, our lab formed collaborations with Dr. Aleem Gangjee’s group 
from Duquesne University.  This cooperation has resulted in several novel series of compounds 
based on the chemical structure of PMX.  These include: (i) 6-substituted pyrrolo[2,3-
d]pyrimidine benzoyl antifolates with carbon bridge length variations of  1- to 6-carbons, 
compounds 1-6, respectively (Deng et al., 2008; Kugel Desmoulin et al., 2010b) (Figure 3.1, 
Panel A); (ii) 6-substituted thieno[2,3-d]pyrimidine benzoyl antifolates with bridge length 
variations from 2-8 carbon atoms, compounds 7-13, respectively (Deng et al., 2009) (Figure 3.1, 
Panel B); (iii) 6-substituted pyrrolo[2,3-d]pyrimidine antifolates with a thienoyl replacement for 
the benzoyl moiety and bridge length variations from 1-6 carbons, compounds 14-19, 
respectively (Kugel Desmoulin et al., 2011; Wang et al., 2010; Wang et al., 2011) (Figure 3.1, 
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Panel C); and the (iv) 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers with a 4-
carbon bridge and different thienoyl ring substitutions (compounds 20-24) (Wang et al., 2012) 
(Figure 3.1, Panel C).   
The rationale behind the synthesis of the 6-substituted pyrrolo[2,3-d]pyrimidine benzoyl 
structures (group (i) above) (Figure 3.1, Panel A) is in part based on the finding that the 6-regio 
isomer of PMX (compound 2) was inactive against the growth of tumor cells expressing RFC in 
culture (Shih, 1993). Gangjee et al. postulated that a possible reason for its inactivity in culture 
could be that transposing the 5-ethylene bridge to the 6-position forces the benzoyl glutamic acid 
side chain in an orientation different from that required for optimal enzyme interaction and 
antitumor activity (Gangjee et al., 2005; Gangjee et al., 2004).  They therefore elongated the 
ethylene bridge between the heterocycle and para-aminobenzoate with 3 (compound 3) or 4 
(compound 4) methylene groups to allow greater conformational flexibility.  Compounds 3 and 4 
were both modest inhibitors of proliferation with CCRF-CEM leukemia cells (express RFC but 
no PCFT or FR) in the presence of micromolar concentrations of folic acid (Gangjee et al., 2005; 
Gangjee et al., 2004). Our laboratory found that the 6-substituted pyrrolo[2,3-d]pyrimidine 
benzoyl analogs were characterized by potent and selective substrate activities for FRα and FRβ, 
and negligible substrate activity for RFC.  Moreover, the intracellular enzyme target of the 6-
substituted pyrrolo[2,3-d]pyrimidine benzoyl antifolates was identified as GARFTase, the first 
folate-dependent reaction in the de novo purine nucleotide biosynthesis pathway (Deng et al., 
2008). 
The synthesis of 6-substituted thieno[2,3-d]pyrimidine benzoyl antifolates with bridge 
length variations (from 2-8 carbon atoms; compounds 7-13 respectively) (group (ii), above) 
(Figure 3.1, Panel B) was pursued to try to find a more potent analog and to understand the  
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structural determinants of transport selectivity.  Isosteric replacement of the pyrrolo ring with a 
thieno ring for this series provided an increase in ring size that more closely approximates the 
pteridine, 6-6 fused ring system of the natural cofactor.  In addition, replacement of the NH of 
the pyrrole with an S also allows for comparison of the relative importance of a hydrogen bond 
donor (NH) with a hydrogen bond acceptor (S).  Our laboratory found that the 6-substituted 
thieno[2,3-d]pyrimidine antifolate series was characterized by potent and selective substrate 
activities for FRα and FRβ, and negligible substrate activities for RFC.  Furthermore, the 6-
substituted thieno[2,3-d]pyrimidine antifolates were found to target both GARFTase and 
AICARFTase (Deng et al., 2009). 
The rationale for the synthesis of 6-substituted pyrrolo[2,3-d]pyrimidines with a thienoyl 
replacement for the benzoyl moiety and bridge length variations from 1-6 carbons antifolates 
(compounds 14-19, respectively) (group (iii) above) (Figure 3.1, Panel C) came from the 
discovery and biochemical evaluation of RTX. RTX was synthesized by replacing the para-
aminobenzoate of ICI 198583 (a precursor analog of RTX) with a thiophene and a N10-methyl 
substituent. This modification reduced TS inhibition compared to earlier analogs but enhanced 
cellular uptake by RFC and polyglutamylation leading to more potent tumor growth inhibition 
both in vitro and in vivo. Therefore, the rationale was that combining the chemical structures of 
the 6-substituted PMX with different carbon bridge lengths with the thienoyl group of RTX 
might give a more potent novel antifolate.   
As an alternative approach for decreasing the distance between the bicyclic pyrrolo[2,3-
d]pyrimidine and the L-glutamate portions, we systematically assessed the effects on cell 
proliferation for an expanded series of pyrrolo[2,3-d]pyrimidine thienoyl regioisomers of 17 with 
a 4-carbon bridge and thienoyl ring substitutions, 2’,3’ (20), 4’,5’ (21), 3’,4’ (22), 3’,5’ (23), and 
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2’,4’ (24) (group (iv) above) (Figure 3.1, Panel C). In analogs 20-24, the [1,2] substitution 
pattern on the thiophene forces the bicyclic scaffold and L-glutamate closer together than in the 
parent 3-atom bridge compound 16 which includes a [1,3] pattern on the thiophene ring. 
This chapter will explore the potential of PCFT to selectively deliver cytotoxic antifolates 
for the chemotherapy of tumors. The transport activity profile for the earlier series of 6-
substituted pyrrolo[2,3-d]pyrimidine benzoyl antifolates (Deng et al., 2008) and 6-substituted 
thieno[2,3-d]pyrimidine benzoyl antifolates (Deng et al., 2009) will be expanded to include 
PCFT and the transport selectivity of the other novel series will be established. The potent 
antiproliferative activities of these compounds, attributable to inhibition of GARFTase and de 
novo purine biosynthesis, will be characterized. The goal is to establish a structure-activity 
relationship for compounds that are selective for PCFT-mediated uptake, have no RFC substrate 
activity and cause cell death through GARFTase inhibition at doses that are pharmacologically 
feasible. The findings presented here will establish that PCFT is an efficient means of delivering 
cytotoxic antifolate drugs and suggest that PCFT provides a unique opportunity to selectively 
target solid tumors with cytotoxic antifolates that are not substrates for the ubiquitously 
expressed RFC. 
3.2 Materials and Methods. 
3.2.1 Chemicals and Reagents. 
[3’,5’,7-3H]MTX (20 Ci/mmol) and [3H]PMX (3.7 Ci/mmol) were purchased from 
Moravek Biochemicals (Brea, CA). Unlabeled MTX and (6 R,S)-5-formyl tetrahydrofolate (5-
CHO-THF) were provided by the Drug Development Branch, National Cancer Institute, 
Bethesda, MD. Both labeled and unlabeled MTX were purified by HPLC prior to use (Fry et al., 
1982).  The sources of the antifolate drugs were as follows. RTX [N-(5-[N-(3,4-dihydro-2-
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methyl-4-oxyquinazolin-6-ylmethyl)-N-methyl-amino]-2-thenoyl)-L-glutamic acid] was 
obtained from AstraZeneca Pharmaceuticals (Maccesfield, Cheshire, England); LMX (5,10-
dideaza-5,6,7,8-tetrahydrofolate) and PMX (Alimta) were from Eli Lilly and Co. (Indianapolis, 
IN); GW1843U89 [(S)-2-(5-(((1,2-dihydro-3-methyl-1-oxo-benzo(F) quinazolin-9-yl) methyl) 
amino)1-oxo-2-isoindolinyl) glutaric acid] was from the GlaxoWellcome-SmithKline Co. 
(Research Triangle Park, NC); and Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl-L-
ornithine (PT523) was a gift of Dr. Andre Rosowsky (Boston, MA).  Restriction and modifying 
enzymes were purchased from Promega (Madison, WI).  Other chemicals were obtained from 
commercial sources in the highest available purities. Synthesis and properties of the 6-substituted 
pyrrolo[2,3-d]pyrimidine benzoyl antifolate compounds 1-6 (1-6 methylene groups in the bridge 
region connecting the pyrrolo[2,3-d]pyrimidine moiety to para-aminobenzoate) were described 
(Deng et al., 2008; Kugel Desmoulin et al., 2010b). Synthesis and properties of the 6-substituted 
thieno[2,3-d]pyrimidine antifolate with bridge variations from 2-8 carbon atoms (compounds 7-
13) were described (Deng et al., 2009). Synthesis and properties of pyrrolo[2,3-d]pyrimidine 
thienoyl antifolate compounds 14-19 (1-6 methylene groups in the bridge region connecting the 
pyrrolo[2,3-d]pyrimidine moiety to para-aminobenzoate) were described (Kugel Desmoulin et 
al., 2011; Wang et al., 2010). Finally, synthesis and properties of 6-substituted pyrrolo[2,3-
d]pyrimidine thienoyl regioisomers with a 4-carbon bridge and different thienoyl ring 
substitutions (compounds 20-24) were described (Wang et al., 2012).    
3.2.2 Cell Culture. 
Novel antifolate preliminary screening was performed in sublines derived from PCFT-, 
RFC-, and FR-null MTXRIIOuaR2-4 (R2) Chinese hamster ovary (CHO) cells (Flintoff and 
Nagainis, 1983), a gift from Dr. Wayne Flintoff (University of Western Ontario, London, 
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Ontario, Canada). R2 cells were cultured in alpha-minimal essential media (MEM) supplemented 
with 10% bovine calf serum (Invitrogen, Carlsbad, CA), 100 units/mL penicillin, 100 µg/mL 
streptomycin, and 2 mM L-glutamine at 37˚C with 5% CO2. PC43-10 and R2/PCFT4 cells are 
R2 cells stably transfected with human RFC (Wong et al., 1995) or human PCFT (Kugel 
Desmoulin et al., 2010b), respectively. Generation of R2/PCFT4 cells is described below. Both 
cell lines were cultured in complete alpha-MEM medium plus 1 mg/mL G418. Using 
LookOut™, a PCR-based Mycoplasma detection kit from Sigma Chemical Company (St. Louis, 
MO), cell lines were periodically determined to be free of Mycoplasma. 
3.2.3 Preparation of a Myc-His6-tagged Human PCFT Construct and Generation of 
Stable Transfectants. 
Total RNA from wild type HeLa cells was reverse transcribed and PCR amplified with 
EasyA proof-reading polymerase (Agilent Technologies, La Jolla, CA) using the following 
primers: 5’-AACTC GGA TCC gca cat gga ggg gag cgc gag cc-3’; and 5’–AACTC GGT ACC 
ggg gct ctg ggg aaa ctg ctg gaa ctc ga-3’ (bold capitals designate the BamHI and KpnI restriction 
sites, respectively). The 1403 bp amplicon was subcloned into pCDNA3.1 (Invitrogen) in-frame 
with a Myc-His6 sequence inserted at the C-terminal amino acid 466 (hereafter designated 
PCFTMyc-His6/pCDNA3.1). The construct was confirmed by automated DNA sequencing at the 
Wayne State University Sequencing Core.  
R2 cells were transfected with PCFTMyc-His6/pCDNA3.1 by electroporation (200 V, 1000 
µF capacitance). After 24 h, the cells were cultured in the presence of G418 (1.5 mg/mL). Stable 
clones were selected by plating for individual colonies in the presence of 1.5 mg/mL G418. 
Colonies were isolated, expanded and screened for expression of PCFTMyc-His6 protein by 
Western blotting and transport assays at pH 5.5 (see below).  One clone (R2/PCFT4) was 
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selected for further study. Vector control R2 cells (R2/VC) transfected with empty pCDNA3.1 
were also prepared and used as a negative control. 
3.2.4 Gel Electrophoresis and Western Blotting. 
For characterizing PCFT and RFC protein expression in R2/PCFT4 and PC43-10 cells, 
respectively, crude plasma membranes were prepared by differential centrifugation. Briefly, cells 
were suspended in 10 mM Tris-HCl, pH 7.0, containing X1 protease inhibitor cocktail tablets 
(Roche, Indianapolis, IN), and disrupted with a probe sonicator. The cell homogenate was 
centrifuged (600 x g, 10 min) to remove cell debris and nuclei; the supernatant was then 
centrifuged at 200,000 x g (48,000 rpm) in a Beckman TL100 ultracentrifuge for 30 min. The 
particulate fraction was solubilized in 10 mM Tris-HCl (pH 7) with 2% SDS in the presence of 
proteolytic inhibitors and proteins were quantified with Folin-phenol reagent (Lowry et al., 
1951). Membrane proteins were electrophoresed on 7.5% polyacrylamide gels in the presence of 
SDS (Laemmli, 1970) and electroblotted onto PVDF (Pierce, Rockford, IL) (Matsudaira, 1987). 
PCFTMyc-His6 protein was detected with monoclonal Myc-specific mouse antibody (Covance, 
Berkeley, CA) and secondary IRDye800CW-conjugated antibody (Rockland, Gilbertsville, PA). 
Detection of immunoreactive proteins used the Odyssey® Infrared Imaging System (LI-COR, 
Lincoln, NE). 
3.2.5 Indirect Immunofluorescence and Confocal Microscopy. 
For confocal microscopy, R2/PCFT4 and R2/VC CHO cells were plated in Lab-Tek®II 
chamber slidesTM (Nalge Nunc International, Naperville, IL).  Cells were fixed with 3.3% 
paraformaldehyde (in DPBS), permeabilized with 0.1% Triton X-100 (in PBS), and stained with 
monoclonal Myc-specific mouse antibody (Covance) and Alexa Fluor® 488 donkey anti-mouse 
IgG (H+L) secondary antibody (Molecular Probes, Eugene, OR). Slides were visualized with a 
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Zeiss laser scanning microscope 510 using a 63x water immersion lens, and exactly the same 
parameter setting for all samples. Confocal analysis was performed at the Imaging Core of the 
Karmanos Cancer Institute.   
3.2.6 Transport Assays. 
The expression and function of PCFT and RFC in R2/PCFT4, R2/VC, PC43-10 and R2 
cell lines was validated by measuring pH-dependent transport of 0.5 µM [3H]MTX over 2 min at 
37°C in cell suspensions. Briefly, three days before transport experiments, cells grown in 
monolayers, under G418 selection, were transferred to Cytostir spinners and maintained in 
suspension at densities of 2-5 x 105 cells/mL. Cells were collected by centrifugation, washed 
with DPBS, and the cell pellets (~2 x 107 cells) were suspended in 2 mL of either  [3H]MTX  
containing HEPES-buffered saline (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, 
and 5 mM glucose) at pH 6.8 or 7.2, or in MES-buffered saline  (20 mM MES, 140 mM NaCl, 5 
mM KCl, 2 mM MgCl2, and 5 mM glucose) at pH 5.5, 6.0, or 6.5 (Zhao et al., 2004b). At the 
end of the incubations, transport was quenched with ice-cold DPBS, cells were washed 3 times 
with ice-cold DPBS, and cellular proteins were solubilized with 0.5 N NaOH. Levels of drug 
uptake were expressed as pmol/mg protein, calculated from direct measurements of radioactivity 
and protein contents of the cell homogenates. Radioactivity was measured with a scintillation 
counter (Model LS6500; Beckman-Coulter, Fullerton, CA) and proteins were quantified using 
Folin-phenol reagent (Lowry et al., 1951). 
To determine [3H]MTX and [3H]PMX kinetic constants for PCFT in R2/PCFT4 cells (Kt 
and Vmax), transport rates were measured at pH 6.8 and pH 5.5, as described above, using 
substrate concentrations from 0.04 to 5.0 µM. Kt and Vmax values were determined from 
Lineweaver-Burke plots. Inhibition of RFC transport by unlabeled antifolates (reflecting 
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transport by the carrier) was measured in PC43-10 cells over 2 min at 37oC in Hank’s balanced 
salts solution (pH 7.2) with 0.5 µM [3H]MTX and 10 µM inhibitor.  For PCFT, inhibition of 
transport was determined from pH 5.5 to 7.2 in the above MES- and HEPES-buffered saline over 
2 min at 37oC with 0.5 µM [3H]MTX and 10 µM inhibitors. Kis for PCFT were calculated from 
Dixon analysis, by plotting reciprocal transport velocities measured over a range (1-5 µM) of 
inhibitor concentrations and 0.5 µM [3H]MTX at pH 5.5 and pH 6.8. Ki values were calculated 
from the slopes, Kt and Vmax values for MTX, and the concentration of [3H]MTX, using the 
equation Ki=Kt/(Vmax)(slope)(S).  
3.2.7 Electrophysiology Experiments. 
Electrophysiology experiments were performed in collaboration with Dr. Michael 
Romero (Mayo Clinic, Rochester, MN). Xenopus oocytes were used to assess currents associated 
with transport of the antifolate substrates.  PCFT cRNA (50 nL of 0.5 µg/µL, i.e., 25 ng) or water 
(50 nL) was injected into stage V/VI oocytes and electrophysiological measurements were made 
3-5 days later (Unal et al., 2009a). Oocytes were voltage clamped to -90 mV to maximize folate-
induced currents, a technique that was previously utilized in studies on the divalent metal 
transporter, DMT1 (Gunshin et al., 1997; Mackenzie et al., 2006) and PCFT (Unal et al., 2009a). 
Oocyte solutions were adjusted to pH 5.5 using MES. During these experiments, oocytes were 
continuously superfused with solution (with and without antifolates as indicated) at 5 mL/min.  
3.2.8 Proliferation and Colony-forming Assays. 
For growth inhibition assays, R2/PCFT4 CHO cells were plated in 96 well culture dishes 
(2500 cells/well, respectively; total volume of 200 µL medium) with a broad concentration range 
of drugs. The drugs were dissolved in DMSO such that after dilution the DMSO concentration 
did not exceed 0.5%. The medium was folate-free RPMI 1640 (pH 7.2) supplemented with 10% 
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dialyzed fetal bovine serum (dFBS) (Invitrogen), 2 mM L-glutamine, 100 units/mL penicillin 
and 100 µg/mL streptomycin (hereafter referred to as complete folate-free RPMI 1640 media), 
containing 25 nM 5-CHO-THF. Cells were routinely incubated for up to 96 h, and metabolically 
active cells (a measure of cell viability) were assayed with CellTiter-Blue™ cell viability assay 
(Promega). Fluorescence was measured (590 nm emission, 560 nm excitation) with a Molecular 
Devices fluorescence plate reader. Data were exported from Softmax Pro software to an Excel 
spreadsheet for analysis and determinations of IC50s, corresponding to drug concentrations that 
result in 50% loss of cell growth. In some experiments, the protective effects of adenosine (60 
µM), thymidine (10 µM), and 5-amino-4-imidazolecarboxamide (AICA) (320 µM) were tested to 
validate the intracellular targeted pathways and enzymes for the cytotoxic antifolates. Growth 
inhibition assays for the PC43-10 CHO were routinely performed in regular RPMI 1640 (pH 7.2) 
supplemented with 10% dFBS (Invitrogen), 2 mM L-glutamine and 100 units/mL penicillin and 
100 µg/mL streptomycin (hereafter referred to as complete RPMI 1640 media), although for a 
few experiments PC43-10 cells were cultured exactly as for the R2/PCFT4 cells. To follow 
changes in pH accompanying cell outgrowth, cells were seeded into T75 flasks, using the same 
media, cell number to volume ratio, and incubation times as for the cytotoxicity assays. Media 
pH values were measured daily with an Orion 2 Star benchtop pH meter. 
For colony-forming assays, R2/PCFT4 cells (500 cells) were harvested in log-phase and 
plated into 60 mm dishes in complete folate-free RPMI 1640 medium, supplemented with 25 nM 
5-CHO-THF and allowed to adhere for 48 h. For continuous drug exposures, R2/PCFT4 cells 
were then treated with increasing concentrations of drugs and colonies were allowed to outgrow 
for 10 days. At the end of the incubations, the dishes were rinsed with DPBS, 5% trichloroacetic 
acid (TCA), and borate buffer (10 mM, pH 8.8), followed by 1% methylene blue (in borate 
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buffer; 30 min). The dishes were again rinsed with borate buffer, and colonies were counted for 
calculating percent colony formation relative to the DMSO control.  
To test the reversibility of compound 3 drug effects, as reflected in inhibition of colony 
formation over time, R2/PCFT4 cells were harvested in log phase and 500 cells were plated, 
allowed to adhere for 48 h, then cultured in the presence or absence of 1 µM antifolate 
compounds and thymidine (10 µM) plus adenosine (60 µM) for 2, 4, 8, 24, or 48 h, before 
rinsing with DPBS and adding medium with or without thymidine (10 µM) plus adenosine (60 
µM). The dishes were incubated for 10 days, and colonies were counted, as described above, for 
calculating percent colony formation compared to control. 
3.2.9 In situ Assays for GARFTase. 
Incorporation of [14C(U)]glycine into [14C]formyl GAR as an in situ measure of 
endogenous GARFTase activity in R2/PCFT4 cells was performed using a modification of 
published methods (Beardsley et al., 1989; Deng et al., 2008).  For these experiments, R2/PCFT4 
cells were seeded in 5 mL of complete folate-free RPMI 1640 plus 25 nM 5-CHO-THF in T25 
flasks at a density of 2 x 105 cells per flask. After 48 h, antifolate inhibitor or DMSO (control) 
was added to the culture medium and the cells were incubated for another 15 h after which the 
pH of the media was determined with an Orion 2 Star benchtop pH meter. Cells were washed 
twice with DPBS and resuspended in 5 mL folate-free, L-glutamine-free RPMI 1640 (Sigma) 
plus penicillin-streptomycin, 10% dFBS, 0.46 g/L NaHCO3 and 1.21 g/L NaCl medium, with or 
without 0.5-100 nM antifolate and azaserine (4 µM final concentration), and incubated for 30 
min.  L-glutamine (2 mM final concentration) and [14C]glycine (final specific activity, 0.1 
mCi/L) were added, followed by incubation at 37o C for 8 h, after which time cells were 
trypsinized and washed twice with ice-cold DPBS. Cell pellets were treated with 2 mL of 5% 
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TCA at 0o C. Cell debris was removed by centrifugation, samples were solubilized in 0.5 N 
NaOH and assayed for protein contents (Lowry et al., 1951). The supernatants were extracted 
twice with 2 mL of ice-cold ether to remove the TCA. The aqueous layer was passed through a 1 
cm column of AG1x8 (chloride form), 100-200 mesh (BioRad), washed with 10 mL of 0.5 N 
formic acid, followed by 10 mL of 4 N formic acid, and eluted with 8 mL of 1 N HCl solution. 
The elutants were collected as 1 mL fractions and determined for radioactivity.   
3.2.10 Determination of Intracellular ATP/GTP Levels. 
For analysis of ATP and GTP levels following antifolate treatments, R2/PCFT4 cells 
were seeded in 10 mL of complete folate-free RPMI 1640 plus 25 nM 5-CHO-THF in T75 flasks 
at a density of 7 x 105 cells per flask. After 48 h, antifolates or DMSO (control) were added to 
the culture medium. After another 24 h, the cells were trypsinized and washed (2x) with ice-cold 
DPBS, with a final additional wash with ice-cold DPBS containing 1 mM EDTA. The final cell 
pellet (2-5 x 106 cells) was resuspended in 100 µL of 155 mM NaCl containing 1 mM EDTA and 
100 µL of ice-cold 0.6 M TCA was added drop-wise while vortexing. Samples were incubated 
10 min on ice with occasional mixing, and then centrifuged (14,000 rpm, 5 min).  The 
supernatant was removed, whereas the protein pellet was solubilized in 0.2 mL of 0.5 N NaOH 
for protein determinations. Tri-n-octylamine (0.5 M) in trichlorotrifluoroethane (Freon) (1 mL) 
was added to the supernatant and the mixtures vortexed and incubated for 20 min on ice. 
Samples were centrifuged and the freon amine (lower) layer was discarded. One mL of 
methylene chloride was added to the upper layer, followed by mixing, incubation (ice, 10 min), 
centrifugation, and removal of the organic (lower) layer. Samples were stored at -80oC until 
analysis. Intracellular adenosine and guanosine triphosphates were measured by a modification 
of the HPLC method of Huang et al. (2003a). The chromatography system consisted of a Varian 
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9010 ternary gradient pump, a 9050 variable wavelength detector, and a Varian Star 5.3 data 
handling system. A 50 µL injection loop was used. The analytical column was a Waters 
Symmetry C18 (5 µm, 150 x 4.6 mm) equipped with a Waters Novapak phenyl pre-column 
(Waters, Milford, MA). The detection wavelength was set at 254 nm.  The flow rate was 1 
mL/min.  The gradient elution was as follows: 0-30 min at 60% A/40% B; 30-50 min linear at 
1%/min to 40% A/60% B; and 50-60 min at 40% A/60% B. Buffer A was comprised of 10 mM 
tetrabutylammonium hydroxide, 10 mM KH2PO4 and 0.25% methanol (MeOH); the pH was 
adjusted to 6.9 with 1 N H3PO4. Buffer B consisted of 5.6 mM tetrabutylammonium hydroxide, 
50 mM KH2PO4 and 30% MeOH; the pH was adjusted to 7.0 with 1 N KOH. Both solutions 
were freshly prepared before each experiment and degassed. External standards were used for 
each assay to construct a standard curve from which cellular levels were calculated. Standards 
ranged from 0-75 µM for ATP and 0-30 µM for GTP in the initial mobile phase. Variations 
between standards were 5% or less. Extraction efficiencies were established by adding known 
amounts of ATP and GTP standards (200 and 50 µM, respectively) to a control sample prior to 
extraction. 
3.3 Results. 
3.3.1 Generation of PCFT Stable Transfectants in Transport-impaired CHO Cells.    
As part of our larger drug discovery endeavor to establish pharmacophores for all the 
major folate transporters and to develop transporter-specific drugs, we previously generated 
novel sublines derived from the RFC, FR-, and PCFT-null MTXRIIOuaR2-4 CHO cells 
(hereafter, simply R2) that ectopically express human RFC protein (designated PC43-10; Figure 
3.2, Panel A and E ) (Wong et al., 1995) and human FRs (designated RT-16). 
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Figure 3.2 Characterization of PCFT protein expression, membrane localization and pH-
dependent transport in R2/PCFT4 and R2/VC cells. Panel A, Western blot analysis of RFC in 
PC43-10 and R2 cells. Panel B, human PCFTMyc-His6 in R2/PCFT4 and R2/VC cells. 
Membrane fractions (10 µg) were analyzed by SDS-PAGE and immunoblotting with human 
RFC and PCFT polyclonal antibody. Panel C, Immunofluorescence of R2/PCFT4 and R2/VC 
cells. Cells were fixed with paraformaldehyde, permeabilized with Triton X-100, stained with 
anti-myc antibody and visualized using confocal microscopy. Panel D, PCFT transport activity 
in R2/PCFT4 and R2/VC cells was assessed by measuring uptake of 0.5 µM [3H]MTX at 37˚C 
for 2 min at pH 5.5 or 6.0 in MES-buffered saline, and at 6.5, 6.8, or 7.2 in HEPES-buffered 
saline. Internalized [3H]MTX was normalized to total protein and expressed as a percent of the 
transport activity at pH 5.5.  Panel E, RFC transport activity in PC43-10 and R2 cells was 
determined by measuring uptake of 0.5 µM [3H]MTX at 37˚C for 2 min at pH 5.5 or 6.0 in MES-
buffered saline, and at 6.5, 6.8, or 7.2 in HEPES-buffered saline. As above, internalized 
[3H]MTX was normalized to total cellular protein and expressed as percent transport at pH 7.2. 
Transport results are presented as mean values ± standard errors from 6 experiments. 
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More recently, we generated another R2 subline (R2/PCFT4) that expressed human PCFT (Deng 
et al., 2009; Kugel Desmoulin et al., 2010b).  R2/PCFT4 cells were made by electroporating R2 
CHO cells with a Myc-His6-tagged human PCFT (PCFTMyc-His6) cDNA construct. Stable 
transfectants were selected with G418. Clones were isolated, expanded, and screened by Western 
blotting. The clonal R2/PCFT4 subline was established that expressed a high level of PCFTMyc-
His6 protein (Figure 3.2, Panel B).  
By indirect immunofluorescence staining with Myc-specific antibody and Alexa 
Fluor488-tagged secondary antibody, PCFTMyc-His6 protein was targeted predominantly to the cell 
surface of R2/PCFT4 cells with some intracellular staining compared to R2/VC (Figure 3.2, 
Panel C). Expression of PCFTMyc-His6 protein was accompanied by substantial [3H]MTX transport 
at pH 5.5 during 2 min over the low level measured in vector control R2/VC cells (Figure 3.2, 
Panel D). Transport at pH 7.2 was ~14% of that at pH 5.5 and at pH 6.8 transport increased to 
~35% of that at pH 5.5. For RFC-expressing PC43-10 cells, [3H]MTX transport was active at pH 
7.2 as reported (Wong et al., 1995), then fell  with decreasing pH and was essentially 
indistinguishable from the residual low level in R2 cells at pH 5.5 (Figure 3.2, Panel E).  
We measured the kinetics for [3H]MTX and [3H]PMX transport in R2/PCFT4 cells over a 
range of concentrations at pH 5.5 and pH 6.8. Data were analyzed by Lineweaver-Burke plots 
and are summarized in Table 3.2. Results for MTX showed a 16-fold decrease in Kt and a 2.3-
fold increase in Vmax when the pH was decreased from 6.8 to 5.5, whereas for PMX, the Kt and 
Vmax changed 3.7-fold and 4.6-fold respectively. Vmax/Kt values, a reflection of overall transport 
efficiency, were calculated for [3H]MTX and [3H]PMX and were 37-, 17-fold higher, 
respectively, at pH 5.5 than at pH 6.8.  
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 Thus, as previously reported, transport by PCFT shows extraordinary pH dependence 
with the greatest activity at acidic pH. Further, the impact of pH on kinetic parameters for PCFT 
membrane transport varies with different transport substrates (Zhao et al., 2009a).  
3.3.2 Chemosensitivities to Classical Antifolate Inhibitors and Identification of Novel  
Antifolates with PCFT Selectivity over RFC.  
We screened R2/PCFT4 and PC43-10 cells for growth inhibition in the continuous 
presence of established antifolates including MTX, GW1843U89, LMX, PMX, PT523 and RTX. 
Growth inhibition results for PC43-10 were compared to those for R2 cells and R2/PCFT4 
results were compared to R2 cells transfected with empty pCDNA3.1 vector (R2/VC) (Deng et 
al., 2009; Kugel Desmoulin et al., 2010b) (Table 3.1). Assays were performed at pH 7.2 in 
complete RPMI 1640 (for RFC-expressing PC43-10 and R2), or in complete folate-free RPMI 
1640 supplemented with 25 nM 5-CHO-THF (for R2/PCFT4 and R2/VC cells). For most of the 
antifolates, drug sensitivities, as reflected in decreased IC50s for inhibition of growth over 96 h, 
were increased in both R2/PCFT4 and PC43-10 cells over respective controls (Table 3.1). With 
RFC-expressing PC43-10 CHO cells, sensitivities to the classical antifolates were significantly 
increased (from 6.5-fold for PMX to >159-fold for RTX) over R2 cells. Likewise, R2/PCFT4 
cells were sensitive to the classical inhibitors (>8.3- to 74-fold, compared to negative controls). 
Neither GW1843U89 nor PT523 showed any activity toward R2/PCFT4 cells. Since PCFT is 
optimally active at acidic pHs (Figure 3.2, Panel D), we measured the changes in media pH 
during the interval of drug exposure. Over 96 h, the pH of the media decreased linearly and 
reached pH 6.7 to 6.9 by day 4 (data not shown). Thus, at extracellular pHs approximating those 
associated with solid tumor microenvironments, several of these classical agents appeared to be 
substrates for PCFT in R2/PCFT4 cells, as reflected in patterns of growth inhibition. PT523 and 
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GW1843U89 were completely selective toward RFC over PCFT. Only PMX showed any 
indication of selective activity toward PCFT over RFC, (i.e., 74-fold increased activity for 
R2/PCFT4 cells versus 6.5-fold for the PC43-10 cells, compared to respective negative controls). 
However, this was incomplete; i.e., PMX was appreciably active toward both PCFT- and RFC-
expressing cells.  
Initial testing of the 6-substituted pyrrolo[2,3-d]pyrimidine benzoyl antifolate series as 
inhibitors of growth in the isogenic CHO sublines, revealed that compounds 1, 2, and 4-6 were 
all completely inert toward PC43-10 cells, establishing a lack of RFC transport activity for this 
series (Table 3.1). The 3-carbon analog of this series, compound 3, showed a low level activity 
toward PC43-10 cells. Compounds 3 and 4 were active toward PCFT-expressing R2/PCFT4 
cells, and 3 was more potent than 4 by ~9-fold (IC50s of ~23 and ~213 nM, respectively). 
Conversely, compounds 1, 2, 5, and 6 were completely inactive (Table 3.1). This result with 
compounds 3 and 4 is the first identification of an antifolate with selectivity for PCFT-mediated 
uptake with no or very little substrate activity for RFC (Deng et al., 2008; Kugel Desmoulin et 
al., 2010b).   
The 6-substituted thieno[2,3-d]pyrimidine benzoyl antifolate series exhibited a different 
substrate specificity than compounds 3 and 4 when growth inhibition was measured in the CHO 
sublines. Compounds 8 and 9 were characterized by potent and selective substrate activities for 
FRα and FRβ (8 = 9 > 10 > 11) (data not shown) and negligible substrate activities for both RFC 
and PCFT (Table 3.1) (Deng et al., 2009; Kugel Desmoulin et al., 2010b). The most potent 
analogs of the series, compounds 8 and 9, with 3- and 4-methylene groups in the bridge region, 
respectively, showed activities similar to those for the most active classical inhibitors, LMX and 
RTX, toward FR-expressing cells, but were somewhat more active than either PMX or MTX. 
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The finding of FR- but not PCFT selectivity for this series is particularly interesting given the 
report of possible direct functional coupling between these transport systems (Zhao et al., 
2009b). Our results with 6-substituted thieno[2,3-d]pyrimidine benzoyl antifolate substrates for 
FR establish that, should FR-PCFT coupling occur, this must not be obligatory.  
Growth Inhibition of the 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate series 
in the isogenic CHO cell line panel found that while 14, 15 and 17-19 were inert toward RFC-
expressing PC43-10 cells and R2 cells up to 1000 nM drug, compound 16 showed evidence of a 
non-FR, non-PCFT cellular uptake process at higher drug concentrations (seemingly in part 
mediated by RFC and also by a non-RFC uptake mechanism), although substantial FR- and 
PCFT-selectivity over RFC (as reflected in relative IC50s) was nonetheless preserved (Table 3.1). 
Of the pyrrolo[2,3-d]pyrimidine thienoyl antifolates, 16 (3-carbon bridge) and 17 (4-carbon 
bridge) are the most potent agents toward PCFT-expressing R2/PCFT4 cells. Compounds 16, 17 
and 18 showed a high level of PCFT-targeted activity, for PCFT-expressing R2/PCFT4 cells 
with IC50s of 3.34, 43 and 101 nM, respectively (Table 3.1). Activity substantially declined for 
compounds 14 and 15 with 1- and 2-carbon bridge lengths, respectively, and compound 19 was 
completely inert. Compound 16 was more active than the classic agents and was likewise more 
so than compound 17. This was most impressively reflected in the ~11-fold decrease in IC50 (~3 
nM) toward PCFT-expressing R2/PCFT4 cells with 16 compared to 17 (Kugel Desmoulin et al., 
2011; Wang et al., 2010; Wang et al., 2011).  
Finally, 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers with 4-carbon 
bridge lengths and with contiguous thiophene substitutions [2’3’ (20); 4’5’ (21); 3’4’(22)] were 
completely inactive toward the RFC- and PCFT-expressing CHO sublines (Table 3.1). 
Compounds 23 and 24 were likewise inert toward PC43-10 cells, although both compounds 
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inhibited proliferation of R2/PCFT4 cells (IC50s of 41.5 and 63.8 nM for 23 and 24, 
respectively), essentially equivalent to compound 17 (IC50 of 43.4 nM) (Table 3.1). This 
establishes cellular uptake of compounds 23 and 24 by PCFT. Drug sensitivities for 23 and 24 
with R2/PCFT4 cells exceeded those for MTX and RTX, and were comparable to those for 
LMX. However, 23 and 24 were less potent than PMX (~3- and ~5-fold, respectively) and 16 
(~12- and ~19-fold, respectively). None of the 6-substituted pyrrolo[2,3-d]pyrimidine 
regioisomers (17 and 20-24) had any impact on proliferation of R2 or R2/VC cells (Wang et al., 
2012).  
Since nucleoside salvage mechanisms circumvent biosynthetic requirements for reduced 
folates and growth inhibitory effects of classical antifolates such as MTX, we tested excess 
adenosine and thymidine for their capacities to abolish the growth inhibitory effects of the most 
potent analogs (compounds 3, 16 and 17).  Results were compared to those for PMX, reported to 
act as an inhibitor of both purine nucleotide biosynthesis primarily at TS and AICARFTase and 
less so at GARFTase  (Racanelli et al., 2009; Shih and Thornton, 1999), and for LMX, an 
established inhibitor of GARFTase (Beardsley et al., 1989; Mendelsohn et al., 1999; Moran et 
al., 1989). Whereas thymidine (10 µM) also protected R2/PCFT4 cells from the growth 
inhibitory effects of low concentrations (<50 nM) of PMX, at higher PMX concentrations, 
protection was incomplete with thymidine either in the presence or absence of AICA (320 µM) 
(Figure 3.3, Panel A), which is metabolized to AICAR (circumvents drug effects at GARFTase). 
Adenosine (60 µM) could not circumvent effects of PMX. However, growth inhibition by PMX 
was completely reversed by adenosine combined with thymidine. Analogous results were 
previously described for nucleoside protection from the inhibitory effects of PMX for CCRF-
CEM cells (Racanelli et al., 2009). In contrast, for LMX and compounds 3, 16 and 17  
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Figure 3.3 Protection of R2/PCFT4 cells from growth inhibition by PMX, compounds 3, 16 
and 17 in the presence of nucleosides and 5-amino-4-imidazole (AICA).  Proliferation 
inhibition was measured for R2/PCFT4 cells over a range of concentrations of PMX (Panel A), 
LMX (Panel B), 3 (Panel C), 16 (Panel D) or 17 (Panel E), as shown, in complete folate-free 
RPMI 1640 with 25 nM 5-CHO-THF, in the presence or absence of adenosine (60 µM) or  
thymidine (10 µM), or AICA (320 nM). Cell densities were measured with CellTiter-Blue™ 
fluorescence dye and a fluorescence plate reader. Results were normalized to cell density in the 
absence of drug.  Results shown are representative data of experiments performed in triplicate. 
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(Figure 3.3, Panels B-D), growth inhibition was abolished by either adenosine or AICA alone. 
These results establish de novo purine nucleotide biosynthesis as the targeted pathway for 
compounds 3, 16 and 17 and GARFTase as the principal intracellular enzyme target, analogous 
to LMX (Beardsley et al., 1989). 
Cytotoxicity assays were extended to include colony-forming assays. Colony-forming 
assays were performed in which R2/PCFT4 cells were continuously exposed to a range of 
concentrations of compounds 3, 16, 17, PMX, or LMX for 10 days (Figure 3.4, Panels A-E). 
Colonies were scored by counting visible colonies after 10 days and are presented as a percent of 
the vehicle control. Composite results are presented as mean values ± standard errors from 3 
experiments (Panel E). As an inhibitor of colony-formation, compounds 3 (Panel B), 16 (Panel 
C) and 17 (Panel D) gave IC50s of 17.14 + 0.74 nM (SEM), 1.41 + 0.03 nM and 27.17 + 2.89 
nM, respectively, whereas IC50s for PMX (Panel A) and LMX were 4.94 + 0.48 nM and 29.70 + 
0.59 nM, respectively.  
To establish the time-dependent requirements for loss of clonogenicity upon exposure to 
compound 3, LMX, or PMX, R2/PCFT4 cells were exposed to the drugs (each at 1 µM) for 
different times (2, 4, 8, 24, 48, and 72 h), after which drug was removed and cells were incubated 
in the presence or absence of adenosine (60 µM) and thymidine (10 µM). A parallel incubation 
was performed in which cells were treated with drugs and nucleosides, after which drugs were 
removed and cells incubated in the presence of adenosine and thymidine. Colonies were counted 
after 10 days, with results compared to those for the untreated vehicle (DMSO) control. 
Nucleoside protection, both during and after drug treatments, completely protected R2/PCFT4 
cells from loss of colony formation. When cells were treated during the initial incubation with 
antifolates without nucleoside protection, colony formation was significantly inhibited whether  
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Figure 3.4 Inhibition of colony formation. R2/PCFT4 cells were plated into 60 mm dishes at a 
density of 500 cells per dish in the presence or absence of different concentrations of PMX 
(Panel A), 3 (Panel B), 16 (Panel C) or 17 (Panel D) from 1 to 100 nM. Colonies were scored by 
counting visible colonies after 10 days and are presented as a percent of the vehicle control. 
Results are presented as mean values ± standard errors from 3 experiments (Panel E). 
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or not nucleosides were included after the drug was removed (Figure 3.5). The difference 
between these two conditions established a time-requirement for irreversible drug effects 
resulting in loss of clonogenicity and ranged from greater than 4 h for PMX (Figure 3.5, Panel 
A) and compound 3 (Panel C), to greater than 8 h for LMX (Panel B).  For all drugs thereafter, 
there was a progressive diminution of the protective effects such that by 48-72 h, loss of colony 
formation was essentially complete. For compound 3 treatments, a visual representation of the 
stained colonies has been included to demonstrate the time-dependent irreversible drug effects 
(Panel D).   
3.3.3 PCFT-selective Transport Characteristics for Compounds 3, 16 and 17.  
   Growth inhibition results (Table 3.1) strongly suggested selective membrane transport by 
PCFT and not RFC for compounds 3, 16 and 17. For further confirmation, we tested these 
compounds (10 µM) as direct competitors for inhibition of PCFT-mediated uptake of [3H]MTX 
(0.5 µM) in R2/PCFT4 cells from pH 5.5 to 7.2, and compared the results to those for PMX and 
PT523, established RFC substrates. A parallel experiment was performed with PC43-10 cells to 
assess the inhibitory effects of compounds 3, 16 and 17 (10 µM) on RFC-mediated [3H]MTX 
uptake (at pH 7.2), compared to other established RFC transport substrates. As shown in (Figure 
3.6, Panel A), with R2/PCFT4 cells, compounds 3, 16 and 17 were potent inhibitors of PCFT 
transport, only slightly less so than PMX and with substantially increased potencies at pH values 
less than 7.2. As expected (Zhao and Goldman, 2007), PT523 did not inhibit [3H]MTX uptake at 
any pH for R2/PCFT4 cells. For RFC-expressing PC43-10 cells at pH 7.2, PT523, PMX, RTX, 
LMX, and 5-CHO-THF all potently inhibited [3H]MTX transport (Figure 3.6, Panel B).  
However, compounds 3, 16 and 17 were essentially inert as inhibitors of RFC. 
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Figure 3.5 Time dependence for loss of clonogenicity in R2/PCFT4 cells treated with PMX, 
LMX and compound 3. R2/PCFT4 cells were plated into 60 mm dishes at 500 cells per dish 
and allowed to adhere for 48 h, after which cells were treated with or without 1 µM drug in the 
presence or absence of adenosine (60 µM) and thymidine (10 µM) for 2, 4, 8, 24 and 48 h.  
Following drug treatment, cells were washed with DPBS and resuspended with drug-free media 
with or without adenosine (60 µM) and thymidine (10 µM) protection. Colonies were 
enumerated after 10 days and results are presented as a percent of vehicle control. Panel A, 
PMX. Panel B, LMX. Panel C, Compound 3. Panel D, Representative image of dishes that were 
counted to produce Panel C. Results are presented as mean values ± standard errors from 3 
experiments. Abbreviations: Ade, adenosine; Thd, thymidine. 
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Figure 3.6 Competitive inhibition of PCFT and RFC transport of [3H]MTX. Panel A, 
R2/PCFT4 cells ectopically expressing PCFT but no FR or RFC were assayed for [3H]MTX 
transport in the presence of 10 µM PMX, compounds 3, 16, 17 and PT523 at pH 5.5-7.2. Panel 
B, R2 cells (vector) expressing no RFC, PCFT or FR and PC43-10 cells expressing RFC but no 
PCFT or FR were assayed for [3H]MTX transport in the presence of 10 µM compounds 3, 16, 
17, PT523, PMX, RTX, LMX, or 5-CHO-THF at pH 7.2. Results are presented as mean values ± 
standard errors from >3 experiments. 
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We used Dixon analysis at pH 5.5 and pH 6.8 with R2/PCFT4 cells and [3H]MTX to 
calculate Kis for PCFT competitors including compounds 3, 16, 17, PMX and LMX (Table 3.2). 
Transport of 0.5 µM [3H]MTX was measured over a range of inhibitor concentrations. The 
relative affinities of our lead compounds to PCFT were similar to PMX and are as follows: PMX 
< 17 < 16 < 3 < LMX. Ki values increase 14-18 fold at pH 6.8 for all compounds except LMX 
which had a 50-fold increased Ki at pH 6.8. For PMX, the Kis closely approximated the Kts 
recorded with [3H]PMX.  
   To confirm that compounds 3, 16, and 17 are transported by PCFT, electrophysiological 
studies were performed in Xenopus oocytes injected with PCFT cRNA. Uptake was assessed in 
oocytes clamped to -90 mV at a bath pH of 5.5. A substrate concentration of 5 µM was used, 
which is saturating for 5-CHO-THF and PMX. These experiments show that the currents induced 
by compounds 3, 16 and 17 were comparable to that produced by 5-CHO-THF (Figure 3.7). 
3.3.4 Identification of de novo Purine Nucleotide Biosynthesis and GARFTase as Primary 
Cellular Targets for Compounds 3, 16 and 17.  
  Our protection studies further identified de novo purine nucleotide biosynthesis as the 
primary targeted pathway following PCFT transport of the 6-substituted pyrrolo[2,3-
d]pyrimidine –benzoyl (3) and –thienoyl antifolates (16 and 17). To confirm the inhibition of 
purine nucleotide biosynthesis by compounds 3, 16 and 17, we measured ATP and GTP pools by 
HPLC in R2/PCFT4 cells for compounds 3, 16 and 17. For compound 3, cells were treated with 
increasing concentrations for 24 h and results were compared to those of LMX; results are shown 
as a percentage of control ATP and GTP levels (Figure 3.8, Panel A). Additionally, cells were 
treated with 1 µM of 16 and 17 for 24 h at pH 6.8, and results were compared to those for LMX 
and PMX (both at 1 µM) (Figure 3.8, Panel B). GTP and ATP pools 
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Figure 3.7 Electrophysiology studies of antifolate transport by PCFT in Xenopus oocytes. 
Substrate-induced currents (nA) were recorded in individual oocytes injected with wild type 
PCFT and voltage clamped to a holding potential (Vh) of -90 mV. Oocytes were perfused with 
ND90 solution at pH 5.5 with 5-CHO-THF followed by compounds 3, 17 and 16. For all 
substrates, concentrations were maintained at a level of 5 µM. 
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Figure 3.8 Intracellular ATP levels and in situ GARFTase inhibition in R2/PCFT4 cells 
treated with compounds 3, 16, 17, LMX, and PMX. Panel A, for analysis of ATP levels, cells 
were treated with various concentrations of compounds 3 or LMX for 24 h. Nucleotides were 
extracted and ATP pools were determined by a modification of the HPLC method of Huang et al. 
(2003a). Details are provided in the Materials and Methods. Panel B, R2/PCFT4 cells were 
treated with 1 µM 17, 16, PMX, or LMX, or solvent (0.5% DMSO for 3, 16 and 17, H2O for 
PMX and LMX) for 24 h. Cells were washed, and nucleotides were extracted and analyzed by 
HPLC. Results are shown for percentage control ATP after the drug treatments. Panel C, 
GARFTase activity and inhibition were evaluated in situ with R2/PCFT4 cells. Accumulation of 
[14C]formyl GAR from [14C]glycine was measured in R2/PCFT4 cells treated with the 
antifolates. The production of [14C]formyl GAR was calculated as a percent of vehicle control 
over a range of antifolate concentrations. Results are presented as the mean values (standard 
errors from 3 experiments. Methodologic details are described in the Experimental Procedures 
section. IC50s were as follows: 0.97 nM, 3; 0.69 nM, 16; 1.96 nM, 17; 31.5 nM LMX; and 7.3 
nM, PMX. 
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were severely depleted (approximately 50 and 75%, respectively) during a 24 h exposure of 
R2/PCFT4 cells to 1 µM of either compound 3 or LMX. For ATP pools, IC50 values of 58 and 
166 nM were measured for compound 3 and LMX, respectively (Figure 3.8, Panel A). For GTP 
pools, IC50 values were 441 and 579 nM, respectively (data not shown). Treatment of R2/PCFT4 
cells with either 1 µM 16 or 17 for 24 h resulted in profound depletion of ATP pools (90%), 
which exceeded the decrease resulting from treatment with LMX (76%). PMX treatment, on the 
other hand only minimally impacted ATP pools (17%) (Figure 3.8, Panel B). Similar results 
were reported by Chen et al. (1998). 
  To confirm GARFTase inhibition and to provide a metabolic “read-out” for PCFT 
transport of compounds 3, 16 and 17 in R2/PCFT4 cells, we used an in situ assay for GARFTase. 
GARFTase catalyzes formylation of the glycine-derived nitrogen of GAR, producing formyl 
GAR with 10-formyl THF as the one-carbon donor. The in situ GARFTase assay measures 
incorporation of [14C]glycine into [14C]formyl GAR in the presence of azaserine (4 µM) 
(Beardsley et al., 1989; Deng et al., 2008).  Modifications were made in the original protocol to 
measure GARFTase inhibition under pH conditions which permitted PCFT transport. Briefly, 
R2/PCFT4 cells were cultured for 48 h in complete folate-free media supplemented with 25 nM 
5-CHO-THF. The 48 h incubation allowed the cells to adhere and the pH of the culture media to 
decrease to ~6.9 accompanying cell growth. Cells were then treated for 15 h with or without a 
range of concentrations of compounds 3, 16 and 17, or with PMX or LMX, after which cells 
were washed, resuspended in complete L-glutamine- and folate-free medium with or without 
drug and then treated with azaserine for 30 min, after which L-glutamine and [14C]glycine were 
added. After an additional 8 h, cells were washed, proteins were precipitated with TCA, and the 
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supernatants were ether-extracted and fractionated on anion exchange columns so that 
[14C]formyl GAR could be measured and IC50s calculated.  
Our results demonstrate that PMX, LMX, and compounds 3, 16 and 17 all inhibited 
[14C]formyl GAR accumulation in R2/PCFT4 cells at ~pH 6.9 when PCFT is the sole mode of 
antifolate drug delivery (Figure 3.8, Panel C). Compound 16 was by far the most potent of these 
drugs with an impressive IC50 for GARFTase inhibition of 0.69 nM. Relative drug sensitivities 
for the other lead compounds and classic antifolates were as follows, IC50s (in nM) are in 
parentheses: 3 (0.97) > 17 (1.96) > PMX (7.3) > LMX (31.5). The most potent inhibitors were 
compounds 3 and 16, suggesting that the chain length of the bridge region is an important 
determinant of GARFTase inhibition regardless of whether the compound is a pyrrolo[2,3-
d]pyrimidine –benzoyl or –thienoyl. GARFTase inhibition is the ultimate determinant of growth 
inhibition, with the IC50s following the same trend, 16  > 3  > 17  (Table 3.1). 
3.4 Discussion. 
Chemotherapy activity of classic antifolates has traditionally been interpreted in terms of 
their active membrane transport into tumors by RFC (Matherly et al., 2007). Furthermore, 
impaired membrane transport due to loss or mutations of RFC was reported to result in antifolate 
resistance (Assaraf, 2007; Matherly et al., 2007; Zhao and Goldman, 2003). However, after 
reports of a novel low-pH transporter termed PCFT (Nakai et al., 2007; Qiu et al., 2006; Zhao 
and Goldman, 2007) and the recognition that PCFT is expressed and functional in human solid 
tumors (Chapter 2) and can efficiently transport cytotoxic antifolates, such as MTX, at pH values 
approximating those of solid tumors (Chapter 2), it becomes necessary to examine the possibility 
that PCFT could represent an important mode of chemotherapy drug transport.  
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Because most cultured cells endogenously express more than one folate transport system 
(Chapter 2), to explore the role of PCFT in delivery of cytotoxic antifolates, we engineered the 
R2/PCFT4 CHO subline from PCFT-, RFC-, and FR-null R2 cells to express PCFT without 
either RFC or FRs. R2/PCFT4 cells exhibited optimal transport activity at acidic over neutral 
pHs, reflecting high-affinity transport of substrates with decreasing pH. The impact of pH on 
transport by PCFT was substantially different between (anti)folate substrates. By growth 
inhibition assays, R2/PCFT4 cells were sensitive to classic antifolates, including MTX, RTX, 
PMX, and LMX, suggesting their membrane transport by PCFT; PMX was the most active 
transport substrate and neither GW1843U89 nor PT523 was growth inhibitory. Although PCFT 
exhibits limited transport at neutral pH typical of culture media, transport of these cytotoxic 
antifolates by PCFT was enhanced by the progressively decreasing pH that accompanies cell 
outgrowth. PMX is a 5-substituted pyrrolo[2,3-d]pyrimidine benzoyl analog and is the best 
substrate previously described for PCFT (Zhao and Goldman, 2007). Because PMX was a potent 
inhibitor of R2/PCFT4 cell growth, we compared the growth inhibitory effects of a number of 
structurally related 6-substituted pyrrolo or thieno[2,3-d]pyrimidine benzoyl or thienoyl 
antifolates with bridge lengths from one to eight methylenes (depending on the drug series) as 
inhibitors of R2/PCFT4 cell proliferation.  
The 6-substituted pyrrolo[2,3-d]pyrimidine with a –benzoyl B ring and three methylenes 
(compound 3) or a -thienoyl B ring and  three or four methylenes (compounds 16 and 17, 
respectively) were potent inhibitors of R2/PCFT4 cell growth or clonogenicity. Additionally, 
these compounds were essentially inert toward RFC-expressing PC43-10 cells, thus establishing 
these analogs as our lead compounds for future studies. It is noteworthy that compounds 3, 16 
and 17 all selectively inhibited transport of [3H]MTX by PCFT with potencies only slightly less 
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than that for PMX, as reflected in Ki  values, and with nearly identical pH dependencies. After 
microinjection of PCFT cRNA into X. laevis oocytes, perfusion with a saturating concentration 
of compounds 3, 16 and 17 elicited a current, confirming that these compounds are 
electrogenically transported by PCFT. Collectively, these results establish that the cytotoxic 6-
substituted pyrrolo[2,3-d]pyrimidine –benzoyl compound 3 and –thienoyl compounds 16 and 17 
are bona fide transport substrates for PCFT, essentially on par with PMX. However, unlike 
PMX, compounds 3, 16, and 17 have nominal transport activity with RFC.  
Compound 3 was previously reported to be cytotoxic toward cells that express high levels 
of FRα, reflecting inhibition of GARFTase, the trifunctional enzyme that catalyzes the second, 
third, and fifth reactions of de novo purine nucleotide biosynthesis, including the first folate-
dependent step (Deng et al., 2008). Consistent with primary inhibition of GARFTase after 
transport by PCFT, both adenosine and AICA protected R2/PCFT4 cells from growth inhibition 
by compounds 3, 16 and 17. By an in situ GARFTase assay, which measures [14C]glycine 
incorporation into formyl GAR, compounds 3, 16 and 17  were disproportionately inhibitory, 
with IC50 values less than 1 nM, far lower than the IC50 for LMX. Although PMX is primarily an 
inhibitor of TS and was recently reported to inhibit AICARFTase in CCRF-CEM cells (Racanelli 
et al., 2009), in R2/PCFT4 CHO cells, appreciable GARFTase inhibition was detected, albeit less 
than that for compounds 3, 16 and 17.  
These results describe the first PCFT-selective antifolates and establish that PCFT is a 
surprisingly efficient means of cytotoxic drug delivery. The much higher concentrations of 
compounds 3, 16 and 17 needed to inhibit colony formation and cell proliferation, or to 
significantly suppress ATP/GTP pools versus those required to inhibit GARFTase in cells, must 
reflect the nature of the enzyme target and requirement for sustained inhibition of GARFTase 
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and de novo purine biosynthesis for cell killing. Indeed, sustained exposures to GARFTase 
inhibitors were required to irreversibly inhibit colony formation of R2/PCFT4 cells, although an 
analogous time-dependence was obtained with PMX. Similar results were previously reported 
when comparing effects on clonogenicity of GARFTase inhibition by LMX versus TS inhibition 
by RTX in WiDr colonic carcinoma cells (Smith et al., 1993). The higher concentrations of LMX 
over compound 3 needed to inhibit GARFTase in cells relative to those required to manifest 
cytotoxicity provide further evidence that GARFTase inhibition is not limiting to cell killing. 
The decreased GARFTase inhibition for LMX in R2/PCFT4 cells probably reflects its reduced 
transport by PCFT compared with compound 3, although factors such as differences in the extent 
of polyglutamate synthesis may also contribute. High-level substrate activity was previously 
reported for compound 3 for human FPGS (Gangjee et al., 2004); however compounds 16 and 17 
have not been directly tested. The delay in irreversible drug effects upon inhibition of 
GARFTase may reflect salvage of purines generated from breakdown of nucleic acids (Bronder 
and Moran, 2002; Smith et al., 1993). Accordingly, the delay for irreversible cell death by 
GARFTase inhibitors may be substantially shortened in cells that have defects in purine salvage, 
increasing dependence on de novo purine synthesis. For instance, deletions of MTAP have been 
described in human malignancies, including ~70% of pleural mesotheliomas (Illei et al., 2003) 
and 38% of NSCLC (Schmid et al., 1998). On this basis, GARFTase inhibitors such as 
compounds 3, 16, and 17 may show far greater potencies in MTAP-deficient tumors, especially 
if there are high levels of PCFT.  
It will be interesting to determine whether the ATP depletion caused by GARFTase 
inhibitors will lead to an increase in NRF-1, upregulation of PCFT transcription and enhanced 
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activity of the drug in tumor cells. Conversely, there could be an upregulation of de novo purine 
biosynthesis enzyme expression and subsequent resistance to GARFTase inhibitors.  
Finally, the present results, combined with earlier studies of 6-substituted pyrrolo- and 
thieno[2,3-d]pyrimidine antifolates (Deng et al., 2009; Wang et al., 2010) begin to establish a 
structure activity relationship for PCFT-selective antifolates and shed light on the impact of both 
aromatic ring systems and the length of the bridge domain on transport by PCFT versus other 
folate transporters. Thus, antifolates with thieno[2,3-d]pyrimidine and benzoyl rings (designated 
A and B rings, respectively) (Figure 3.1) are effective transport substrates for FRs but not for 
RFC or PCFT, with optimal activity for the 3- and 4-carbon bridge analogs (Deng et al., 2009). 
Replacement of the thieno[2,3-d]pyrimidine A ring with a pyrrolo[2,3-d]pyrimidine system 
favors binding and transport by both PCFT and FRs, regardless of whether the B ring is a 
benzoyl (3) or thiophene (16 and 17). For the pyrrolo[2,3-d]pyrimidine -benzoyl and -thienoyl 
series, decreasing the bridge lengths between the bicyclic scaffold and L-glutamate from 8- to 4-
carbons (4 and 17) substantially increased the antiproliferative activities of the analogs, 
reflecting transport by PCFT. Further decreasing the bridge length of these compounds from 4- 
to 3-carbons (3 and 16) increased drug potencies; however, this appeared to be accompanied by 
some loss of absolute transporter specificity for PCFT over RFC. Decreasing the bridge length to 
1- or 2-carbons caused complete loss of activity.  
In conclusion, we document PCFT-selective transport over RFC for the potent 6 
substituted pyrrolo[2,3-d]pyrimidine -benzoyl and -thienoyl antifolate series, particularly 
compounds 3, 16 and 17. Our results strongly suggest the therapeutic potential of PCFT for 
targeting drugs to tumors. The notion of PCFT drug targeting is appealing given the acidic pH 
optimum for this system and the low pH microenvironment of many solid tumors (Anderson and 
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Thwaites, 2010; Helmlinger et al., 1997; Webb et al., 2011). For drugs such as compounds 3, 16 
and 17 which exhibit PCFT selectivity over RFC, tumor selectivity would be enhanced because 
transport by PCFT would be extensive under the low pH conditions in solid tumors yet should be 
limited at neutral pH typical of most normal tissues. This would result in significantly lower 
toxicity. Although compounds 3, 16 and 17 are also cytotoxic toward FR-expressing cells (Deng 
et al., 2008), given the frequent association of FRs with malignant cells (Chapter 2) (Elnakat and 
Ratnam, 2004), this may serve to broaden potential therapeutic applications of this drug 
platform. Our drug discovery efforts are currently focused toward identifying PCFT-specific 
agents without transport by FR or RFC to test this. Validation of these concepts will undoubtedly 
depend on establishing cytotoxicity of 3, 16 and 17 in human solid tumor cell lines with 
endogenous levels of PCFT (~10 fold lower than levels found in R2/PCFT4 cells) delivered at 
pHs that resemble the solid tumor microenvironment (pH 6.8), determining whether these novel 
analogs are polyglutamylated and establishing their affinities for FPGS, identifying the effects of 
the analogs on the cell cycle and the mechanisms of cell death. Further, it will be important to 
establish in vivo activity of the drugs against transplanted tumors that express PCFT as the sole 
means of drug delivery and also determining the impact of functional RFC on the pharmacology 
of these drugs. These questions will be studied in Chapters 4 and 5 of this dissertation.  
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CHAPTER 4 
 
SOLID TUMOR TARGETING BY PCFT-MEDIATED UPTAKE OF NOVEL ANTIFOLATES 
 
4.1 Introduction. 
PCFT transport function may be enhanced in many solid tumors by the acidic pH of the 
tumor microenvironment, which has been reported to reach as low as pH 6.2 to 6.8 (Helmlinger 
et al., 1997; Webb et al., 2011). Intracellular pH is normally alkaline, which creates a substantial 
transmembrane pH gradient directed intracellularly (Fais et al., 2007). Clearly, harnessing this 
proton-motive gradient to transport cytotoxic antifolates into tumor cells by PCFT offers a 
uniquely attractive mechanism of therapeutic targeting solid tumors. Importantly, as described in 
Chapter 2, PCFT is expressed and is functional in a wide range of human solid tumor cell lines. 
PCFT expression was confirmed in primary human tumors. For tumor targeting of cytotoxic 
drugs via FR or PCFT, ideally, therapeutic agents are specifically transported by FRs and/or 
PCFT and not by RFC (Deng et al., 2008; Deng et al., 2009; Gibbs et al., 2005; Hilgenbrink and 
Low, 2005; Kugel Desmoulin et al., 2010b; Salazar and Ratnam, 2007; Wang et al., 2010). This 
strategy is necessary because antifolate membrane transport by RFC precludes tumor selectivity, 
in that RFC is expressed in both normal and tumor cells, and RFC transport is optimal at neutral 
pH characterizing most normal tissues (Matherly et al., 2007; Zhao and Goldman, 2003). Indeed, 
a major obstacle in implementing this approach has been a lack of FR- or PCFT-selective agents, 
since all of the clinically useful antifolates with significant FR- and PCFT substrate activity (e.g., 
MTX and PMX) are also transported by RFC (Matherly et al., 2007). In Chapter 3, we described 
a novel 6-substituted pyrrolo[2,3-d]pyrimidine antifolate with a thienoyl-for-benzoyl B ring 
replacement and a bridge length of four carbons (compound 17) (Figure 3.1, Panel C) (Kugel 
Desmoulin et al., 2011; Wang et al., 2010). Cellular uptake of compound 17 by FRα and PCFT 
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was substantial in the absence of its membrane transport by RFC, resulting in potent antitumor 
activity in vitro because of its inhibition of GARFTase in de novo purine nucleotide biosynthesis.  
This chapter will focus on directly testing the capacity of PCFT to deliver a cytotoxic 
dose of compound 17 under conditions relevant to the solid tumor microenvironment. 
Characteristics of drug transport, polyglutamylation, GARFTase inhibition, ATP levels, cell 
cycle analysis and mechanism of cell death will be evaluated in human solid tumor cell lines that 
have modest endogenous levels of PCFT. Drug treatments will be studied at pHs that are similar 
to those surrounding many solid tumors (pH 6.8), or performed in vivo where a true acidic tumor 
microenvironment can be created by the growing tumor (Raghunand et al., 1999). This chapter 
describes such experiments with compound 17 to establish the feasibility of selectively targeting 
chemotherapy to human solid tumors based upon drug membrane transport by PCFT. The 
majority of this work has been published (Kugel Desmoulin et al., 2011). 
4.2 Materials and Methods. 
4.2.1 Chemicals and Reagents. 
[3’,5’,7-3H]MTX (20 Ci/mmol), [3H]PMX (2.5 Ci/mmol), and custom-radiolabeled 
[3H]compound 17 (1.3 Ci/mmol) were purchased from Moravek Biochemicals (Brea, CA). 
(6R,S)-5-formyl tetrahydrofolate (5-CHO-THF) was provided by the Drug Development Branch, 
National Cancer Institute (Bethesda, MD). PMX [N-(4-[2-(2-amino-3,4-dihydro-4-oxo-7H-
pyrrolo[2,3-d]pyrimidin-5-yl)ethyl] benzoyl)-L-glutamic acid] (Alimta) was provided by Eli 
Lilly and Co. (Indianapolis, IN). Synthesis and properties of the 6-substituted pyrrolo[2,3-
d]pyrimidine thienoyl antifolate compound 17 were described previously (Kugel Desmoulin et 
al., 2011; Wang et al., 2010). Other chemicals were obtained from commercial sources in the 
highest available purities. 
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4.2.2 Cell Culture. 
To determine the efficacies of the novel antifolates in human solid tumor cell lines, RFC-
/PCFT-null HeLa (R1-11) sublines were obtained from Dr. I. David Goldman (Albert Einstein 
School of Medicine, Bronx, NY). R1-11-RFC6 and R1-11-PCFT4 cells were derived from R1-
11 cells by stable transfection with HA-tagged pZeoSV2(+)-RFC and pZeoSV2(+)-PCFT 
constructs, respectively. Cells were maintained in regular RPMI 1640 medium supplemented 
with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100 units/mL penicillin, 100 µg/mL 
streptomycin, 2 mM L-glutamine and 0.1 mg/mL zeocin (Invitrogen, Carlsbad, CA)  at 37˚C 
with 5% CO2. Characteristics of the HeLa sublines were described previously (Zhao et al., 2008). 
Additionally, HepG2 cells were purchased from ATCC and were routinely grown in Eagle’s 
MEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Thermo Fisher 
Scientific, Waltham, MA), 100 units/mL penicillin, 100 µg/mL streptomycin and 2 mM L-
glutamine. 
4.2.3 Real-time RT-PCR Analysis of RFC, FRα, and PCFT Transcripts.  
For characterizing human PCFT, RFC and FRα transcript levels, RNAs were isolated using 
TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturers instructions, from  the 
HepG2 human hepatocellular carcinoma cell line, the IGROV1 human ovarian adenocarcinoma 
cell line, engineered R1-11 HeLa sublines (R1-11 mock, R1-11-RFC6, and R1-11-PCFT4) and 
in vivo HepG2 tumor samples (see section 4.2.10 for trial information). For isolation of RNA 
from HepG2 tumor xenografts, dry ice was used to ensure that the snap-frozen tumors remained 
cold to prevent RNase degradation of tumor RNA. Tumors were cut into thin sections using an 
ice cold razor blade. Tumor fragments were transferred into a microcentrifuge tube containing 1 
mL TRIzol (Invitrogen) and quickly homogenized using a Kontes pellet pestle motor and 
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RNAase-free pellet pestle (Sigma-Aldrich, St. Louis, MO). The tumor fragments, resuspended in 
TRIzol (Invitrogen), were vortexed, pelleted by microcentrifugation and homogenized until all 
solid tumor fragments were solubilized. The remaining protocol for RNA isolation was the same 
as above. cDNAs for all samples were synthesized using random hexamers, RNase inhibitor, and 
MuLV reverse transcriptase and purified with the QIAquick PCR Purification Kit (Qiagen). 
Real-time RT-PCR was performed on a Roche LightCycler 1.2 (Roche, Indianapolis, IN) with  
gene-specific primers (Table 2.1) and FastStart DNA Master SYBR Green I enzyme reaction 
mix (Roche), as described (Ge et al., 2007). Transcript levels for human PCFT, RFC and FRα 
were normalized to those for GAPDH. External standard curves were constructed for each gene 
of interest using serial dilutions of linearized templates, prepared by amplification from suitable 
cDNA templates, subcloning into a TA-cloning vector (PCR-Topo; Invitrogen), and restriction 
digestions.  
4.2.4 Proliferation and Colony-forming Assays.  
For growth inhibition assays, R1-11-PCFT4, R1-11-RFC6 HeLa, and HepG2 cells were 
cultured in complete folate-free RPMI 1640 medium, pH 7.2, supplemented with 25 nM 5-CHO-
THF, for at least 2 weeks prior to the experiment (folate-depleted). Cells were plated in 96-well 
culture dishes (5000 cells/well; 200 µL/well) in the above medium with a broad concentration 
range of drugs (depending on the compound, drug dilutions were in DMSO or water with 
appropriate vehicle controls); cells were incubated for up to 96 h at 37°C in a CO2 incubator. 
Metabolically active cells (a measure of cell viability) were assayed with CellTiter-Blue™ cell 
viability assay (Promega, Madison, WI) and a fluorescent plate reader (emission at 590 nm, 
excitation at 560 nm) for determining IC50 values, corresponding to drug concentrations that 
result in 50% loss of cell growth. For colony-forming assays, folate-depleted R1-11-PCFT4 cells 
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(500 cells) in log-phase were plated into 60-mm dishes in complete folate-free RPMI 1640 
medium, pH 7.2, supplemented with 25 nM 5-CHO-THF and allowed to adhere for 48 h. Cells 
were then treated with compound 17 or PMX in the above media, supplemented with 25 mM 
PIPES and 25 mM HEPES (complete buffered folate-free RPMI 1640 medium) to maintain the 
pH at 6.8. After 16, 24, or 48 h, cells were rinsed with DPBS, and then incubated in drug-free, 
complete folate-free RPMI 1640 medium, supplemented with 25 nM 5-CHO-THF, pH 7.2. Cells 
were allowed to outgrow for 12 days, at which time the dishes were rinsed with DPBS, 5% TCA, 
and borate buffer (10 mM, pH 8.8), followed by 1% methylene blue (in borate buffer). The 
dishes were again rinsed with borate buffer, and colonies were counted for calculating 
percentage colony formation relative to the DMSO controls. 
4.2.5 Transport Assays.  
For comparison of PCFT transport activities in R2/PCFT4 and R1-11-PCFT4 cells, PCFT 
transport activities in R2/VC, R2/PCFT4, R1-11-mock and R1-11-PCFT4 cells were assessed in 
cell monolayers by measuring uptake of 0.5 µM [3H]MTX at 37˚C for 5 min at pH 7.2 in 
HEPES-buffered saline (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM 
glucose), or at pH 5.5 in MES-buffered saline  (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM 
MgCl2, and 5 mM glucose) (Zhao et al., 2004b). To determine the pH-dependent transport of 
[3H]compound 17 and [3H]PMX (both at 0.25 µM) in R1-11-PCFT4, R1-11-mock, and HepG2 
cells, uptake was assayed at 37°C in cell monolayers over 2 to 30 min at 37°C in complete 
buffered folate-free RPMI 1640 (pH 5.5, 6.8, and 7.2). At the end of the incubations, transport 
was quenched with ice-cold DPBS, cells were washed three times with ice-cold DPBS, and 
cellular proteins were solubilized with 0.5 N NaOH. Levels of drug uptake were expressed as 
picomoles per milligram of protein, calculated from direct measurements of radioactivity and 
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protein contents of cell homogenates. Proteins were quantified using Folin-phenol reagent 
(Lowry et al., 1951). For PCFT transport kinetic analyses, R1-11-PCFT4 cells were grown in 
suspension using spinner flasks at densities of 2 to 5 X 105 cells/mL. Cells were collected by 
centrifugation, washed with DPBS, and suspended (at 1.5 X 107 cells) in 2 mL of transport 
buffer (below) for cellular uptake assays. To determine [3H]compound 17 and [3H]PMX kinetic 
constants for PCFT (Kt and Vmax), initial uptake rates were measured at 37°C over 2 min in 
HEPES-buffered saline at pH 6.8, or in MES-buffered saline at pH 5.5 (Zhao et al., 2004b), 
using substrate concentrations from 0.04 to 5 µM. Kt and Vmax values were determined from 
Lineweaver-Burk plots. 
4.2.6 HPLC Analysis of Polyglutamyl Derivatives of Compound 17 and PMX.  
Folate-depleted R1-11-PCFT4 and HepG2 cells were grown in complete folate-free 
RPMI 1640 medium, supplemented with 25 nM 5-CHO-THF. Cells were washed with DPBS 
and incubated in complete buffered folate-free RPMI 1640 medium, pH 6.8, with 1 µM 
[3H]compound 17 or [3H]PMX at 37°C in the presence of 60 µM adenosine, or 60 µM adenosine 
plus 10 µM thymidine, respectively. After 16 h, cells were washed three times with ice-cold 
DPBS, then scraped mechanically into 5 mL of ice cold DPBS, pelleted, and flash-frozen. The 
cell pellets were resuspended into 0.5 mL of 50 mM sodium phosphate buffer, pH 6.0, and 100 
mM 2-mercaptoethanol, including unlabeled compound 17 (or PMX) and MTX–diglutamate, –
triglutamate, and –tetraglutamate standards (Schircks Laboratories, Jona, Switzerland) (50 µM 
each). A portion (50 µL) was used to determine total [3H]compound 17 or PMX (in picomoles 
per milligram of protein). Proteins were measured by the Bio-Rad protein assay (Bio-Rad 
Laboratories, Richmond, CA). The remaining extract was boiled (10 min), the supernatant 
containing radiolabeled compound 17 (or PMX) and its metabolites was centrifuged, then (250 
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µL) injected into a Waters 4 µm Nova-Pak C-18 column (3.9 X 150 mm) with a Nova-Pak 4 µm 
C-18 guard column. A Varian 9012 ternary gradient-programmable pump was used for gradient 
development, and a 9050 Varian UV/Vis detector set to 313 nm was used for detection of 
compound 17, PMX, or MTX polyglutamate standards. HPLC analysis involved a binary 
gradient. Mobile phase A consisted of 100 mM sodium acetate at pH 5.5; mobile phase B 
consisted of 100% acetonitrile. The flow rate was set at 1.6 mL/min. The gradient consisted of 
100% A from 0 to 5 min, then 85% A/15% B from 5 to 27.5 min. Fractions were mechanically 
collected every min for the first 10 min and then every 10 s for the duration of the run. 
Radioactivity of the fractions was measured with a scintillation counter. Intracellular levels of 
radiolabeled compounds are expressed as picomoles per milligram of protein, based on 
calculated percentages in the peaks from the HPLC chromatogram and total picomoles per 
milligram of cellular [3H]antifolate. To confirm the identities of the early-eluting peaks as 
polyglutamate metabolites of compound 17, samples were hydrolyzed to their parent drug forms 
by an overnight treatment at 32°C with a preparation of partially purified chicken pancreas 
conjugase in 0.5 mL of 0.1 M sodium borate, pH 7.8, containing 10 mM 2-mercaptoethanol 
(Matherly et al., 1985). Samples were deproteinized by boiling (5 min), then analyzed by HPLC. 
4.2.7 In situ GARFTase Enzyme Inhibition Assay. 
Incorporation of [14C(U)]glycine into [14C]formyl GAR as an in situ measure of 
endogenous GARFTase activity in folate-depleted R1-11-PCFT4 cells at pH 6.8 was performed 
using a modification of published methods (Beardsley et al., 1989; Deng et al., 2008; Kugel 
Desmoulin et al., 2010b). For these experiments, R1-11-PCFT4 cells were seeded in 5 mL of 
complete folate-free RPMI 1640 medium plus 25 nM 5-CHO-THF in 60 mm dishes and allowed 
to adhere overnight. Cells were washed twice with DPBS and resuspended in 5 mL of complete 
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buffered folate-free RPMI 1640 medium, pH 6.8, and 25 nM 5-CHO-THF. Antifolate inhibitor 
or an equivalent amount of vehicle (e.g., DMSO) (“control”) was added to the culture medium, 
and the cells were incubated for another 16 h. Cells were washed twice with DPBS and 
resuspended in 5 mL of complete folate-free, L-glutamine-free RPMI 1640 medium/10% dFBS 
plus 25 mM PIPES/25 mM HEPES, pH 6.8, and 25 nM 5-CHO-THF, with or without 0.5 to 100 
nM antifolate and azaserine (final concentration, 4 µM), and incubated for 30 min. L-Glutamine 
(final concentration, 2 mM) and [14C]glycine (final specific activity, 0.1 mCi/L) were added, 
followed by incubation at 37°C for 8 h, after which time cells were washed three times with ice-
cold DPBS and trypsinized. Cell pellets were suspended in 2 mL of 5% TCA at 0°C. Cell debris 
was removed by centrifugation; samples were solubilized in 0.5 N NaOH and assayed for protein 
contents (Lowry et al., 1951). The supernatants were extracted twice with 2 mL of ice-cold ether. 
The aqueous layer was passed through a 1 cm column of AG1x8 (chloride form, 100–200 mesh) 
(BioRad Laboratories, Hercules, CA), washed with 10 mL of 0.5 N formic acid, followed by 10 
mL of 4 N formic acid, and eluted with 8 mL of 1 N HCl solution. The elutants were collected as 
1 mL fractions and determined for radioactivity. 
4.2.8 Determination of Intracellular ATP levels.  
For analysis of ATP levels after antifolate treatments, R1-11-PCFT4 cells were seeded in 
10 mL of complete buffered folate-free RPMI 1640 medium, pH 6.8, and 25 nM 5-CHO-THF. 
After 24 h, 10 µM compound 17 or DMSO (final concentration, 0.5%) (control) was added to the 
culture medium. Cells were incubated for an additional 24 to 72 h, after which they were 
trypsinized and washed twice with ice-cold DPBS. Nucleotides were extracted and ATP levels 
quantitated by HPLC exactly as described in Chapter 3 (Kugel Desmoulin et al., 2010b). 
4.2.9 Assessment of Apoptosis and Cell Cycle Distribution.   
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R1-11-PCFT4 cells were treated with 10 µM compound 17 for 48 h at pH 6.8 in complete 
buffered folate-free RPMI 1640 medium, pH 6.8, and 25 nM 5-CHO-THF. Cells were 
trypsinized, pelleted, and washed once with ice-cold DPBS. Samples were divided so that the 
cell cycle profile and apoptosis analysis could be performed on the same sample. The amount of 
apoptosis was measured by staining cells with fluorescein isothiocyanate (FITC)-conjugated 
annexin V and propidium iodide (PI) with the apoptotic cells determined using the CELL LAB 
ApoScreen Annexin V-FITC Apoptosis Kit (Beckman Coulter, Fullerton, CA), as recommended 
by the manufacturer. Cells were analyzed for the presence of viable (annexin V-and PI-), early 
apoptotic (annexin V+and PI-), and late apoptotic/necrotic (annexin V+ and PI-) cells by flow 
cytometry. To determine compound 17 concentration-dependent effects on cell cycle 
progression, R1-11-PCFT4 cells (106) were treated with 0, 0.5, 1, 5, and 10 µM compound 17 in 
complete buffered folate-free RPMI 1640 medium, pH 6.8, and 25 nM 5-CHO-THF for 48 h. 
Cells (106) were fixed in ethanol (at least 1 h), then stained by resuspension in 0.5 mL of DPBS 
containing 50 µg/mL PI and 100 µg/mL RNase type I-A (Sigma Aldrich, St. Louis, MO). The 
cells were analyzed by flow cytometry for determining the percentage of cells in each phase of 
the cell cycle. Flow cytometry was performed at the Karmanos Cancer Institute Imaging and 
Cytometry Core using the BD FACSCanto II operated with BD FACSDiva software (v6.0) (BD 
Biosciences, San Jose, CA). In each experiment, 2 X104 cells were assessed for apoptosis and 
cell cycle distribution. Data were analyzed with the FlowJo software (ver. 7.6.1; Tree Star, Inc, 
Ashland, OR). 
4.2.10 In vivo Efficacy Study of Compound 17 in HepG2 Xenografts.  
Cultured HepG2 human hepatoma tumor cells were implanted subcutaneously (~107 
cells/flank) to establish a solid tumor xenograft model in female ICR SCID mice (National 
  
121
Institutes of Health DCT/DTP Animal Production Program, Frederick, MD). For the efficacy 
study, mice were 8 weeks old on day 0 (tumor implant) with an average body weight of 17.6 g. 
Mice were provided food and water ad libitum. Study mice were maintained on either a folate 
deficient diet (Harlan-Teklad, Madison, WI) or a folate-replete diet (autoclavable mouse breeder 
diet) starting 16 days before subcutaneous tumor implant to ensure serum folate levels would 
approximate those of humans. Folate serum levels were determined before tumor implantation 
and after the study with a Lactobacillus casei bioassay (Varela-Moreiras and Selhub, 1992). The 
animals were pooled and implanted bilaterally subcutaneously with 30- to 60-mg tumor 
fragments by a 12-gauge trocar and again pooled before unselective distribution to the various 
treatment and control groups. Chemotherapy was begun 4 days after tumor implantation, when 
the number of cells was relatively small (107–108 cells; before the established limit of palpation). 
Tumors were measured with a caliper two or three times weekly. Mice were sacrificed when the 
cumulative tumor burden reached 1500 mg. Tumor weights were estimated from two 
dimensional measurements [i.e., tumor mass (in milligrams) = (ab2)/2, where a and b are the 
tumor length and width in millimeters, respectively]. For calculation of end points, both tumors 
on each mouse were added together, and the total mass per mouse was used. The following 
quantitative end points were used to assess antitumor activities: 1) T/C and T - C (tumor growth 
delay) [where T is the median time in days required for the treatment group tumors to reach a 
predetermined size (e.g., 500 mg) and C is the median time in days for the control group tumors 
to reach the same size; tumor free survivors are excluded from these calculations]; and 2) 
calculation of tumor cell kill [log10 cell kill total (gross) = (T - C)/(3.32)(Td), where (T - C) is the 
tumor growth delay, as described above, and Td is the tumor volume doubling time in days, 
estimated from the best fit straight line from a log-linear growth plot of control group tumors in 
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exponential growth (100- to 800-mg range)]. With the exception of the xenograft model, these 
methods are essentially identical to those described previously (Wang et al., 2010). 
4.3 Results. 
4.3.1 Effects of Compound 17 on Cell Growth Inhibition and Colony Formation in HeLa  
and HepG2 Human Tumor Sublines. 
In Chapter 3, studies established that the novel pyrrolo[2,3-d]pyrimidine thienoyl 
antifolate compound 17 (Figure 3.1 and Table 3.1) was a potent (nanomolar) inhibitor of 
proliferation of a R2/PCFT4 CHO subline engineered to express PCFT in the absence of other 
folate transporters (RFC and FRs) and to inhibit [3H]MTX transport by PCFT (Figure 3.6, Panel 
A). Conversely, the data strongly suggested that compound 17 was not transported by RFC in a 
CHO subline similarly engineered to exclusively express human RFC. To begin to establish the 
therapeutic potential of PCFT as a selective approach for chemotherapy drug delivery to human 
solid tumors, we used isogenic HeLa sublines derived by stable transfections of RFC- and PCFT-
null R1-11 HeLa cells, designated R1-11-PCFT4 (express physiologic levels of PCFT in the 
absence of RFC, as measured by real-time RT-PCR) and R1-11-RFC6 (engineered to express 
RFC without PCFT), (Zhao et al., 2008) (Figure 4.1, Panel A and B). Low levels of FRα were 
detected in all the R1-11 sublines (Panel C). As a tumor prototype with endogenous PCFT 
expression, we used HepG2 cells established from our tumor cell line screen to express 
significant levels of PCFT and RFC (Figure 2.3, Panels A and B) without FRα (expression levels 
for PCFT and RFC in HepG2 cells are compared with those for the R1-11 sublines in Figure 4.1, 
Panel A-C). We measured inhibition of cell proliferation by compound 17 and results were 
compared with those for PMX. PMX inhibited cell growth in both the R1-11-PCFT4 and R1-11-
RFC6 lines with IC50 values (mean ± S.E.M.) of 59.3 ± 7.37 and 81.7 ± 5.49 nM, respectively 
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(Figure 4.2, Panel A), demonstrating its lack of specificity for PCFT over RFC despite its high 
PCFT substrate activity (Kugel Desmoulin et al., 2010b; Zhao et al., 2008). Conversely, 
compound 17 inhibited cell growth in R1-11-PCFT4 cells (IC50, 99.2 ±  20.2 nM) but not R1-11-
RFC6 (Figure 4.2, Panel B), indicating selective PCFT transport. The decreased (~2-fold) 
sensitivity in the R1-11-PCFT4 cells versus R2/PCFT4 CHO cells (Table 3.1) probably reflects 
differences (~10-fold) in PCFT transport activity at pH 5.5 between these engineered sublines 
(Figure 4.1, Panel D). In HepG2 cells, both PMX (IC50, 40.63 ± 4.52 nM) and compound 17 
(IC50, 227.50 ± 8.98 nM) were growth inhibitory (data not shown). The decreased sensitivity to 
compound 17 for HepG2 cells compared with R1-11-PCFT4 cells probably reflects the presence 
of RFC in HepG2 cells. Although not active for transport with compound 17, RFC still transports 
folates and elevates intracellular folate pools, resulting in decreased cytotoxic drug effects on this 
basis (see Chapter 5). Proliferation assays were extended to include colony-forming assays, in 
which R1-11-PCFT4 cells were exposed to a range of concentrations (1–10 µM) of PMX (Figure 
4.2, Panel C) or compound 17 (Panel D) for 16, 24, or 48 h. Drug exposures were performed at 
pH 6.8, after which drugs were removed and colonies allowed to outgrow for 12 days. As an 
inhibitor of colony formation, PMX and compound 17 showed both concentration- and time-
dependence, although this effect was more pronounced for compound 17, and PMX was more 
active at 16 h for the lower drug concentrations. Despite the latter activity, the maximum extent 
of inhibition after 48 h at 10 µM drug was greater for compound 17 (95%) than for PMX (87%). 
Collectively, these results demonstrate that compound 17, like PMX, is cytotoxic toward cells 
that express PCFT, and under acidic conditions (pH 6.8) achievable in solid tumors. Unlike 
PMX, compound 17 is selectively active toward cells expressing PCFT and is inactive toward 
cells expressing exclusively RFC. 
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Figure 4.1 Characterization of folate transporter expression in solid tumor, HeLa, CHO 
sublines and HepG2 in vivo tumor samples. RT-PCR was used to measure: Panel A, PCFT; 
Panel B, RFC; and Panel C, FRα transcript levels. The cell lines included R1-11 sublines, 
IGROV1 and HepG2 cells and HepG2 tumors from the in vivo efficacy trial treated with 
compound 17 or untreated. RNAs were isolated using TRIzol reagent, cDNAs were synthesized 
using random hexamers and RT-PCR was performed using SYBR green and gene-specific 
primers (primer sequences are reported in Table 2.1). Transcript levels were normalized to 
GAPDH. Panel D, PCFT transport activities in R2/VC, R2/PCFT4, R1-11-mock and R1-11-
PCFT4 cells were assessed in cell monolayers by measuring uptake of 0.5 µM [3H]MTX at 37˚C 
for 5 min at pH 5.5 or 7.2 in MES-buffered saline, and at 7.2 in HEPES-buffered saline. 
Internalized [3H]MTX was normalized to total protein. 
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Figure 4.2 Compound 17 and PMX growth inhibition and inhibition of colony formation in 
R1-11 sublines. Panels A and B, Growth inhibition curves for folate-depleted R1-11-PCFT4 and 
-RFC6 cells treated with PMX (Panel A) or compound 17  (Panel B) for 96 h are shown. Panels 
C and D, R1-11-PCFT4 cells were plated in 60 mm dishes at a density of 500 cells per dish and 
allowed to adhere overnight. Cells were treated at pH 6.8 in the presence or absence of different 
concentrations of PMX (Panel C) or compound 17 (Panel D) from 0 to 10 µM for 16, 24 and 48 
h, followed by removal of drug. Plates were scored by counting visible colonies after 12 days (by 
staining with methylene blue) and presented as a percent of vehicle control. 
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4.3.2 Transport Characteristics for [3H]Compound 17 in HeLa R1-11-PCFT4 and HepG2  
Cells. 
To directly measure PCFT membrane transport of the cytotoxic antifolates into HeLa R1-
11-PCFT4 and HepG2 cells, we used radiolabeled compound 17 and PMX. For R1-11-PCFT4 
cells, uptake of [3H]compound 17 (0.25 µM) was time- and pH dependent with maximum drug 
accumulation at pH 5.5 (Figure 4.3, Panels A–C). Uptake in R1-11-PCFT4 cells exceeded that of 
its PCFT-null isogenic counterpart (R1-11-mock transfectant), unequivocally establishing 
transport of compound 17 by PCFT. A modest time-dependent uptake in the PCFT null R1-11-
mock transfected subline was particularly obvious at 30 min and probably reflects the presence 
of low levels of FR in these cells (Figure 4.1, Panel C).  
We compared the uptake of [3H]PMX with that of [3H]compound 17 in HepG2 cells 
(Figure 4.3, Panel D and E). For compound 17, pH-dependent uptake in HepG2 cells showed a 
profile (despite the ~2-fold increased net uptake) similar to that of R1-11-PCFT4 HeLa cells. Net 
uptake of [3H]PMX exceeded that of [3H]compound 17 in HepG2 cells by ~50 to 100% and 
showed a greater uptake fraction at neutral pH, most likely due to the presence of RFC in HepG2 
cells (Figure 4.1, Panel B).  
We measured transport kinetics over 2 min for [3H]compound 17 and [3H]PMX in R1-
11-PCFT4 cells using a range of drug concentrations at pH 5.5 and 6.8 (Table 4.1). The data 
show nearly identical Kt values for compound 17 and PMX at pH 5.5 and only modest (within 
~40%) differences in Vmax. Increases in both Kt (increased ~300- to 400-fold, respectively, 
compared with values at pH 5.5) and Vmax values (~70% increased) were observed at pH 6.8. 
Vmax /Kt ratios for compound 17 and PMX were similar (within ~2-fold) at both pH 5.5 and pH  
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Figure 4.3 pH- and time-dependent transport of compound 17 and PMX into R1-11-PCFT4 
and HepG2 cells. Panels A-D, Direct PCFT transport activity of compound 17 and Panel E, 
PMX in R1-11-PCFT4 (A-C) and HepG2 (D and E) cells was assessed by measuring uptake of 
0.25 µM [3H]compound 17 or [3H]PMX over 2-30 min at 37°C in complete folate-free RPMI 
1640 (pH 5.5, 6.8 and 7.2), supplemented with 10% dFBS, and 25 mM HEPES/25 mM PIPES. 
Internalized [3H]compound 17 and [3H]PMX were normalized to total protein and expressed as 
pmol/mg protein. 
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6.8. These results establish that for both R1-11-PCFT4 and HepG2 cells, compound 17 is an 
excellent substrate for PCFT, essentially equivalent to PMX. 
4.3.3 Polyglutamylation of Compound 17 in R1-11-PCFT4 and HepG2 Cells.  
Polyglutamylation of classic antifolates is a critical factor in drug activity, because these 
conjugated drug forms are retained within cells and they typically inhibit folate-dependent 
enzyme targets to a greater extent than their nonpolyglutamyl forms (Goldman and Matherly, 
1985; Shane, 1989). To assess the extent of this metabolism for compound 17 in R1-11-PCFT4 
and HepG2 cells, cells were treated with 1 µM [3H]compound 17 for 16 h at pH 6.8 in the 
presence of adenosine (60 µM). For HepG2 cells, parallel incubations were performed with 
[3H]PMX [in presence of thymidine (10 µM) and adenosine (60 µM)]. 3H-labeled metabolites 
were extracted and analyzed by reversed-phase HPLC. Figure 4.4 shows HPLC chromatographs 
for compound 17 (Panel A) and PMX (Panel B) in HepG2 cells. Up to five polyglutamyl (PG) 
metabolites of [3H]compound 17 and [3H]PMX (PG2–6) were resolved by HPLC. The identities 
of the peaks were confirmed by comparing elution times with those for MTX polyglutamyl 
standards and by treatment with chicken pancreas conjugase which reverted the majority of the 
polyglutamyl metabolites to the parental drug. The distributions of the individual compound 17 
and PMX drug forms in R1-11-PCFT4 and HepG2 cells are summarized in Table 4.2. Although 
there were differences in the relative amounts of total intracellular compound 17 between the R1-
11-PCFT4 and HepG2 sublines (as expected from the transport results in Figure 4.3), in both 
cases, compound 17 was predominantly polyglutamylated (64 and 84% of the total intracellular 
drug, respectively). For HepG2 cells, the increased accumulation of [3H]compound 17 over that 
of R1-11-PCFT4 cells was reflected in the polyglutamate levels. Analogous results were 
obtained with [3H]PMX in HepG2 cells, although the net extent of drug uptake and metabolism 
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Figure 4.4 HPLC analysis of polyglutamyl derivatives of compound 17 in HepG2 cells at 
pH 6.8.  HepG2 cells were treated with 1 µM [3H]compound 17 (Panel A) and 1 µM [3H]PMX 
(Panel B) at pH 6.8 in the presence of adenosine (60 µM) for 16 h. Polyglutamates were 
extracted by boiling in 50 mM phosphate buffer (pH 6.0) containing 100 mM 2-mercaptoethanol 
and separated on a 5 µm Spherisorb C-18 ODS-2 column (4.6 mm x 250mm) with a Nova-Pak 4 
µm C-18 guard column. Fractions were collected and radioactivity was measured. Percent 
monoglutamate and polyglutamate (PG2-6) drug forms were determined by chromatographic 
analysis and the total intracellular radiolabel calculated in units of pmol/mg protein (Table 4.2).  
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of [3H]PMX was elevated over that of [3H]compound 17. Collectively, these results establish 
that, like PMX, compound 17 is an excellent substrate for polyglutamylation under conditions 
(pH 6.8) that favor its membrane transport by PCFT. 
4.3.4 Validation of GARFTase and De novo Purine Nucleotide Biosynthesis as the Primary 
Cellular Targets for Compound 17 in R1-11-PCFT4 Cells.  
In Chapter 3 the principal intracellular target of compound 17 was established in PCFT-
expressing CHO cells as GARFTase, the first folate-dependent enzyme in de novo purine 
nucleotide biosynthesis (Wang et al., 2010). To confirm this result in R1-11-PCFT4 HeLa cells 
under acidic conditions (pH 6.8) that favor PCFT transport, we used an in situ metabolic assay 
that quantifies incorporation of [14C]glycine into [14C]formyl GAR as a measure of GARFTase 
inhibition. Results were compared with those of PMX, an established GARFTase inhibitor, along 
with its documented effects on TS (Chattopadhyay et al., 2007) and AICARFTase (Racanelli et 
al., 2009) (Figure 4.5, Panel A). IC50 values for GARFTase inhibition in R1-11-PCFT4 cells by 
compound 17 and PMX were 43.6 and 69.7 nM, respectively. Although the IC50 for GARFTase 
inhibition by compound 17 closely approximated the IC50 for growth inhibition of R1-11-PCFT4 
cells (Table 3.1), GARFTase inhibition by PMX was incomplete up to 5 µM. Analogous results 
were described for PMX with PCFT-expressing CHO cells (R2/PCFT4) (Chapter 3) (Kugel 
Desmoulin et al., 2010b) and with CCRF-CEM cells by Moran and coworkers (Racanelli et al., 
2009). To confirm that potent inhibition of GARFTase in R1-11-PCFT4 cells by compound 17 
also results in decreased ATP pools, we measured intracellular ATP levels in cells treated with 
10 µM compound 17 for 16, 24 and 48 h under conditions (pH 6.8) analogous to those used for 
our clonogenicity studies (Figure 4.2, Panel D). Compound 17 caused a time-dependent and 
concentration-dependent decrease in cellular ATP levels, such that treatment for 48 h led to an  
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Figure 4.5 in situ GARFTase inhibition and intracellular ATP levels in R1-11-PCFT4 cells 
treated with compound 17 and PMX. Panel A, GARFTase activity and inhibition were 
evaluated in situ with R1-11-PCFT4 cells. R1-11-PCFT4 cells were treated with drug for 16 h at 
pH 6.8 in complete buffered folate-free RPMI 1640 supplemented with 25 nM  5-CHO-THF 
before incubating in the presence of 4 µM azaserine for 30 min, followed by [14C]glycine and L-
glutamine treatment. After 8 h, radioactive metabolites were extracted and fractionated on 1 cm 
columns of AG1x8(Cl-) and the fractions were collected and radioactivity measured. 
Accumulation of [14C]formyl GAR was calculated as a percent of vehicle control over a range of 
antifolate concentrations. Panel B, For analysis of ATP levels, cells were treated with 10 µM 
compound 17 or left untreated (DMSO) for 48 h at pH 6.8. Nucleotides were extracted and ATP 
pools were determined by a modification of the HPLC method of Huang et al. (2003a), as 
previously described (Kugel Desmoulin et al., 2010b). Details are provided in the Materials and 
Methods. 
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88% decrease in ATP pools (Figure 4.5, Panel B). These results demonstrate that PCFT-delivery 
of compound 17 is an efficient mode of drug uptake that effects a potent inhibition of GARFTase 
and ATP depletion in R1-11-PCFT4 cells. 
4.3.5 Effect of Compound 17 on Cell Cycle Progression and Apoptosis Induction in 
R1-11-PCFT4 Cells.  
To determine the impact of GARFTase inhibition and ATP depletion on cell-cycle 
progression, we treated R1-11-PCFT4 cells with compound 17 (10 µM) for 48 h at pH 6.8, along 
with a vehicle control. Cells were fixed, stained with PI, and analyzed for cell cycle distribution 
by flow cytometry. Treatment with 10 µM compound 17 caused an accumulation of cells in S-
phase such that 38.9% of cells were in S-phase, compared with 16.8% of the control (Figure 4.6, 
Panel A and B). When a range of concentrations (0.5, 1, 5, and 10 µM) of compound 17 were 
tested for their abilities to induce S-phase accumulation, we found that maximal arrest was 
achieved at 1 µM. Because treatment with compound 17 (10 µM, 48 h at pH 6.8) causes loss of 
clonogenicity in R1-11-PCFT4 cells (Figure 4.2, Panel D) and a modest increase in the sub-G1 
fraction (Figure 4.6, Panel A and B), we were interested in measuring apoptosis under these 
same conditions using annexin V/PI staining. Results were compared with those for R1-11-
PCFT4 cells treated with etoposide (5 µM) and with a no-drug control. Whereas etoposide 
strongly induced apoptosis (12.2% early apoptotic and 22.3% late apoptotic/necrotic) compared 
with the negative controls (2.9 and 10.3%, respectively), compound 17 was less apoptotic (8.4 
and 15.7%, respectively) (Figure 4.6, Panel C). These results are consistent with previous reports 
that GARFTase inhibitors are distinctly cytotoxic, yet modestly apoptotic (Deng et al., 2008; 
Smith et al., 1993). 
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Figure 4.6 Compound 17 treatment induces an S-phase accumulation, accompanied by a 
modest level of apoptosis in R1-11-PCFT4 cells. Panel A, Representative cell cycle profiles 
were determined in R1-11-PCFT4 cells treated with a range of concentrations of compound 17 
for 48 h by measuring the cellular DNA content with PI staining and flow cytometry. SubG1 
(apoptotic fraction) (white trace), G1 (dark grey trace), S (light grey trace), and G2 (grey trace). 
Panel B, The percentages of cells in each phase of the cell cycle (G1, S, and G2), including those 
in the subG1 fraction for all concentrations of compound 17. Panel C, Pseudo-color dot plots 
show the flow cytometric analysis of cells stained with annexin V-FITC and PI. The percentages 
of viable cells (annexin V-/PI-), early apoptotic cells (annexin V+/PI-), and late 
apoptotic/necrotic cells (annexin V+/PI+) are noted.  As a positive control, cells were treated 
with 5 µM etoposide for 48 h at pH 6.8 to induce apoptosis. 
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4.3.6 In vivo Efficacy Study of Compound 17 Against HepG2 Xenografts.  
As proof of concept that in vivo antitumor efficacy can result from tumor targeting of 
compound 17 via its transport by PCFT, an in vivo efficacy trial was performed with 8-week-old 
female ICR SCID mice implanted with subcutaneous HepG2 tumors that express PCFT and RFC 
but not FRα (Figure 4.1, Panel A). Mice were maintained ad libitum on folate-deficient or 
standard folate-replete diets. Serum folate concentrations were measured in mice after 14 days on 
the folate-deficient diet by an L. casei bioassay; the value was 90.2 nM (median) [range, 79.2–
120.7 nM (n = 3)]. This value slightly exceeds serum folate levels (31 and 35 nM, respectively) 
reported previously in humans (Ganji and Kafai, 2009). With the standard diet, by comparison, 
serum folate was 715.2 nM (median) [range, 652.8–742.8 nM (n = 3)]. For the trial, control and 
drug treatment groups were nonselectively randomized (five mice per group); compound 17 was 
administered intravenously on a schedule of every 4 days for three treatments (180 mg/kg per 
injection) on days 4, 8, and 12 after implantation (total dose 540 mg/kg). Results were compared 
with those for paclitaxel (Taxol; every 2 days for six treatments, 7.5 mg/kg per injection). Mice 
were weighed daily and tumors were measured 2 to 3 times per week. For the mice maintained 
on the folate-deficient diet, appreciable antitumor activity was recorded with compound 17 (T/C 
of 0% on day 21; T - C = 13 days; 1.4 gross log kill) (Table 4.3), exceeding that for paclitaxel 
(T/C = 16%; 0.8 gross log kill). Antitumor drug efficacy for 17 was completely abolished (99% 
T/C) for the standard folate-replete diet. The treatment regimen was well tolerated with dose-
limiting symptoms manifesting as reversible body weight loss for mice maintained on the folate-
deficient diet. Results for the in vivo efficacy experiment shown in Figure 4.7 are summarized in 
Table 4.3. Tumor samples treated with compound 17 and untreated controls were harvested, 
RNA was extracted and PCFT, RFC and FRα transcripts were measured.  
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 Figure 4.7 in vivo efficacy trial of compound 17 in HepG2 xenografts. Female ICR SCID 
mice were maintained on a folate-deficient diet ad libitum.  Human HepG2 tumors were 
implanted bilaterally and mice were non-selectively randomized into 5 mice/group. Compound 
17 [dissolved in 5% ethanol (v/v), 1% Tween-80 (v/v), 0.5% NaHCO3] was administered on a 
Q4dx3 schedule intravenously on days 4, 8, and 12 (indicated with arrows) at 180 
mg/kg/injection.  Taxol (dissolved in water) was administered on a Q2dx6 schedule (7.5 
mg/kg/injection) beginning on day 4. Mice were observed and weighed daily; tumors were 
measured twice per week. For the mice maintained on the folate-deficient diet and treated with 
compound 17, appreciable antitumor activity was recorded (T/C=0%; T-C=13 days; 1.4 gross 
log kill).  
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In vivo passage of HepG2 cells did not change the expression of RFC (Figure 4.1, Panel 
B) or FRα (Panel C) transcripts; PCFT (Panel A) on the other hand increased expression in the in 
vivo environment in both treated and untreated tumor samples, suggesting that tumor cells 
expressing PCFT may be selected for in vivo or that the acidic environment may have induced 
PCFT expression. The results of the in vivo efficacy trial demonstrate potent antitumor activity 
for compound 17 toward subcutaneously engrafted HepG2 tumors associated with significant 
transport by PCFT and a lack of membrane transport by RFC.  
4.4 Discussion.  
This chapter significantly expands upon previous results (Chapter 3) (Anderson and 
Thwaites, 2010; Kugel Desmoulin et al., 2010b; Zhao and Goldman, 2007) suggesting that PCFT 
may be therapeutically exploitable for treating solid tumors. We further show that the novel 6-
substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate compound 17 can be selectively 
transported by PCFT in a pH- and time-dependent manner. The tumor models employed, R1-11-
PCFT4 HeLa and HepG2 cells, express similar levels of PCFT, although they differ in the 
presence of RFC and FRα. The premise behind our drug discovery efforts, exemplified by 
compound 17, is that membrane transport of cytotoxic antifolates is a critical determinant of 
antitumor drug selectivity. Compound 17 is not transported by the ubiquitously expressed RFC 
(Wang et al., 2010). This is particularly important because drugs such as compound 17 that target 
FRα and/or PCFT, yet are not substrates for RFC, have the potential to selectively target tumor 
cells and decrease toxicity to normal tissues. This is a substantial advantage over chemotherapy 
drugs currently in use; indeed, pursuing the development of these novel antifolates could yield a 
new class of clinically relevant antitumor agents. Our previous work used engineered CHO 
models (Chapter 3), as well as KB (nasopharyngeal) and IGROV1 (ovarian) human tumor cells 
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that express FRα and/or PCFT to deliver cytotoxic antifolates, including compound 17, that are 
not substrates for RFC (Deng et al., 2008; Deng et al., 2009; Kugel Desmoulin et al., 2011; 
Wang et al., 2010).  
The present report significantly expands upon this concept by demonstrating exclusive 
transport of compound 17 by PCFT into human tumor cell lines at pH values characterizing the 
tumor microenvironment. For R1-11-PCFT4 and HepG2 cells, after its internalization at pH 6.8, 
compound 17 was extensively polyglutamylated, such that the predominant metabolite was the 
pentaglutamate form (compound 17 conjugated to 4 glutamate residues). Moreover, compound 
17 potently inhibited GARFTase, leading to R1-11-PCFT4 HeLa cell death in vitro and HepG2 
tumor growth delay in vivo.  
Expression of PCFT transcripts and protein in normal human tissues is more restrictive 
than for RFC, high PCFT levels being observed in the liver, kidney, and small intestine and very 
low levels in the bone marrow and colon (Chapter 2 and Kugel Desmoulin et al. (2010a)). This 
pattern of PCFT transcripts was also generally observed in mouse tissues (Qiu et al., 2007). Our 
finding that PCFT transcripts are low in human bone marrow is particularly significant and 
suggests that PCFT-targeted therapeutics may be less marrow toxic than antifolates presently in 
clinical use. The microenvironments for most normal tissues probably exhibit a neutral pH 
(Martin and Jain, 1994), such that even if PCFT is present, the electrochemical proton gradient is 
reduced, leading to less accumulation of PCFT substrates such as compound 17. Conversely, 
RFC would exhibit a far greater activity under these conditions. This, when combined with the 
greater capacity of RFC to transport reduced folates across the cell membrane compared with 
PCFT (Zhao et al., 2008), would result in elevated levels of cellular folates in normal tissues. 
The increased availability of reduced folates would result in competition with internalized 
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antifolates for polyglutamylation and/or for binding to intracellular drug targets (e.g., 
GARFTase), thus protecting normal cells from drug cytotoxicity. Likewise, for PCFT-targeted 
agents in solid tumors, if sufficient RFC were present, enough transport of folates might occur 
even at slightly acidic pH values to decrease drug efficacy on this basis. This implies that the 
ratio of PCFT to RFC in tumors is critical to antitumor activities of PCFT-selective cytotoxic 
antifolates and that MTX-resistant tumors that have substantially lost RFC function may be 
exquisitely sensitive to the effects of PCFT selective drugs such as compounds 16 and 17 
(Chapter 5). Thus, for compound 17 and related agents, tumor selectivity is not only reliant upon 
differential PCFT levels between normal tissues and solid tumors but is also affected by 
interstitial pH and activity of RFC.  
It is interesting that under nearly the same conditions, the IC50 for GARFTase inhibition 
in R1-11-PCFT4 cells by the in situ GARFTase assay is virtually identical to the IC50 for 
inhibition of cell proliferation. This result differs somewhat from our previous finding with an 
analogous 6-substituted pyrrolo[2,3 d]pyrimidine benozyl antifolate compound 3 in CHO cells 
for which the IC50 for GARFTase inhibition was substantially lower, suggesting that sustained 
GARFTase inhibition was necessary to manifest as cytotoxicity (Chapter 3 and Kugel Desmoulin 
et al. (2010b)). This quantitative difference may reflect differences in the size of purine pools 
between the human and hamster sublines such that R1-11-PCFT4 HeLa cells would be more 
sensitive to the inhibition of GARFTase. Of course, other factors could also contribute. For 
instance, differences in drug polyglutamylation and polyglutamate turnover could result in 
disparate potencies for sustained GARFTase inhibition in different cell lines. Finally, our studies 
with compound 17 assess the impact of GARFTase inhibition on ATP levels and the 
mechanism(s) of tumor cell death.  
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Treatment of R1-11-PCFT4 cells with compound 17 substantially reduced ATP levels 
and caused S-phase accumulation. Apoptosis resulting from compound 17 was reduced 
compared with etoposide. This could (at least in part) reflect the requirement of ATP for 
apoptosis, because ATP levels must be maintained above a minimal level for apoptosis induction 
(Tsujimoto, 1997). 
 In conclusion, our in vitro studies suggest the feasibility of using PCFT and the acidic 
tumor microenvironment to selectively deliver a novel PCFT-targeted antifolate to human solid 
tumors endogenously expressing modest levels of PCFT. Our in vivo results with HepG2 tumor 
cells that express only PCFT and RFC provide compelling proof-of-principle validation and 
rationale for developing drugs whose transport by PCFT, but not RFC, allows for GARFTase 
inhibition. 
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CHAPTER 5 
 
THE IMPACT OF RFC FUNCTION ON THE ACTIVITY OF ANTIFOLATES 
SELECTIVELY TRANSPORTED BY PCFT 
 
5.1 Introduction. 
Classic antifolates such as MTX and PMX, like folate cofactors, have minimal lipid 
solubility and therefore require specific transport mechanisms to enter tumor cells. There are 
three primary folate transporters, including RFC, PCFT and FRα (Assaraf, 2007; Goldman et al., 
2010).  RFC is the predominant transport route for the major circulating folate, 5-methylTHF, 
and (6S) 5-CHO-THF in mammalian cells and tissues. RFC also mediates cellular uptake of 
MTX and is essential to MTX antitumor activity (Matherly et al., 2007). Impaired RFC function 
is a major mechanism of MTX resistance in cultured tumor cells selected in vitro (Matherly et 
al., 2007; Zhao and Goldman, 2003) and in murine leukemia cells in vivo (Sirotnak et al., 1981). 
Loss of RFC function in clinical specimens has also been reported (Gorlick et al., 1997; Guo et 
al., 1999; Yang et al., 2003).  RFC transport of cytotoxic antifolates can also be undesirable since 
RFC is ubiquitously expressed and exhibits a high level of activity at the physiological  pH of 
most normal tissues (Matherly et al., 2007). Thus, transport of antifolates by RFC could easily 
preclude tumor selectivity and cause toxicity to normal tissues.  
The novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with 3- (compound 
16) or 4- (compound 17) carbon bridge lengths (Chapters 3 and 4; Figure 3.1, Panel C) represent 
an entirely new class of antitumor agents that exhibit a lack of significant membrane transport by 
RFC (Chapters 3 and 4) (Kugel Desmoulin et al., 2011; Wang et al., 2010; Wang et al., 2011). 
Cellular uptake of compounds 16 and 17 by PCFT and FRα is efficient and offers a promising 
new strategy for tumor targeting. (Anderson and Thwaites, 2010). Since PCFT functions 
optimally at acidic pHs (Qiu et al., 2006; Umapathy et al., 2007; Zhao et al., 2008), transport of 
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16 and 17 by this mechanism may lead to enhanced tumor selectivity owing to the acidic 
microenvironments of many solid tumors (Anderson and Thwaites, 2010; Helmlinger et al., 
1997; Webb et al., 2011). Following internalization, compound 17 is metabolized to 
polyglutamates (Chapter 4) (Kugel Desmoulin et al., 2011), although this has not been 
previously confirmed for compound 16. Both 16 and 17 inhibit de novo purine nucleotide 
synthesis by targeting the first folate-dependent enzyme, GARFTase, causing a dramatic drop in 
purine nucleotide pools (Chapters 3 and 4) (Kugel Desmoulin et al., 2011; Wang et al., 2010; 
Wang et al., 2011). In the case of compound 17, treatment results in S-phase accumulation and 
cell death, in part by a non-apoptotic mechanism (Kugel Desmoulin et al., 2011). Not 
surprisingly, compounds 16 and 17 are potent inhibitors of tumor cell proliferation both in vitro 
and in vivo (Chapters 3 and 4) (Kugel Desmoulin et al., 2011; Wang et al., 2010; Wang et al., 
2011). 
For agents such as PMX that are excellent substrates for both RFC and PCFT, loss of 
RFC has limited impact on overall activity , since PMX uptake is maintained by PCFT (Zhao et 
al., 2004c; Zhao et al., 2008). Paradoxically, RFC loss has been shown to enhance antitumor 
activity (i.e., collateral sensitivity) of PMX via decreased intracellular THF cofactor pools 
(Chattopadhyay et al., 2007; Chattopadhyay et al., 2006; Zhao et al., 2004c). This response to 
RFC loss can be further impacted by the type and amount of extracellular folate (Chattopadhyay 
et al., 2006; Zhao et al., 2004b; Zhao et al., 2004c). 
An analogous effect may exist for PCFT-selective substrates such as compounds 16 and 
17 (Kugel Desmoulin et al., 2011), although this has never been systematically tested. In this 
chapter, the complex interplay between RFC and extracellular reduced folates is examined. 
Specifically, we investigate the mechanistic ramifications of loss of RFC function toward in vitro 
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and in vivo antitumor efficacies of these novel PCFT-targeted antifolates, including the impact 
on their membrane transport, polyglutamylation, and GARFTase inhibition. The results strongly 
imply that levels of RFC transport in tumors are a critical determinant of drug efficacy for this 
novel class of PCFT-selective antitumor agents.  
5.2 Materials and Methods. 
5.2.1 Chemicals and Reagents. 
[3’,5’,7-3H]MTX (20 Ci/mmol), [3H]PMX (2.5 Ci/mmol), [3’,5’,7,9-3H(N)](6S)5-formyl 
tetrahydrofolate (5-CHO-THF) (16.6 Ci/mmol), and custom-radiolabeled [3H]compound 16 (16 
Ci/mmol) and [3H]compound 17 (1.3 Ci/mmol) were purchased from Moravek Biochemicals 
(Brea, CA). Unlabeled MTX and (6R,S) 5-CHO-THF were provided by the Drug Development 
Branch, National Cancer Institute, Bethesda, MD. Sources of the antifolate drugs were as 
follows. LMX (5,10-dideaza-5,6,7,8-tetrahydrofolate) and PMX [N-(4-[2-(2-amino-3,4-dihydro-
4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl] benzoyl)(4)-L-glutamic acid] (Alimta) were from 
Eli Lilly and Co. (Indianapolis, IN); RTX [N-(5-[N-(3,4-dihydro-2-methyl-4-oxyquinazolin-6-
ylmethyl)-N-methyl-amino]-2-thenoyl)-L-glutamic acid] was obtained from AstraZeneca 
Pharmaceuticals (Maccesfield, Cheshire, England); and Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-
hemiphthaloyl-L-ornithine (PT523) was a gift of Dr. Andre Rosowsky (Boston, MA).  
Restriction and modifying enzymes were purchased from Promega (Madison, WI).  Other 
chemicals were obtained from commercial sources in the highest available purities. Synthesis 
and properties of the 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate compounds 16 
and 17 were previously described (Wang et al., 2010; Wang et al., 2011). 
5.2.2 Cell Culture. 
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HeLa cells were purchased from ATCC (Manassas, VA). RFC-null R5 HeLa cells in 
which RFC is deleted from the genome were selected by high dose MTX and 
ethylmethanesulfonate treatments (Zhao et al., 2004b). R1-11-mock and R1-11-PCFT4 HeLa 
cells were derived from RFC- and PCFT-null R1-11 cells by stable transfection with 
pZeoSV2(+) vector only, or HA-tagged pZeoSV2(+)-PCFT constructs, respectively. 
Characteristics of the R1-11 HeLa sublines were previously described by Zhao et al. (2008) and 
Chapter 4). The R5 and R1-11 sublines were gifts from Dr. I. David Goldman (Albert Einstein 
School of Medicine, Bronx, NY). All cell lines were maintained in regular RPMI 1640 
supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100 units/mL penicillin, 
100 µg/mL streptomycin, and 2 mM L-glutamine at 37˚C with 5% CO2. For many experiments, 
cells were maintained at physiologic folate levels for at least two weeks prior to the experiment. 
These details are listed in the individual sections. 
5.2.3 Preparation of  the RFCHA/pZeoSV2 Construct and Generation of Stable RFC  
Transfectants. 
Full length human RFC was subcloned using BamHI and Xho1 restriction enzymes into 
pZeoSV2(+) (Invitrogen) in-frame with an HA sequence inserted at the C-terminus (hereafter, 
designated RFCHA/pZeoSV2). The plasmid was transformed into XL10-Gold ultracompetent 
cells (Agilent) and selected using low salt (<90 mM) LB agar plates containing 25 µg/mL 
Zeocin. Plasmids were isolated and the WT RFC construct was confirmed by automated DNA 
sequencing by Genewiz Corp. (South Plainfield, NJ).  
R5 cells were transfected with pZeoSV2 vector control or RFCHA/pZeoSV2 WT with 
Lipofectamine 2000 and opti-MEM (Invitrogen). After 24 h, the cells were cultured in the 
presence of zeocin (0.1 mg/mL). Stable clones were selected by plating for individual colonies in 
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the presence of 0.1 mg/mL zeocin. Colonies were isolated, expanded and screened for expression 
of RFCHA protein by real-time RT-PCR, Western blotting and transport assays at pH 7.2 (see 
below). A representative clone (R5-RFC2) was selected for further study. R5 cells transfected 
with empty pZeoSV2 (R5-mock) were also prepared and used as a negative experimental 
control. R5-RFC2 and R5-mock cells were cultured in regular RPMI 1640 supplemented with 
10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100 units/mL penicillin, 100 µg/mL 
streptomycin, and 2 mM L-glutamine with 0.1 mg/mL zeocin. 
5.2.4 Gel Electrophoresis and Western Blotting.  
To characterize PCFT and RFC protein levels in the assorted solid tumor cell lines and 
the R5-RFC transfectants, sucrose gradient-enriched plasma membranes were prepared, exactly 
as described in Chapter 2 (Matherly et al., 1991). Proteins were quantified with Folin-phenol 
reagent (Lowry et al., 1951). Membrane proteins were electrophoresed on 7.5% polyacrylamide 
gels in the presence of SDS (Laemmli, 1970) and electroblotted onto PVDF membranes (Pierce, 
Rockford, IL) (Matsudaira, 1987). For the solid tumor cell lines and RFC clones, 
immunoreactive human PCFT and human RFC proteins were detected on PVDF membranes 
with the PCFT or RFC-specific polyclonal antibodies described in Chapter 2.  An IRDye800CW-
conjugated goat anti-rabbit IgG (Rockland, Gilbertsville, PA) secondary antibody was used. For 
detection of HA-tagged proteins (R5-RFCHA) HA-specific mouse monoclonal antibody 
(Covance, Emeryville, CA) and an IRDye800CW-conjugated goat anti-mouse IgG (Rockland, 
Gilbertsville, PA) secondary antibody were used. Membranes were scanned with the Odyssey® 
Imaging System. PCFT and RFC levels were normalized to Na+/K+ ATPase protein levels 
(mouse antibody from Novus Biologicals, Littleton, CO).   
5.2.5 Transport Assays.  
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To measure the pH-dependent uptake of [3H]compound 16, [3H]compound 17, [3H]PMX 
and [3H]MTX (0.5 µM) in WT and R5 HeLa cells, drug uptake was assayed at 37o C in cell 
monolayers in 60 mm dishes over 2 min at 37°C in 2 mL “anion-free” HEPES-sucrose-Mg+2 
buffer (20 mM HEPES, 235 mM sucrose, pH adjusted to 7.14 with MgO) (AFB) (Wong et al., 
1997) or in MES-buffered saline  (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 
mM glucose) at pH 5.5. In either case, transport fluxes were stopped by aspirating the incubation 
buffer and quenching with excess (>5 mL) ice-cold DPBS, followed by 3 washes with ice-cold 
DPBS. Cellular proteins were solubilized with 0.5 N NaOH and quantified using Folin-phenol 
reagent (Lowry et al., 1951). Levels of drug uptake were expressed as pmol/mg protein, 
calculated from direct measurements of radioactivity with a Beckman Model LS6500 liquid 
scintillation counter (Beckman-Coulter, Fullerton, CA) and protein contents of the cell 
homogenates.  
5.2.6 Real-time RT-PCR Analysis of RFC, FRα, and PCFT Transcripts.  
RNAs were isolated from HeLa, R5 and R5-RFC2 cells using TRIzol reagent 
(Invitrogen). cDNAs were synthesized using random hexamers, RNase inhibitor, and MuLV 
reverse transcriptase and purified with the QIAquick PCR Purification Kit (Qiagen). Real-time 
RT-PCR was performed on a Roche LightCycler 2.1 (Roche, Indianapolis, IN) with  gene-
specific primers and FastStart DNA Master SYBR Green I enzyme reaction mix (Roche), as 
described (Ge et al., 2007). Primers are included in Table 2.1. Transcript levels for RFC were 
normalized to those for GAPDH. External standard curves were constructed for each gene of 
interest using serial dilutions of linearized templates, prepared by amplification from suitable 
cDNA templates, subcloning into a TA-cloning vector (PCR-Topo; Invitrogen), and restriction 
digestions.  
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5.2.7 Cell Proliferation Assays.  
For cell proliferation assays, WT and R5 HeLa sublines were cultured in folate-free 
RPMI 1640 (pH 7.2), supplemented with 10% dialyzed fetal bovine serum (dFBS), 2 mM L-
glutamine and 100 units/mL penicillin 100 µg/mL streptomycin (hereafter, designated complete 
folate-free RPMI 1640 medium), containing 25 nM 5-CHO-THF, for at least 2 weeks prior to 
experiment. For assays of drug inhibitions, the cells were plated in 96 well culture dishes (5000 
cells/well; 200 µL/well) in the above medium with a broad concentration range of drugs 
(depending on the compound, drug dilutions were in DMSO or water with appropriate vehicle 
controls); cells were incubated for up to 96 h at 37oC in a CO2 incubator. Metabolically active 
cells (a measure of cell viability) were assayed with CellTiter-Blue™ cell viability assays 
(Promega, Madison, WI) with a fluorescent plate reader (590 nm emission, 560 nm excitation) 
for determining IC50s, corresponding to drug concentrations that result in 50% loss of cell 
growth. To test the impact of extracellular folates on the collateral sensitivities of 16 and 17 in 
R5 and HeLa cells, some growth inhibition experiments included increasing concentrations (25, 
100, 1000 nM) of 5-CHO-THF. 
5.2.8 Accumulation of [3H]5-CHO-THF.  
WT and R5 HeLa sublines were cultured in complete folate-free RMPI 1640 
supplemented with 0.06 mM adenosine and 0.01 mM thymidine for five days prior to the 
experiment. Cells were treated with 0, 25, 100 and 1000 nM [3H]5-CHO-THF (since [3H] (6S)5-
CHO-THF was diluted with non-radioactive (6R,S)5-CHO-THF for these experiments, the actual 
concentration of (6S) stereoisomer was 12.5, 50, 500 nM, respectively) for four days, followed 
by 3 washes with ice-cold DPBS. 0.06 mM adenosine and 0.01 mM thymidine was added to 
control dishes that had no [3H]5-CHO-THF to maintain cell viability. Cellular proteins were 
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solubilized with 0.5 N NaOH and quantified using Folin-phenol reagent (Lowry et al., 1951). 
Total cellular [3H]5-CHO-THF accumulations were expressed as pmol/mg protein, calculated 
from direct measurements of radioactivity and protein contents of cell homogenates. Since 
[3H](6S)5-CHO-THF was diluted with unlabeled (6R,S)5-CHO-THF, as noted above, for 
purposes of calculating intracellular folate metabolites only the unlabeled (6S) isomer was 
considered. To measure the impact of the PCFT-targeted therapeutics 16 and 17 on [3H]5-CHO-
THF accumulations, some experiments analyzed the uptake of 25 nM [3H]5-CHO-THF in the 
presence of increasing concentrations (0-1000 nM) of compounds 16 and 17 in complete folate-
free RPMI 1640 supplemented with 0.06 mM adenosine. 
5.2.9 Measurement of Compound 16 and Compound 17 Polyglutamylation.  
Folate-depleted HeLa and R5 cells were plated in complete folate-free RPMI 1640 
medium, supplemented with 25 nM 5-CHO-THF, and allowed to adhere overnight. Cells were 
washed with DPBS and incubated in the same media, supplemented with 25 mM PIPES/25 mM 
HEPES (pH 6.8), 0.06 mM adenosine and 1 µM [3H]compound 16 or [3H]compound 17. After 
16 h, cells were washed three times with ice-cold DPBS and scraped mechanically into 5 mL of 
ice-cold DPBS, pelleted (1500 rpm) and flash frozen. Polyglutamyl and unmetabolized drug 
forms were extracted and drug levels quantified by HPLC exactly as previously described in 
Chapter 4 and by Kugel Desmoulin et al. (2011). Cellular proteins were precipitated with ice-
cold TCA. The TCA precipitates were solubilized in 0.5 N NaOH before quantifying with Folin-
phenol reagent (Lowry et al., 1951).   
5.2.10 In vivo Efficacy Study of Compounds 16 and 17 in HeLa and R5 Xenografts.  
Cultured WT and R5 HeLa tumor cells were implanted subcutaneously (~ 107 cells/flank) to 
establish a solid tumor xenograft model in female ICR SCID mice (National Institutes of Health 
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DCT/DTP Animal Production Program, Frederick, MD). The mice were supplied food and water 
ad libitum. Study mice were maintained on a folate-deficient diet (Harlan-Teklad; Product ID: 
TD.00434) starting 18 days before subcutaneous tumor implant to ensure serum folate levels 
would approximate those of humans prior to the start of therapy (Kugel Desmoulin et al., 2011; 
Wang et al., 2010; Wang et al., 2011). This design is analogous to those previously published by 
others (Alati et al., 1996; Gibbs et al., 2005). Individual mouse body weights for each experiment 
were within 2 g, and all mice were 19 g (WT) or 19.5 g (R5) HeLa at the start of therapy.  
For the efficacy trial, the experimental animals were pooled and implanted bilaterally 
subcutaneously with 30-60 mg tumor fragments using a 12-gauge trocar as described in Chapter 
4 for the HepG2 in vivo tumor model (Figure 4.7) and chemotherapy began on day 3 post tumor 
implantation, when the number of cells was relatively small (between 107-108 cells; below the 
established limit of palpation). An organic solvent (ethanol, 5% v/v), carrier (Tween-80, 1% v/v) 
and sodium bicarbonate (0.5% v/v) was used to effect water solubilization of compounds 16 and 
17.  Injection volumes were 0.2 mL IV, pH adjusted to 7.0. Tumors were measured with a caliper 
two to three times weekly. Mice were sacrificed when the cumulative tumor burden reached 
1500 mg. Tumor weights were estimated as described previously (Chapter 4). Experimental 
parameters as qualitative and quantitative end points to assess antitumor activities include T/C 
and T-C (tumor growth delay) [where T is the median time in days required for the treatment 
group tumors to reach a predetermined size (e.g., 500 mg) and C is the median time in days for 
the control group tumors to reach the same size; tumor-free survivors are excluded from these 
calculations], and tumor cell kill [log10 cell kill total (gross) = (T - C)/(3.32)(Td), where (T – C) 
is the tumor growth delay, as described above, and Td is the tumor volume doubling time in 
days, estimated from the best fit straight line from a log-linear growth plot of control group 
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tumors in exponential growth (100-800 mg range)]. For comparison of antitumor activity with 
standard agents and comparisons of activity between tumors, the log10 kill values were converted 
to an arbitrary activity rating (Corbett et al., 1998; Corbett et al., 1997; Polin et al., 2011; Polin et 
al., 1997). For duration of treatment between 5 - 20 days: >2.8 log10 kill (Highly active ++++); 
2.0-2.8 (+++); 1.3-1.9 (++); 0.7-1.2 (+); <0.7 (Inactive; –). Both tumor studies (WT and R5 
HeLa cells) used 4 mice per group. The day of tumor implant was day 0. With the exception of 
the xenograft model, these methods are essentially identical to those described previously in 
Chapter 4 (Kugel Desmoulin et al., 2011; Wang et al., 2010). 
5.3 Results. 
5.3.1 PCFT Transport of [3H]Compound 16 in R1-11-PCFT4 HeLa Cells.  
The expression of high levels of PCFT in diverse human tumor cell lines (Chapter 2) 
gives credence to the notion that folate-based cytotoxins with specificity for PCFT over RFC 
membrane transport could be used for chemotherapy of human solid tumors. We found that the 
novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates 16 and 17 (Figure 3.1) were 
potent (nM) inhibitors of cell proliferation in cells engineered to express PCFT in the absence of 
RFC or FRs (Kugel Desmoulin et al., 2011; Wang et al., 2010; Wang et al., 2011) (Table 3.1), 
suggesting that 16 and 17 are substrates for PCFT-mediated cellular uptake (Chapter 3). This 
was extended to human HepG2 human hepatoma cells endogenously expressing PCFT without 
FRs (Chapter 4) (Kugel Desmoulin et al., 2011). In engineered cell lines, compounds 16 and 17 
appeared to be poorly transported by RFC (Chapter 3 and 4) (Kugel Desmoulin et al., 2011; 
Wang et al., 2010; Wang et al., 2011). Both analogs induced current at -90 mV and pH 5.5 in 
Xenopus oocytes microinjected with PCFT cRNAs, and both were competitive inhibitors of 
[3H]MTX transport in PCFT transfectants from pH 5.5 to pH 6.8 (Chapter 3) (Kugel Desmoulin 
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et al., 2011; Wang et al., 2011). Transport of [3H]compound 17 by PCFT was directly 
demonstrated in R1-11-PCFT4 HeLa cells (Chapter 4) (Kugel Desmoulin et al., 2011).  
By analogy, to confirm PCFT transport of compound 16, R1-11-PCFT4 cells were 
incubated with [3H]compound 16 (0.5 µM, 5 min, 37 ˚C) at pH 5.5 and pH 6.8 in the presence 
and absence of unlabeled compound 17 (10 µM) as a competitive inhibitor. Transport was 
detected at a ~4-fold higher level at pH 5.5 than at pH 6.8, and at either pH uptake was 
substantially abolished in the presence of unlabeled compound 17 (Figure 5.1).  These results 
establish that compound 16, like its 4-carbon analog, compound 17, is a bona fide substrate for 
membrane transport by PCFT.  
5.3.2 Transport and Membrane Expression of  PCFT and RFC in WT and R5 HeLa  
Sublines.  
While compounds 16 and 17 are not RFC transport substrates, levels of RFC could 
nonetheless markedly impact the anti-proliferative effects of these agents, via expansion or 
contraction of intracellular THF cofactor pools. This could be further impacted by varying 
concentrations of extracellular THF cofactors. Thus, RFC levels or ratios of PCFT to RFC 
transport might effectively predict anti-tumor potencies of these prototypical PCFT-targeted 
antifolates (Figure 2.2, Panel E and Figure 2.5, Panel C).  
To explore this concept, we used WT and R5 HeLa cells which express comparable 
levels of PCFT with or without RFC at the protein (Figure 5.2, Panel A) and transcript levels 
Figure 5.2, Panel B). R5 cells are resistant to MTX (Figure 5.4, Panel A) because of a genomic 
deletion that results in loss of RFC (Zhao et al., 2004a). MTX resistance is completely reversible 
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Figure 5.1 PCFT transport activity of compound 16 in R1-11-PCFT4 HeLa cells. Uptake of 
[3H]compound 16 (0.5 µM) was measured at 37˚C for 5 min at pH 5.5 (MES-buffered saline) 
and 6.8 (HEPES-buffered saline) in the presence or absence of unlabeled compound 17 (10µM). 
Internalized [3H]compound 16 was normalized to total protein. Details are provided in Materials 
and Methods. Results are shown for mean values + SEMs for 3 independent experiments. 
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Figure 5.2 Characterization of WT and R5 HeLa sublines.  Panel A, Western blots of sucrose 
gradient purified membrane fractions (25 µg) using human polyclonal PCFT and RFC and 
monoclonal HA antibodies to detect WT and HA-tagged proteins (R5-RFCHA). Panel B, RT-
PCR was used to measure RFC transcript levels in WT and R5 HeLa sublines, RNA was isolated 
using TRIzol reagent, cDNA was synthesized using random hexamers and RT-PCR was 
performed using SYBR green and gene-specific primers (primer sequences are reported in Table 
2.1) and transcript levels were normalized to GAPDH. Panel C, the uptake of [3H]MTX was 
measured at 37˚C for 2 min in WT and R5 HeLa monolayers at pH 7.2 (Anion-free buffer). 
Uptake of 0.5 µM [3H]MTX, [3H]PMX, [3H]compound 17 and [3H]compound 16 was measured 
at 37˚C for 2 min in WT and R5 HeLa cell monolayers at pH 5.5 in MES-buffered saline  (Panel 
D) and pH 7.2 (Anion-free buffer) (Panel E). Internalized [3H]drug was normalized to total 
protein. The data in panels D and E represent mean values + SEMs for 3 independent 
experiments. While there were slight differences in initial rates of uptake for compounds 16 and 
17 in panel D, these were not statistically significant (p>0.1). 
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upon transfection with WT RFC (R5-RFC2 cells), which restores RFC transport (Figure 5.2, 
Panel C); confirming that loss of RFC transport is causal to the resistant phenotype.  
While [3H]MTX (0.5 µM) transport at pH 5.5 was nearly identical for WT and R5 HeLa 
cells at pH 5.5 (Figure 5.2, Panel D), MTX uptake in R5 cells in Anion-free buffer at pH 7.2 was 
decreased ~3-fold compared to WT cells (Figure 5.2, Panel E), consistent with the loss of RFC. 
pH 5.5 (PCFT) to pH 7.2 (RFC) MTX transport ratios for R5 and HeLa cells were ~11- and ~3-
fold, respectively (Figure 2.5, Panel C). Transport was also measured for [3H]compounds 16 and 
17 (both at 0.5 µM; 2 min, 37o C) and for [3H]PMX at  pH 5.5 and  pH 7.2. Results were 
compared to those for [3H]MTX.  For all compounds and both cell lines, transport by PCFT over 
RFC clearly predominated, as uptake showed a characteristic pH dependence for PCFT with the 
highest levels at pH 5.5. While there were differences in cellular uptake of the various analogs at 
pH 5.5 with 16 > 17 > PMX~MTX, there were no obvious differences in net membrane transport 
of the individual analogs between WT HeLa and R5 cell lines (Figure 5.2, Panels D and E).  
5.3.3 Impact of RFC and Extracellular Folate on Antitumor Activities of Compounds 16 
and 17.  
5-CHO-THF is poorly transported by PCFT at neutral pH and is less effective in 
supporting proliferation of PCFT-expressing cells (without RFC) than RFC-expressing cells 
(without PCFT) (Zhao et al., 2008). Thus, the loss of RFC in R5 cells would be predicted to 
impact THF cofactor requirements for cell proliferation and to contract intracellular pools of 
reduced folates derived from 5-CHO-THF, compared to those in WT HeLa cells (Chattopadhyay 
et al., 2006; Zhao et al., 2004b). This response may be exacerbated in the presence of high 
affinity PCFT-selective substrates which could further restrict the modest levels of THF cofactor 
uptake via PCFT through direct competition.  
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To examine these possibilities, folate-depleted WT, R5 and R5-RFC2 cells were cultured 
in 25, 100, or 1000 nM [3H]5-CHO-THF [corresponding to 12.5, 50, or 500 nM of the active 
(6S) stereoisomer] for 96 h in order to determine cellular accumulation of [3H]THF metabolites. 
During sustained culture, the media pH decreases to ~6.8 (Kugel Desmoulin et al., 2010b) and 
was accompanied by a dose-dependent accumulations of [3H]5-CHO-THF (Figure 5.3, Panel A). 
At 25 nM extracellular [3H]5-CHO-THF, R5 HeLa cells experienced a 31.6% decreased net 
accumulation of [3H]5-CHO-THF compared to WT cells (p<0.05), and a 49.6% decrease 
compared to R5-RFC2 cells (p<0.005). 
We measured proliferation for WT HeLa and R5 cells grown in 25 nM 5-CHO-THF in 
the presence of antifolates (over a range of concentrations up to 1000 nM), including PCFT-
selective compounds 16 and 17, for comparison with MTX, LMX, RTX and PMX, classic 
antifolates which are transported by both RFC and PCFT (Goldman et al., 2010; Kugel 
Desmoulin et al., 2011; Kugel Desmoulin et al., 2010b), and with PT523, which is transported by 
RFC but not PCFT (Kugel Desmoulin et al., 2011; Kugel Desmoulin et al., 2010b; Zhao and 
Goldman, 2007). Cytotoxicity and transport inhibition experiments have demonstrated that 
MTX, PDX, RTX, and LMX can be transported by PCFT, albeit to a lower extent than RFC. 
Similar to published results (Zhao et al., 2004c), R5 (and R5 mock-transfectant) cells were 
substantially resistant to PT523 compared to WT (>213-fold) and R5-RFC2 (>303-fold) cells 
(Figure 5.4, Panel A and Table 5.1). Further, compared to WT HeLa cells, R5 cells were 1.4-, 
4.6-, 6.5-, 13.28- and >213-fold resistant to PMX, MTX, LMX, RTX and PT523, respectively. 
Thus, the greater the affinity of the antifolate for RFC, the more its cytotoxicity is reduced by 
RFC loss, especially if the drug has a lower selectivity for PCFT over RFC. For PMX, WT and 
R5 cells showed similar sensitivities (IC50s of 48.3 and 66.1 nM, respectively). Notably, RFC- 
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Figure 5.3 [3H]5-CHO-THF accumulation in WT and R5 HeLa sublines. Folate depleted R5 
HeLa sublines were treated with increasing concentrations of [3H]5-CHO-THF (0-1000nM) for 
96 h in the absence (Panel A) or presence (0-1000nM) of unlabeled compound 17 (Panel B) or 
compound 16 (Panel C). Internalized [3H]5-CHO-THF was normalized to total protein. The data 
in panel A summarize the results as mean values + SEMs for 3 independent experiments. For 
each 5-CHO-THF concentration, statistically significant differences were calculated between 
WT HeLa or R5-RFC2 cells and R5 cells and are noted with * (p<0.05) and ** (p<0.005).  For 
panels B and C, both R5 and HeLa cells showed decreased total folate metabolites derived from 
[3H]5-CHO-THF, accompanying treatment with increased concentrations of compounds 17 or 16 
(results as mean values + SEMs for 3-5 independent experiments). This difference was 
somewhat greater for R5 cells over WT HeLa cells (52.9% versus 72.9% and 52.7% versus 
71.1%, respectively). Statistical analyses were performed and for compound 16, the difference 
between the two sublines was statistically significant (p=0.006), although statistical significance 
was not quite reached for compound 17 (p=0.078). 
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Figure 5.4 Growth inhibition by antifolate drugs toward WT and R5 HeLa sublines. (Panel 
A) Growth inhibitions were measured by a fluorescence (CellTiter-Blue™)-based assay after 96 
h of exposure of folate-depleted WT and R5 HeLa sublines to a range of inhibitor concentrations. 
Results are presented as 50% inhibitory concentrations (IC50s) as mean IC50 values ± SEMs from 
5-12 independent experiments. IC50 values are summarized in Table 5.1. Statistically significant 
differences between results for WT HeLa or R5-RFC2 cells and those for R5 cells are noted with 
a * (p<0.01). For compound 17 (Panel B) and compound 16 (Panel C), growth inhibition 
experiments were performed in the presence of increasing concentrations (25-1000 nM) of 
extracellular 5-CHO-THF. Results are summarized as mean IC50 values ± SEMs from 3-11 
independent experiments. Statistically significant differences between results for WT HeLa and 
those for R5 cells are noted with a * (p<0.005). 
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deficient R5 cells were more sensitive to the PCFT-specific antifolates 16 and 17 than were WT 
HeLa cells (3.6- and 3.2-fold, respectively) and the R5-RFC2 transfected cells (3.6- and 8.3-fold, 
respectively). While differences in growth inhibitions between R5 and WT HeLa cells for 16 and 
17 were preserved at 100 nM 5-CHO-THF (4.3- and 15-fold, respectively), the effects of both 
drugs were abolished when the concentration of 5-CHO-THF was increased to 1000 nM (Figure 
5.4, Panels B and C). 
   Since compounds 16 and 17 are high affinity substrates for PCFT (Kugel Desmoulin et 
al., 2011; Wang et al., 2010; Wang et al., 2011), we hypothesized that these drugs compete with 
[3H]5-CHO-THF for PCFT-mediated uptake, leading to a more severe contraction of the cellular 
folate pool in R5 cells compared to WT cells than in their absence. Indeed, both compounds 16 
and 17 affected a striking dose-dependent decrease in net accumulation of [3H]5-CHO-THF 
which were greater in RFC-null R5 cells than in WT HeLa cells. At 1000 nM compound 17, 
levels of [3H]5-CHO-THF accumulation in R5 and WT HeLa cells were 52.9% and 72.9%, 
respectively, of levels without drug; for compound 16, the corresponding values were 52.7% and 
71.1%, respectively (Figure 5.3, Panels B and C).  
  Collectively, these results establish that loss of RFC contributes to a contraction of 
cellular folate pools, which is exacerbated in the presence of the PCFT-selective analogs 
compounds 16 and 17.  Importantly, decreased intracellular folates were accompanied by 
markedly increased antiproliferative effects of compounds 16 and 17.  
5.3.4 Polyglutamylation of Compounds 16 and 17 in WT and R5 HeLa Cells.  
Analogous to physiologic folates and other classic antifolate drugs such as MTX 
(Goldman and Matherly, 1985; Shane, 1989), compound 17 is metabolized to polyglutamates 
(Chapter 4 and Kugel Desmoulin et al. (2011)), catalyzed by FPGS. Polyglutamylation of 
  
162
compound 16 has not been previously assessed. For classic antifolates, polyglutamylation is 
critical to drug activity since polyglutamates are retained in cells and typically inhibit folate-
dependent enzyme targets more than their non-polyglutamyl forms (Stokstad, 1990). As 
polyglutamylation of antifolate drugs by FPGS can be regulated by elevated extra- and 
intracellular folates (Shane, 1989), it seemed possible that the impact of RFC and cellular THF 
cofactors on the anti-proliferative effects of compounds 16 and 17 (Figure 5.4, Panel A and 
Table 5.1) may be partly explained in this manner.  
To assess this possibility, HeLa and R5 cells were incubated with 1 µM [3H]compound 
16 or [3H]compound 17 for 16 h at pH 6.8 in the presence of 25 nM 5-CHO-THF and 0.06 mM 
adenosine. Total cellular radiolabeled drug levels were quantitated and tritiated parent drug and 
PGs were extracted and analyzed by reverse-phase HPLC as described in Chapter 4. At least four 
polyglutamyl metabolites (PG2-5) of [3H]compound 17 and five metabolites for [3H]compound 
16 (PG2-6) were resolved by HPLC. Migrations were compared to those for non-polyglutamyl 16 
or 17, and to MTX and MTX polyglutamate standards. Further, samples were treated in parallel 
with conjugase (Kugel Desmoulin et al., 2011), which reverted the majority of the polyglutamyl 
metabolites to the parental drug (data not shown). Results are summarized in Figure 5.5 (Panels 
A and B). HPLC chromatograms for the compound 16 in WT HeLa and R5 cells are shown in 
Figure 5.5  (Panels C and D). For R5 and WT cells, there was a 7-8-fold greater accumulation of 
total and polyglutamyl [3H]compound 16 than [3H]compound 17. WT and R5 cells accumulated 
similar levels of total 16 and 17 drug forms, although there were slight differences in relative 
accumulations of individual PGs between the cell lines. This difference was most obvious for the 
longest chain-length PGs (PG5 and PG6) and appears to be somewhat greater for 17 than 16. 
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Figure 5.5 HPLC analysis of polyglutamyl derivatives of compound 17 and 16 in WT and 
R5 HeLa cells at pH 6.8.  Folate depleted WT and R5 HeLa cells were treated with 1 µM 
[3H]compound 17 (Panel A) and 16 (Panel B) at pH 6.8 in the presence of adenosine (0.06 mM) 
and 25 nM 5-CHO-THF for 16 h. Polyglutamate drug forms were extracted and analyzed as 
described in Materials and Methods. Percent monoglutamate and polyglutamate drug forms were 
determined by chromatographic analysis and the total intracellular radiolabel calculated in units 
of pmol/mg protein. Results are presented as average values plus/minus ranges for two 
independent experiments. Panels C and D, show representative HPLC chromatograms for R5 
and HeLa cells treated with compound 16. 
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These results establish that: (i) compounds 16 and 17 are both excellent substrates for 
polyglutamylation under conditions (pH 6.8) that favor their membrane transport by PCFT; (ii) 
net drug accumulation and polyglutamylation of compound 16 far exceeds that for compound 17; 
and (iii) expression of functional RFC exerts only a modest effect on net polyglutamate synthesis 
of compounds 16 and 17.  
5.3.5 In vivo Efficacy Study of Compounds 16 and 17 Against HeLa and R5 Xenografts.  
To extend our in vitro cell proliferation studies in vivo, we performed in vivo antitumor 
efficacy studies with 8 week old female ICR SCID mice implanted with subcutaneous R5 or WT 
HeLa cells.  
Mice were maintained ad libitum on a folate-deficient diet which decreases serum folates 
to levels approximating those seen in humans (Kugel Desmoulin et al., 2011; Wang et al., 2010; 
Wang et al., 2011). For the drug trial, control and drug treatment groups were non-selectively 
randomized (four mice/group); compounds 17 or 16 were administered intravenously (180 and 
32 mg/kg per injection, respectively) on days 3, 7, 14 and 18 post-implantation.  Mice were 
weighed daily and tumors were measured 2-3 times per week. As reported for other tumor 
models (Kugel Desmoulin et al., 2011; Wang et al., 2011), compounds 17 and 16 showed 
substantial efficacy toward R5 and WT HeLa xenografts (Table 5.2). Both compound 17 and 
compound 16 showed greater efficacy toward R5 cells (0% T/C, (T-C (tumor growth delay) = 23 
days, 3.3 gross log kill, ++++ activity for compound 17; 3% T/C, T-C = 17.5 days, 2.5 gross log 
kill, +++ activity for compound 16) than toward WT HeLa cells (6% T/C, T-C = 13 days, 1.9 
gross log kill, ++ activity for compound 17; 7% T/C, T-C=13 days, 1.9 gross log kill, ++ activity 
for compound 16). The treatment regimens with compounds 16 and 17 were well tolerated with 
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 dose-limiting symptoms manifesting as reversible body weight loss (nadirs sustained for body 
weight loss.   
The results of the in vivo efficacy trial provide proof-of-principal confirmation of our in 
vitro findings that the antitumor effects of both compounds 16 and 17 are greater in RFC-
deficient R5 cells than in WT HeLa cells. Interestingly, the impact of loss of RFC is greater with 
compound 17 than compound 16 in vivo.   
5.4 Discussion. 
In this chapter, we significantly expanded upon previous reports (Kugel Desmoulin et al., 
2011; Kugel Desmoulin et al., 2010b; Wang et al., 2010; Wang et al., 2011; Zhao and Goldman, 
2007) that PCFT may be therapeutically exploitable for treating solid tumors, reflecting unique 
patterns of PCFT expression and transport activity at pHs approximating the tumor 
microenvironment (Chapters 2-4). 
We demonstrated that functional loss of RFC in R5 cells caused a contraction of total cellular 
THF cofactor pools derived from 5-CHO-THF which enhanced the antitumor activities of both 
compounds 16 and 17 compared to WT cells. Importantly, reduction of total cellular folate pools 
in R5 cells was exacerbated in the presence of compounds 16 and 17,  through direct competition 
at PCFT, which further restricted cellular uptake of exogenous 5-CHO-THF.   Efficacies of 
compounds 16 and 17 were also increased toward R5 tumors compared to WT tumors 
transplanted into SCID mice with serum folate concentrations approximating those achieved in 
humans.   
There is ample precedent for an impact of extra- and intracellular folate pools on antifolate 
drug efficacy. Indeed, this is the premise of leucovorin rescue from MTX toxicity (Matherly et 
al., 1987a) or of low-dose folic acid protection from LMX in vivo toxicity (Roberts et al., 2000a), 
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whereby elevated extra- and intracellular folates compete at multiple levels to reverse drug 
activity (Zhao et al., 2001a). In vitro studies in assorted cell line models have extended these 
findings to both classic (PMX, LMX) and non-classic (trimetrexate) antifolates, which inhibit a 
range of cellular targets (DHFR, TS, and GARFTase) (Goldman et al., 2010; Tse and Moran, 
1998; Zhao et al., 2001a). Further, effects on antifolate drug activities are enhanced by decreased 
intracellular folates resulting from a RFC genomic deletion (Chattopadhyay et al., 2006; Zhao et 
al., 2004b; Zhao et al., 2004c) or RFC mutations (Zhao et al., 2000a). Similarly antifolate 
activities are reduced by increased intracellular folates resulting from impaired efflux of folic 
acid by MRP1 (Assaraf and Goldman, 1997) or enhanced folic acid influx by a mutant RFC (Tse 
et al., 1998; Tse and Moran, 1998).  
Regardless of the underlying mechanism and intracellular drug target involved, markedly 
decreased total intracellular THF pools can result in collateral sensitivities to antifolates, often in 
the face of substantially decreased levels of drug uptake (Chattopadhyay et al., 2006; Zhao et al., 
2000b; Zhao et al., 2004c). This could reflect inhibitory effects on antifolate polyglutamylation 
(with consequent impact on drug retention and inhibition of folate-dependent enzyme targets) 
due to competitive feedback inhibition at FPGS by high levels of THF cofactor PGs (Shane, 
1989). Additionally, FPGS activity has been found to increase in response to decreased extra- 
and intracellular folates (Gates et al., 1996). There can also be direct competitive interactions 
between polyglutamyl folates and antifolates that interfere with drug binding and inhibition at 
their enzyme targets, as documented for MTX and other classic antifolates (Matherly et al., 
1983). Changes in drug efflux are also possible, as ABC transporter (ABCG2, ABCC1) levels 
and/or intracellular distributions have been described in response to folate deprivation (Ifergan et 
al., 2005).   
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In the present study, we found that transport of compounds 16 and 17 by PCFT was virtually 
identical between the RFC-deficient R5 and WT HeLa cell lines. By analogy with other classical 
antifolates (Mendelsohn et al., 1999; Shih and Thornton, 1999), the increased accumulation of 
long chain polyglutamyl forms of compounds 16 and 17  observed in the R5 subline might be 
expected to result in increased inhibition of intracellular GARFTase and de novo purine 
nucleotide biosynthesis (Kugel Desmoulin et al., 2011; Wang et al., 2010; Wang et al., 2011). 
However, even though total and polyglutamyl accumulations of compounds 16 and 17 during 
sustained drug exposures were similar between WT and R5 cells; there were slight differences in 
distributions of compounds 16 and 17 polyglutamates between the lines. This difference was 
greatest for the longest chain length PGs (PG5 and PG6) and appeared to be somewhat greater for 
compound 17 than 16.  
The results provide proof-of-principal evidence that RFC levels and function are critical 
determinants of in vitro antitumor activities and in vivo efficacies of PCFT-targeted antifolates 
that are not themselves substrates for RFC. It is this lack of RFC transport which should confer 
tumor selectivity and decreased toxicity to normal tissues for this novel class of agents. Tumor 
selectivity would be enhanced by substantial levels of PCFT protein in solid tumors and by 
acidic pHs characterizing the tumor microenvironment which favor PCFT over RFC transport 
(Kugel Desmoulin et al., 2011). Conversely, at neutral pHs characterizing most normal tissues, 
RFC transport of reduced folates would be increased, resulting in elevated levels of THF 
cofactors within cells which further protect from untoward drug effects. Of course, in tumors 
with sufficiently high RFC levels, uptake of THF cofactors by this process may still occur even 
at somewhat acidic pHs. Accordingly, any decrease in RFC function would serve to augment the 
inherent antitumor selectivity and increase sensitivities to PCFT-selective antifolates.  
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CONCLUSIONS 
 
The goal of this dissertation research was to determine the therapeutic potential of using 
PCFT-mediated membrane transport to selectively deliver novel cytotoxic antifolates into tumor 
cells. To establish the feasibility of this approach the expression and function of PCFT in normal 
and tumor tissues was determined and compared to RFC levels (Chapter 2). Additionally, novel 
antifolates with selective uptake by PCFT were identified and characterized in vitro and in vivo 
to evaluate their preclinical antitumor efficacies (Chapters 3 and 4). Finally, the influence of 
RFC-mediated folate uptake on drug efficacy was determined for these novel PCFT-selective 
antifolates (Chapter 5).   
The comprehensive analysis of PCFT expression and function in human normal and 
tumor tissue established for the first time that PCFT is present in tumor tissue and is functional at 
the acidic pH surrounding most solid tumors. There were significant levels of PCFT transcripts 
in the majority of human solid tumor tissues and cell lines of different origins (e.g., breast, 
prostate, ovarian, etc.), and uniformly low PCFT transcript levels in human leukemias, including 
both ALL and AML. PCFT levels were highest in Caco-2 (colorectal) SKOV3 (ovarian), HepG2 
(hepatoma), HeLa (cervical), and T47D (breast) cancer cells. In human normal tissues, PCFT 
expression was detected in the small intestine, kidney, liver, and the adrenal gland. When 
compared to the ubiquitously expressed RFC, the presence of PCFT was more limited. This 
suggests, based on PCFT expression patterns, antifolates preferentially using PCFT and not RFC 
as a means of drug entry into tumor cells may be less toxic compared to antifolates presently 
used in cancer therapy. 
The rational drug design and screening of novel 6-substituted pyrrolo[2,3-d]pyrimidine 
benzoyl (compound 3) or thienoyl (compounds 16 and 17) analogs identified the first antifolates 
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that are selective for PCFT-mediated uptake and have no appreciable transport by RFC. The 
novel antifolates were identified and characterized in multiple engineered cell lines that express 
PCFT alone (R2/PCFT4 CHO and R1-11-PCFT4 HeLa sublines), or RFC alone (PC43-10 CHO 
and R1-11-RFC6 HeLa sublines), to determine selectivity, as well as solid tumor cell lines such 
as HeLa and HepG2 that express both PCFT and RFC to determine therapeutic potential. The 
PCFT-mediated uptake of the novel antifolates was very efficient and led to growth inhibition in 
all cells tested expressing PCFT.   
When further characterized these analogs were found to be directly transported by PCFT 
in a pH- and time-dependent manner, where uptake was enhanced at acidic pHs that are relevant 
to the solid tumor microenvironment. Once internalized the novel antifolate compounds were 
polyglutamylated and up to five or six polyglutamyl metabolites were identified. The principle 
intracellular folate-dependent enzyme target for compounds 3, 16 and 17 was GARFTase, a key 
de novo purine nucleotide biosynthesis enzyme. This was determined by both nucleoside 
protection and an in situ GARFTase assay. Inhibition of GARFTase led to a dose- and time-
dependent decrease in ATP and GTP levels, which caused an S-phase accumulation and 
irreversible cell death as measured by discontinuous colony formation. The mechanism of cell 
death was partially through apoptosis and partially through an unidentified process that remains 
to be elucidated. 
RFC function had a large impact on the cytotoxicity of analogs selective for PCFT-
mediated uptake. While the novel compounds are not RFC transport substrates, levels of RFC 
nonetheless markedly impacted the anti-proliferative effects of these agents, via expansion or 
contraction of intracellular THF cofactor pools. Loss of RFC, which occurs in clinical cases of 
de novo and acquired resistance to the classic antifolates, leads to enhanced sensitivity to 
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antifolates selective for PCFT-mediated uptake. This was due to contraction of reduced folate 
pools and enhanced polyglutamylation of the novel drugs presumably leading to better 
GARFTase inhibition.     
The in vitro cytotoxicity of compounds 16 and 17 has been recapitulated in vivo in 
subcutaneous HepG2 and HeLa xenografts in which PCFT was the predominant mode of drug 
uptake. Treatment with compound 16 led to potent tumor growth delay of HepG2 tumors, 
providing compelling proof-of-principle validation that PCFT is an efficient mechanism of drug 
delivery. Additionally, subcutaneous HeLa tumors that lacked RFC function were exquisitely 
more sensitive to PCFT-targeted drugs compared to wild-type HeLa tumors that expressed 
functional RFC. These data suggests that drugs selective for PCFT may be useful in tumors with 
antifolate resistance due to lack of RFC function. Importantly, RFC levels or ratios of PCFT to 
RFC transport might effectively predict anti-tumor potencies of these novel PCFT-selective 
antifolates. 
The evidence in this dissertation of widespread PCFT expression in human solid tumors 
paired with the discovery of novel antifolates selective for PCFT-mediated uptake offers exciting 
new therapeutic possibilities to selectively deliver novel antifolate drugs to tumors by exploiting 
the acidic tumor microenvironment. Data presented here suggests that PCFT is a surprisingly 
efficient means of delivering antifolates into a tumor cell both in vitro and in vivo and there is a 
strong rationale for developing drugs whose transport by PCFT, but not RFC, allows for 
GARFTase inhibition.  
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Folates are essential cofactors of tumor cell proliferation and survival required for 
nucleotide biosynthesis and amino acid metabolism. In cancer therapy, inhibition of folate-
dependent metabolic pathways has been achieved through the use of antifolates. Unfortunately, 
the efficacy of many clinically approved antifolates is limited by a lack of tumor selectivity. 
Facilitative transport of folates into mammalian cells is achieved by the reduced folate carrier 
(RFC) and proton-coupled folate transporter (PCFT). As PCFT is a folate-proton symporter with 
an acidic pH optimum, PCFT may provide a mechanism for targeting cytotoxic antifolates to 
tumors, based on their acidic microenvironments. To establish the feasibility of this approach, we 
systematically determined the expression profiles for PCFT and RFC. In various human 
malignant cell lines and tissues PCFT was highly expressed and functional, while its expression 
in normal tissue was more limited compared to RFC.  
Screening and characterization of multiple series of novel antifolates led to the 
identification of 6-substituted pyrrolo[2,3-d]pyrimidine benzoyl and thienoyl antifolates, which 
were selective for PCFT-mediated uptake, but not RFC. Upon internalization, these novel 
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antifolates were extensively polyglutamylated, as detected by high performance liquid 
chromatography (HPLC). Growth inhibition assay paired with nucleoside protection identified 
glycinamide ribonucleotide (GAR) formyltransferase (GARFTase) in the de novo purine 
biosynthesis pathway as the principle drug target. This was confirmed by in situ measurement of 
[14C]glycine incorporation into [14C]formylGAR in treated cells. Furthermore, contraction of 
intracellular purine nucleotide triphosphate pools occurred in a dose- and time-dependent 
manner, as demonstrated by quantitative HPLC analysis. Further, drug treatment induced S-
phase accumulation eventually leading to irreversible cell death. Drug treatment caused a 
significant delay in tumor growth in an in vivo efficacy trial of SCID mice implanted with 
subcutaneous human tumors where PCFT was the sole mechanism of drug uptake.    
Although these compounds are not substrates for RFC, its expression does impact drug 
efficacy by influencing intracellular tetrahydrofolate (THF) cofactor pools. Loss of functional 
RFC leads to increased polyglutamylation of these analogs within the cell causing enhanced 
cytotoxicity. Similarly, these novel PCFT-selective antifolates displayed increased in vivo 
efficacy in subcutaneously implanted human tumors lacking RFC.  
Our finding of widespread PCFT expression in human solid tumors paired with our 
discovery of novel antifolates internalized via PCFT offers exciting new therapeutic possibilities 
for selectively targeting tumors based on their acidic microenvironments. These compounds 
display immense therapeutic potential, especially in tumors with de novo or acquired resistance 
to classic antifolates caused by lack of RFC function. 
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